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Abstract
The overall survival of patients with malignant gliomas remains dismal despite
multimodality treatments. Computed tomography (CT) perfusion is a functional imaging tool
for assessing tumour hemodynamics. The goals of this thesis are to 1) improve measurements
of various CT perfusion parameters and 2) assess treatment outcomes in a rat glioma model
and in patients with malignant gliomas.
Chapter 2 addressed the effect of scan duration on the measurements of blood flow
(BF), blood volume (BV), and permeability-surface area product (PS). Measurement errors
of these parameters increased with shorter scan duration. A minimum scan duration of 90 s is
recommended.
Chapter 3 evaluated the improvement in the measurements of these parameters by
filtering the CT perfusion images with principal component analysis (PCA). From computer
simulation, measurement errors of BF, BV, and PS were found to be reduced. Experiments
showed that CT perfusion image contrast-to-noise ratio was improved.
Chapter 4 investigated the efficacy of CT perfusion as a potential early imaging
biomarker of response to stereotactic radiosurgery (SRS). Using the C6 glioma model, we
showed that responders to SRS (surviving > 15 days) had lower relative BV and PS on day 7
post-SRS when compared to controls and non-responders (P < 0.05). Relative BV and PS on
day 7 post-SRS were predictive of survival with 92% accuracy.
Chapter 5 examined the use of multiparametric imaging with CT perfusion and 18FFluorodeoxyglucose positron emission tomography (FDG-PET) to identify tumour sites that
are likely to correlate with the eventual location of tumour progression. We developed a
method to generate probability maps of tumour progression based on these imaging data.
Chapter 6 investigated serial changes in tumour volumetric and CT perfusion
parameters and their predictive ability in stratifying patients by overall survival. Pre-surgery
BF in the non-enhancing lesion and BV in the contrast-enhancing lesion three months after
radiotherapy had the highest combination of sensitivities and specificities of ≥ 80% in
predicting 24 months overall survival.
ii

Optimization and standardization of CT perfusion scans were proposed. This thesis
also provided corroborating evidence to support the use of CT perfusion as a biomarker of
outcomes in patients with malignant gliomas.

Keywords
Blood flow, blood volume, brain tumour, permeability-surface area product, dynamic
contrast-enhanced computed tomography, CT perfusion, image noise, principal component
analysis, radiotherapy, stereotactic radiosurgery
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Introduction

1.1 Overview
Until recently, clinical imaging of brain tumours has been limited largely to
magnetic resonance (MR) and computed tomography (CT). MR is used routinely for
diagnosis, surgical and radiotherapy guidance, and assessment of treatment response. CT
is the workhorse for radiotherapy planning. Both imaging modalities are used for
depicting the anatomy, size, and location of brain tumours. However, they have limited
capabilities in providing functional information that relate to tumour pathophysiology.
There is mounting evidence that functional imaging techniques, such as tumour perfusion
imaging, are promising tools in this regard. Perfusion imaging, using CT or MR, can
evaluate brain tumour hemodynamics. At present, perfusion imaging is not incorporated
into the routine clinical care of patients because the uncertainties in the acquisition and
analysis of these images make optimization and standardization difficult. Moreover,
perfusion changes in response to different treatments are complex and not yet well
understood. These problems make clinical interpretation of perfusion imaging
information difficult. Optimization and standardization of image acquisition and analysis
can help facilitate the implementation of perfusion imaging in clinical practice. Serial
imaging of perfusion changes can improve the interpretation of the perfusion imaging
data for evaluating response and prognosis in patients. This thesis focuses on optimizing
the use and interpretation of CT perfusion imaging data based on computer simulation,
pre-clinical experiments, and clinical studies. This introductory chapter provides an
overview of the basic biology and treatment of malignant glioma, angiogenesis, a review
of clinical perfusion imaging studies, and an outline of this thesis.
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1.2 Malignant Glioma
More than 22,200 North Americans are diagnosed with cancers of the brain and
central nervous system each year (1,2). Glial cells are non-neuronal cells that maintain
homeostasis, and support and protect neurons in the central nervous system. Gliomas are
brain tumours derived from glial cells with astrocytomas being the most common type of
glioma. The World Health Organization (WHO) classifies astrocytomas into four grades
based on histological features (3). Both pilocytic (WHO grade I) and diffuse (WHO grade
II) gliomas are considered low-grade gliomas and typically behave in an indolent fashion.
WHO grade III and IV gliomas are high-grade or malignant gliomas, and they account
for approximately 70% of all malignant brain tumours (1,4). Anaplastic astrocytomas
(WHO grade III) are diffusely infiltrating, demonstrate a high degree of anaplasia, and
tend to progress to glioblastoma multiformes (GBMs). Nuclear atypia and mitotic activity
are the criteria for diagnosing anaplastic astrocytomas. GBM (WHO grade IV) is the
most malignant form of astrocytoma. It is composed of differentiated neoplastic
astrocytes. It shows increased mitotic activity, proliferation of microvasculature, and
necrosis. Neovascularization and necrosis are histologic hallmarks of GBM reflecting the
dysregulated blood supply of these tumours. Despite aggressive treatment with
combinations of surgery, radiation and chemotherapy, the median survival of patients
with GBM is approximately 12 to 15 months, while it is two to five years for those with
anaplastic gliomas (4).

1.3 Current Treatment Strategy for Malignant Glioma
The standard of care for patients with malignant gliomas involves maximal
surgical resection when feasible, followed by radiotherapy and concurrent and adjuvant
Temozolomide chemotherapy (4,5). Patients usually undergo at least a biopsy to
determine tumour grade and often undergo surgical resection to debulk the tumour mass
to palliate symptoms and improve function. Within six weeks after surgery, patients will
receive 40 to 60 Gy of external beam radiotherapy. The target for radiotherapy is defined
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using MR and CT. The gross tumour volume includes the contrast-enhancing lesion
(CEL) depicted on pre-surgical MR/CT. The clinical target volume includes a margin (2
– 3 cm) to encompass microscopic spread of cancer (6). The planning target volume is
created by an additional 0.3 cm margin to encompass treatment uncertainties (6). External
beam radiotherapy is delivered in 2 Gy per fraction, given once daily for five days a week
over a period of four to six weeks. Patients also receive concurrent Temozolomide at a
dose of 75 mg/m2 per day, given 7 days per week until the last day of radiotherapy. Six
cycles of adjuvant Temozolomide start at four weeks after the end of radiotherapy based
on a five day schedule every 28 days (5).

1.4 Prognostic Factors and Recurrence Patterns
Advanced age (≥ 50 years old), WHO grade IV, poor Karnofsky performance
status, and unresectable tumours are the most important pretreatment prognostic factors
that predict poor survival (7). The extent of resection, radiation dose, and O6methylguanine-DNA methyltransferase (MGMT) promoter status are predictors of
survival and recurrence patterns after treatment of GBM.
Malignant gliomas often cannot be completely resected due to its infiltrative
nature and its proximity to adjacent brain tissues that serve important neurologic
functions. In a retrospective study that involved 1215 patients with malignant gliomas,
the median survival times after gross-total resection, near-total resection, and subtotal
resection were 13, 11, and 8 months, respectively. Survival benefits were significant for
gross-total resection versus near-total resection (P < 0.05), and near-total resection versus
subtotal resection (P < 0.05) (8). Therefore, maximal surgical resection is favorable
because survival is influenced by the extent of resection (8–10).
Radiotherapy plays an important role in prolonging the survival of these patients.
It has long been established that a dose-survival relationship exist below 60 Gy (11).
However, radiotherapy does not eliminate the risk of recurrence, and most patients will
recur despite adjuvant radiotherapy. Over 80% of recurrence occurs within 2 cm of the
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irradiated volume (12–17). For this reason, treatment volume is limited to the nearby
surrounding region of the brain in order to reduce the toxicity associated with large field
radiotherapy. The adoption of partial brain radiotherapy and new radiation technologies
including three-dimensional conformal radiotherapy (18–20), intensity-modulated
radiotherapy (21–23), stereotactic radiosurgery (SRS) (24–29), and interstitial
brachytherapy have attempted to escalate the dose to beyond 60 Gy (30–34). Despite the
use of high dose radiotherapy (90-120 Gy), dose escalation alone has not resulted in
survival benefit. The target for dose escalation in these studies was typically defined as
the CEL on CT or MR after contrast injection, but a few reports showed such procedure
may not represent the entire tumour. Using 123I-α-methyl-tyrosine single-photon emission
computed tomography (SPECT) and
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C-methionine positron emission tomography

(PET) studies have detected areas of increased metabolic activity that were not visible on
contrast-enhanced CT or MR (35–38). In a group of patients with recurrent malignant
gliomas, reirradiation of gross tumour volumes based on PET/SPECT + CT/MRI resulted
in improved survival compared to reirradiation of gross tumour volumes based on
CT/MR alone (9 vs. 5 months, log-rank P = 0.03) (35). This result suggests that
functional imaging can provide complimentary information to that of CT/MR, and may
define a biologic target for dose escalation that is distinct from that delineated by typical
contrast-enhanced imaging.
Gliomas are known to be infiltrative neoplasms with the ability to migrate large
distances in the brain. It is postulated that as treatment of the local tumour improves,
distant failures beyond the typical 2 cm boundary around the irradiated brain volume may
become more common.

As of yet, however, even in the most favorable instances

(completely resected tumours + receiving adjuvant radiotherapy and chemotherapy), the
majority of failures are still in close proximity to the original tumour. The O(6)methylguanine-DNA methyltransferase (MGMT) promoter methylation is a prognostic
factor of survival and recurrence patterns after radiotherapy and Temozolomide
chemotherapy. One mechanism of DNA injury induced by Temozolomide is the
methylation

of

DNA

(39).

The

DNA-repair

protein

O6-alkylguanine-DNA-

alkyltransferase is encoded by the gene MGMT, which repairs Temozolomide-induced
DNA damage by removing the alkylating lesions at the O6 position of guanine. The
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MGMT gene promoter is often methylated in malignant gliomas leading to the silencing
of the MGMT gene and rendering tumour cells unable to repair Temozolomide-induced
DNA damage (40). Patients with methylated MGMT promoter (i.e. silenced) had
significantly longer survival than patients with unmethylated MGMT promoter (21.7 vs.
12.7 months, respectively; log-rank P < 0001) (41). MGMT promoter gene status is also
associated with different patterns of recurrence. Recurrences within or at the margin of
the irradiated volume were more frequent amongst patients with unmethylated MGMT
status than those with methylated MGMT status (P = 0.01) although local recurrences
still predominated (42).

1.5 The Blood Brain Barrier and Tumour Angiogenesis
A solid tumour cannot grow beyond 1 to 2 mm3 unless new vasculatures are
formed to supply oxygen and nutrients to the growing tumour (43–45). Blood flow and
the exchange of materials between the brain and systemic circulation are tightly regulated
by the blood brain barrier (BBB). The BBB has important implications in tumour
development and the growth of new blood vessels.
Brain vasculature is highly specialized and is unlike those found in other organs.
The passage of molecules between the systemic circulation and the cerebral parenchyma
is regulated physically (via tight junctions) and metabolically (via enzymes and transport
systems) by the BBB. It maintains a constant supply of oxygen, glucose and other
nutrients for neurons, and excludes exogenous molecules from entering the brain. This
regulation is primarily established by three types of cells: endothelial cells, pericytes, and
astrocytes (Figure 1-1). Endothelial cells form the lumen of blood vessels, which is the
interface for material exchange between the blood and the brain. Pericytes are
undifferentiated perivascular cells that envelope the outer surface of arterioles, venules,
and capillaries (46). They play important roles in regulating blood flow (47) and
maintaining the integrity of the BBB (48). Astrocytes are glial cells that cover more than
99% of the BBB endothelium (46).
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Figure 1-1: Schematic diagram of a brain capillary. The capillary lumen is
surrounded by an endothelial cell, which is connected at both ends by tight
junctions. Pericytes are attached to the outer surface of the endothelial cell.
The endothelial cell and pericyte are ensheathed by a layer of basal lamina.
This capillary is then enveloped by astrocytes. Figure adapted from
Hawkins and Davis. Pharmacol Rev. 2005;57(2):173-185. Reprinted with
permission.

Tight junctions between adjacent endothelial cells are responsible for the unique
impermeability of the BBB. They are regions where adjacent endothelial cell membranes
are tightly associated with each other through the interactions of various tight junction
proteins (46). This arrangement is continuous and lacks fenestration. The outer leaflets of
adjacent endothelial cell membranes appear to be fused. The BBB physically prevents
plasma proteins and hydrophilic molecules (> 500 kDa) from passively diffusing into the
brain parenchyma (49). For exogenous molecules that can cross the BBB, there are
several active, receptor-mediated transport proteins that function to export these
molecules from the brain back into the systemic circulation (50,51). The brain is
considered a “sanctuary” site for cancer cells because the BBB contributes to drug-
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resistance by excluding many exogenous molecules (e.g. drugs) from entering the brain
(49).

1.5.1

The Blood Brain Barrier in Brain Tumours
The integrity of the blood brain barrier is compromised in malignant brain

tumours. The expressions of tight junction proteins are decreased or completely lost in
primary and metastatic brain tumours (52–54). This leads to increased vascular
permeability and may clinically manifest as vasogenic edema. The reduced number of
pericytes (55) and astrocytes (56,57) in an aggressive brain tumour further contributes to
a dysfunctional BBB. Tumour cells further increase BBB permeability by secreting a
variety of factors that down regulate the expression of tight junction proteins (58,59).
One such factor is the vascular endothelial growth factor (VEGF), which was originally
discovered as the vascular permeability factor (49,58). VEGF is also a driver of tumour
vessel formation. The resulting vessels are structurally and functionally compromised and
lack the BBB of normal vasculature.

1.5.2

Tumour Hypoxia
Mammalian cells are usually located within 100 to 200 μm of nearby blood

vessels, which is the oxygen diffusion limit (60,61). The partial pressure of oxygen (PO2)
in normal tissue ranges between 10 to 80 mm Hg, but PO2 within certain tumour regions
are often less than 5 mm Hg (62). Hypoxia occurs when the tumour grows beyond the
oxygen diffusion limit because the vascular supply cannot meet its metabolic demand.
This type of hypoxia is called chronic hypoxia, which can lead to tumour necrosis.
Cycling hypoxia, sometimes known as acute or intermittent hypoxia, occurs in tumour
regions that are poorly perfused due to chaotic and sluggish tumour vasculature (63).
Hypoxia is associated with treatment resistance (64,65) and promotes the formation of
new tumour blood vessels (66,67). The growth of a solid tumour is dependent on the
growth of new blood vessels (44). There are four mechanisms for brain tumours to form
new blood vessels, they are co-option, angiogenesis, vasculogenesis, and intussusception.
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1.5.3

Formation of Tumour Blood Vessels

1.5.3.1

Co-option

Initial brain tumour vessel formation (< 1 mm in diameter) is believed to occur by the cooption of pre-existing blood vessels (68,69). Early reports demonstrated that pre-existing
vessels that were co-opted by tumour cells were not influenced by the tumour as these
vessels were not leaky (68,70). This also suggests that this type of vessel formation might
not be detected by contrast-enhanced CT or MR since these imaging techniques detect
tumour based on the extravasation of contrast agents (68).

1.5.3.2

Angiogenesis

Angiogenesis is a common mechanism for gliomas to grow and progress. Tumour
angiogenesis in the brain involves three major steps: 1) regression of pre-existing blood
vessels, 2) breakdown of the basement membrane and extracellular matrix, and 3) the
migration of endothelial cells to form new blood vessels. The initiation of angiogenesis is
known as the angiogenic switch. This switch is turned on when the pro-angiogenic
factors in a tumour outweigh the anti-angiogenic factors. The secretion of pro-angiogenic
factors are triggered by microenvironmental conditions including hypoxia and acidosis
(71), and by genetic factors such as alterations in oncogene (e.g. ras) or tumour
suppressor gene (e.g. p53) functions (72,73). The hypoxia-inducible factor 1 (HIF-1)
pathway is a well-characterized signaling pathway by which hypoxic tumours initiate and
orchestrate cellular responses to hypoxia. HIF-1 activates the transcription of more than
100 genes that help tumour cells “cope” with low oxygen conditions (74). The expression
of VEGF, one of the most potent pro-angiogenic factors, is activated by this pathway
(71,73).
The initial response to VEGF overexpression includes increased vascular
permeability (75–77) and diameter (49). In a normal brain, angiopoietin (Ang-1) binds to
its receptor Tie-2 to facilitate a close association between endothelial cells and pericytes
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(48,78). Under hypoxic conditions, Ang-2, an antagonist of Tie-2, is upregulated and is
suggested to be involved in the detachment of pericytes from endothelial cells and leads
to the regression of blood vessels (79–81). Increased Ang-2 and hypoxia then lead to the
expression of matrix-metalloproteinase molecules that mediate the breakdown of the
basement membrane and the extracellular matrix (82). At the same time, molecules
including VEGF, Ang-1, and Ang-2 stimulate endothelial cell proliferation and migration
towards the cancer cells (49,79). The end product of angiogenesis is an abnormal, highly
tortuous, sluggish, and leaky vascular network (49,63).

1.5.3.3

Vasculogenesis

Angiogenesis forms new blood vessels from pre-existing ones, whereas
vasculogenesis forms blood vessels without pre-existing endothelial cells. It is a process
by which bone marrow-derived cells (83–85), such as circulating progenitor cells (86,87),
are recruited to the tumour to form new blood vessels. This process is also initiated by
hypoxia through the HIF-1 pathway (88,89). It has been shown that blocking
vasculogenesis can prevent or delay local recurrence of GBM after irradiation (88). This
suggests circulating cells outside the radiation field colonize and stabilize tumour
vasculature and support the remaining viable tumour cells after irradiation.

1.5.3.4

Intussusception

Intussusception refers to the remodeling and expansion of pre-existing blood
vessels by inserting transluminal pillars into vessel lumens that result in partitioning of
vessel lumens (79,90). Intussusception occurs faster than angiogenesis; it does not
primarily depend on the proliferation of endothelial cells, degradation of basement
membrane, and invasion of connective tissue (90,91). It appears to increase the
complexity and density of tumour vascular networks established by angiogenesis (90).
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1.6 Conventional Imaging of Malignant Gliomas
Visualization of brain tumours on contrast-enhanced MR and CT is made possible
because the compromised BBB in brain tumours allow imaging contrast to extravasate
into the brain parenchyma after contrast injection. The standard MR protocol for imaging
brain tumours usually involves a T2-weighted or a fluid attenuated inversion recovery
(FLAIR) MR and a gadolinium-enhanced T1-weighted MR (Figure 1-2) (92).
Gadolinium-enhanced T1-weighted MR provides excellent soft tissue contrast, and
depicts the contrast-enhancing component of the tumour. However, malignant gliomas
are infiltrative tumours with microscopic processes that extend beyond regions of
contrast-enhancement. Vasogenic edema, which may be induced by infiltrating tumour
cells, is a major clinical feature of the non-enhancing portions of these tumours and can
be visualized on T2-weighted or FLAIR MR.

Figure 1-2: Contrast-enhanced T1-weighted magnetic resonance (MR) and T2weighted MR of a patient with glioblastoma multiforme (GBM).

1.7 Criteria for Assessing Treatment Response
Radiographic response assessment of brain tumours is primarily based on changes
in the size of the contrast-enhancing part of the tumour. The Macdonald criteria were
introduced in 1990 for assessing response in gliomas (93). Tumour size is measured using
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the product of the maximal perpendicular diameters of the enhancing tumour depicted on
gadolinium-enhanced T1-weighted MR or iodinated contrast-enhanced CT. The use of
corticosteroid and clinical status are also taken into account. Response can be categorized
into four categories; they are complete response, partial response, stable disease, and
progression (Table 1-1).

Table 1-1: The Macdonald criteria for assessing treatment response of malignant
gliomas.*
Response

Criteria

Complete
Response

Requires all of the following: complete disappearance of all enhancing
measurable and non-measurable diseases sustained for at least 4
weeks; no new lesions; no corticosteroid; and stable or improved
clinically

Partial Response

Requires all of the following: ≥ 50% decrease compared with baseline in
the sum of products of perpendicular diameters of all measurable
enhancing lesions sustained for at least 4 weeks; no new lesions; stable
or reduced corticosteroid dose; and stable or improved clinically

Stable Disease

Requires all of the following: does not qualify for complete response,
partial response, or progression; and stable clinically

Progression

Defined by any of the following: ≥ 25% increase in the sum of products
of perpendicular diameters of enhancing lesions; any new lesion; or
clinical deterioration

*Reprinted with permission. © (2010) American Society of Clinical Oncology. All rights
reserved. Table adapted from Wen PY, Macdonald DR, Reardon DA, et al. J Clin Oncol.
2010;28(11):1963-1972.

The Macdonald criteria have a few limitations. A two dimensional measurement
of tumour size can be influenced by a number of factors (94–96). Measurement is
difficult with an irregularly shaped tumour, multifocal tumour, and enhancing wall of a
surgical cavity. It is also prone to interobserver variability (97). Contrast-enhanced MR or
CT is a snapshot of tissue contrast-enhancement after contrast injection, so it reflects the
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extravasation of materials across a disrupted BBB regardless of the cause of disruption.
Changes in corticosteroid dose, inflammation, post-surgical changes, pseudoprogression
due to treatment effects, radiation-induced necrosis, and pseudoresponse due to antiangiogenic therapies are all factors that can influence contrast-enhancement (98–102). In
addition, the Macdonald criteria do not take into account the non-enhancing component
of the tumour.
Recently, the Macdonald criteria were updated. In 2010, The Response
Assessment in Neuro-Oncology (RANO) Working Group developed new standardized
criteria for assessing response in patients with malignant gliomas (92). Size measurement
of the non-enhancing component of the tumour using T2-weighted or FLAIR MR is
incorporated into the assessment criteria. It also recognized early changes in contrastenhancement could be treatment related (e.g. pseudoprogression and pseudoresponse),
which could confound the diagnosis of tumour progression or response. To address this
issue, a time period has been defined for which pseudoprogression can be excluded from
true progression. For instance, true progression can only be determined within the first 12
weeks of completion of radiotherapy if the majority of new contrast-enhancement is
outside the radiation field (80% isodose line) or if there is pathologic confirmation of
tumour progression (92).
The RANO working group recognized that there are still unsolved problems
associated with these criteria. Better imaging techniques are needed to predict tumour
response, differentiate treatment-induced changes from tumour progression, and
differentiate non-enhancing tumours from other etiologies of increased T2-weighted or
FLAIR signals. The group also recognized that functional imaging, particularly the
imaging of tumour perfusion and permeability, are promising tools to address these
challenges.
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1.8 Perfusion Imaging of Malignant Gliomas
A growing number of studies demonstrated that perfusion imaging can provide
physiologic information about tumour aggressiveness and disease prognosis. Dynamic
susceptibility-contrast MR (DSC-MR), dynamic contrast-enhanced MR (DCE-MR), and
DCE-CT are commonly used perfusion imaging techniques for evaluating tumour
hemodynamics and vessel permeability surface area (PS) product in the research setting.
In this thesis, DCE-CT and CT perfusion are used interchangeably.
Perfusion imaging refers to imaging techniques that characterize tissue
hemodynamics by tracking the passage of a bolus of contrast agent as it traverses through
human tissue. Following injection, contrast passes through the microvasculature of brain
tissue and produces a change in image signal intensity. DCE-MR and DSC-MR measure
gadolinium contrast concentration via its effect on surrounding water molecules, while
DCE-CT measures iodinated contrast concentration via its attenuation of x-rays.
Quantitative evaluation of hemodynamics and PS from tracer kinetic analysis (103)
consists of three main steps:
1. Image signal intensity is converted to contrast concentration to obtain the
time-concentration curve Ct(t) of brain (tumour) tissue.
2. Image signal intensity in pixels corresponding to an input artery to the brain is
similarly converted to the arterial input function Ca(t). It is the timeconcentration curve of contrast that enters the tissue of interest via the selected
input artery.
3. Based on the tracer kinetic model adopted, hemodynamic parameters such as
blood flow (BF) and PS can be estimated. Definitions of the different tracer
kinetic parameters that can be derived are listed in Table 1-2. The tissue timeconcentration curve Ct(t) is equal to blood flow (BF) multiplying the
convolution of the arterial input function Ca(t) and an impulse residue
function R(t). This relationship can be mathematically expressed as:
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𝐶𝑡 (𝑡) = 𝐵𝐹 ⋅ 𝐶𝑎 (𝑡)⨂𝑅(𝑡) = 𝐶𝑎 (𝑡) ⊗ 𝐵𝐹 ⋅ 𝑅(𝑡)
𝑡

𝐶𝑡 (𝑡) = ∫0 𝐶𝑎 (𝜏) ∙ [𝐵𝐹 ∙ 𝑅(𝑡 − 𝜏)]𝑑𝜏 … Equation 1-1
The impulse residue function R(t) describes the tissue time-concentration curve when the
1

arterial input function is 𝐵𝐹 𝛿(𝑡) or when an unit amount of contrast is introduced into the
arterial input of the tissue instantaneously. Empirically, it is the fraction of contrast that
remains in the tissue as a function of time after instantaneous contrast injection at the
arterial input. In practice, contrast is injected intravenously over a period of time (15-25
s) such that the arterial input function Ca(t) is dispersed in time instead of a delta function
𝛿(𝑡). Provided the image signal varies linearly with concentration and BF is stationary
(constant within the period of measurement), the tissue time-concentration curve Ct(t) is
by the convolution between the arterial input function Ca(t) and the impulse residue
function R(t) using the principle of linear superposition.
Below we discuss the technical aspects of DSC-MR, DCE-MR, and DCE-CT.

Table 1-2: Glossary of perfusion imaging parameters.
Terms

Definitions (units)

Blood flow (BF)

Flow rate of blood per unit mass or volume of tissue
(ml∙min∙100g-1 or ml∙min∙100ml-1).

Blood volume (BV)

Volume of ‘flowing’ blood within the vasculature per unit
mass or volume of tissue (ml∙100g-1 or ml∙100ml-1).

Extraction fraction (E)

Fraction of contrast that extravasates from the intravascular
space into the EES in the first pass through the vasculature

Initial Area Under the
Curve (iAUC)

A semi-quantitative measure of contrast enhancement used
in DCE-MR. It is related to the dose of contrast injected, the
blood volume, and permeability surface product of the BBB.

mAUCRH

The ratio between the iAUC and the final AUC from a DCEMR scan gives the AUCR. The histogram of AUCR of a
region is bimodal or skewed, the mean for the higher peak of
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this distribution is calculated to give the mAUCRH.
Mean transit time
(MTT)

Average time (s) for blood to traverse from the arterial to the
venous end of the vasculature.

Normalized BV (nBV)

BV of a region-of-interest normalized to the contralateral
normal brain. The normal appearing white matter is used for
normalization.

Normalized Maximum
Slope

A semi-quantitative estimation of BF. It is the maximum
slope of a tissue time-contrast enhancement curve
normalized by the maximum of the arterial time-contrast
enhancement curve.

Peak Height (PH)

A measure of maximum contrast enhancement from the
baseline signal during the first pass of contrast.

Normalized Peak
Height

PH of the tumour can be normalized to the contralateral
normal brain to give the normalized peak height.

Percent Recovery

It is the measure of how much signal has recovered from the
baseline signal after the first pass of contrast. It is a semiquantitative measure of microvascular leakage in DSC-MR.

Permeability

Unidirectional flux rate of contrast agent from the blood
plasma into the brain parenchyma (i.e. interstitial space)
normalized by the total surface area of capillaries per unit
mass of tissue. It is often estimated using the parameters
permeability-surface area product (PS) and transfer rate
constant (Ktrans).

Permeability-surface
area product (PS)

Product of permeability and total surface area of capillaries
per unit mass of tissue (ml∙min∙100g-1).

Efflux Rate constant
(kep)

Rate constant of contrast efflux rate from the brain
parenchyma back into the blood plasma (min-1).

Transfer Constant
(Ktrans)

Flow rate constant of contrast from the blood plasma to the
brain parenchyma (min-1).

Vp

Volume of ‘flowing’ blood within the vasculature per unit
mass or volume of tissue (ml∙100g-1 or unitless)

Extravascular volume
(ve)

Volume of extravascular extracellular space per unit volume
of tissue for contrast to distribute into (ml∙100g-1 or unitless).
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Abbreviations: EES, extravascular extracellular space; DCE-MR, dynamic contrastenhanced magnetic resonance; BBB, blood brain barrier; DSC-MR, dynamic
susceptibility-contrast magnetic resonance

1.8.1

Dynamic Susceptibility-Contrast Magnetic Resonance (DSCMR)
DSC-MR imaging measures signal change during the first passage of contrast

through the tissue vasculature when the contrast remains intravascular using a T2- or
T2*-weighted sequence. At high concentration (0.1 – 0.2 mmol/kg), the contrast agent
creates a susceptibility gradient in tissue that decreases T2* signal intensity. A temporal
resolution of 1 – 2 s is required because the minimum transit time of contrast agent in
brain tissue is a few seconds. A typical scan duration of 1 – 2 minutes is used. The
indicator dilution method is appropriate for calculating BF and BV in DSC-MR imaging
(104). DSC-MR assumes that the degree at which contrast is diluted in the blood is a
function of blood flow (BF) and blood volume (BV) and that contrast remains
intravascular during imaging. BV is estimated from the ratio of the areas under the tissue
time-concentration curve Ct(t) and the arterial time-concentration curve Ca(t). BF can be
solved by the deconvolution of Equation 1-1. DSC-MR assumes that the contrast agent
compartmentalizes in the intravascular space and does not leak into the brain
parenchyma. However, violation of this assumption can underestimate BV when high
leakage of contrast material occurs (105). This effect can be minimized by pre-saturating
the brain parenchyma with a pre-loading dose of contrast agent, dual echo sequence, or
post-processing mathematical correction (105,106).
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1.8.2

Dynamic Contrast-Enhanced Magnetic Resonance (DCEMR)
DCE-MR refers to the acquisition of serial MR images using a T1-weighted

sequence. The increase in T1 relaxation rate from corresponding increase in contrast
concentration is measured as an increase in signal intensity. DCE-MR scan duration is 5
– 10 min in order to measure the rate of extravasation of contrast from the intravascular
space into the extravascular extracellular space (EES) (i.e. PS or Ktrans). By assuming the
intravascular space and the EES as two well-mixed tissue compartments, the
compartmental model is used to estimate the rate of contrast transfer from the
intravascular space into the EES (107). This quantity is commonly called Ktrans and can
be solved using the following equation:
𝑡

𝐶𝑡 (𝑡) = 𝐵𝑉 ⋅ 𝐶𝑎 (𝑡) + 𝐾 𝑡𝑟𝑎𝑛𝑠 ∫0 𝐶𝑎 (𝑢)𝑒

−

𝐾𝑡𝑟𝑎𝑛𝑠
(𝑡−𝑢)
𝑣𝑒

𝑑𝑢… Equation 1-2

where ve is the volume of extravascular extracellular space per unit volume of tissue.
Ktrans is generally interpreted as a measure of tissue permeability (107). However, Ktrans is
the product between BF and extraction fraction (E). Thus, Ktrans should be used for
permeability interpretation with caution because either BF or E may be the dominating
factor. A temporal resolution of 5 – 10 s per image is commonly used to balance spatial
resolution, scan coverage, and signal-to-noise ratio, but it is too slow for the
measurements of BF and BV where a finer temporal resolution (1 – 2 s) is required (108).
However, techniques such as multi-channel parallel imaging and compressed sensing can
achieve a finer temporal resolution (109).

1.8.3

Dynamic Contrast-Enhanced Computed Tomography (DCECT)
DCE-CT refers to the acquisition of serial CT images to track the passage of a

bolus of iodinated contrast agent. The typical DCE-CT protocol takes 2 – 3 minutes, and
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it involves rapid acquisition of images (1 – 2 s per image) during the initial phase of
imaging (45 s) to capture the first pass of contrast for the calculation of BF and BV. A
second phase that involves less frequent acquisition (10 – 15 s per image) is required to
calculate PS or Ktrans (110). Both compartmental and distributed parameter models have
been used to calculate tracer kinetic parameters from DCE-CT images. The Johnson and
Wilson model (111) is an example of a distributed parameter model. An adiabatic
approximation to the Johnson and Wilson model allows the simultaneous determination
of BF, BV, and permeability-surface area product (PS) by giving a closed-form solution
to the impulse residue function R(t) (112). The R(t) is defined as:
1
𝑅(𝑡) = { −𝐵𝐹⋅𝐸(𝑡−𝐵𝑉)
𝐵𝐹
𝐸𝑒 𝑣𝑒

𝐵𝑉

0 < 𝑡 ≤ 𝐵𝐹
𝐵𝑉

… Equation 1-3

𝑡 > 𝐵𝐹

The extraction fraction E is calculated as:
𝑃𝑆

𝐸 = 1 − 𝑒 −𝐵𝐹 … Equation 1-4
The distributed parameter model enables the separation of BF and E; thus, enabling the
calculation of the permeability-surface area product (PS). It assumes a contrast
concentration gradient inside the intravascular space along the length of capillaries (110).
An advantage of the distributed parameter model is the determination of BF, BV, and PS
from a single perfusion scan.
The clinical use of DCE-CT was slow to progress initially due to its relatively
limited scan volume (2 – 4 cm coverage) and associated radiation dose (2 – 5 mSv) (113).
The advent of large multi-row detector technology enables the coverage of 16 cm of
anatomy (114). Shuttle mode imaging can also increase the scan coverage (115).
Reconstruction methods such as adaptive statistical iterative reconstruction technique
(116) and reducing the temporal resolution of image acquisition (≤ 3 s) in the first phase
(117) are effective ways to reduce radiation dose. Figure 1-3 shows maps of BF, BV, and
PS from a DCE-CT study of a patient with GBM. Table 1-3 summarizes and compares
the key aspects of DSC-MR, DCE-MR, and DCE-CT.
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Figure 1-3: Blood flow (BF), blood volume (BV), and permeability-surface area (PS)
product maps calculated from dynamic contrast-enhanced computed tomography
(DCE-CT) images of the same patient as Figure 1-2.

Table 1-3: Comparison of typical brain perfusion imaging techniques.
Parameter

DSC-MR

DCE-MR

DCE-CT

Typical contrast
agent

Gadopentetate
dimeglumine

Gadopentetate
dimeglumine

Iopamidol

Tracer kinetic
analysis
method

Indicator dilution theory

Compartmental model

Compartmental and
distributed parameter
models

Scan coverage

8 – 10 or 16 – 20 slices
covering the entire brain
(~ 10 cm)

16 – 32 slices covering
3 to 16 cm of anatomy

4, 8, and 16 cm
coverage with multidetector CT.
Shuttle mode imaging
can achieve whole
brain coverage

Molecular
weight of
contrast agent

938 g/mol
(0.938 kDa)

938 g/mol
(0.938 kDa)

777 g/mol
(0.777 kDa)

Typical
temporal
resolution

1–2s

5 – 10 s

First phase: 1 – 2 s
Second phase: ≤ 5 s for
Patlak analysis and 10
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– 15 s for Johnson and
Wilson model
Typical scan
duration

1 – 2 min

5 – 10 min

2 – 3 min

Source of signal

Decrease in T2* (or T2) of
surrounding water
molecules

Decrease in T1 of
surrounding water
molecules

Attenuation of x-ray by
iodinated contrast

Change in signal
intensity

Signal loss

Signal gain

Signal gain

Signal-tocontrast
concentration
relationship

R2 t   

Quantitative
Techniques

*

C  k  R2

1  S t  

ln 
TE  S 0  

*

Mostly relative

 1
1
 
 T 1 T 10
C
R1





Relative and absolute

Linear

Relative and Absolute

Abbreviations: DSC-MR, dynamic-susceptibility contrast magnetic resonance; DCE-MR,
dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced
computed tomography; ΔR2*, Change in relaxation rate; S(0), baseline signal intensity;
S(t), signal intensity at time t; R1, longitudinal relaxivity of the contrast agent; C,
concentration; Hct, hematocrit; k, proportionality constant that depends on the tissue,
contrast agent, field strength, and pulse sequence parameters.

1.8.4

Other Important Perfusion Imaging Techniques
Arterial spin labeling (ASL) is a promising technique that can measure BF in

brain tumours. ASL uses arterial blood water as an endogenous tracer by magnetically
labeling blood water that is proximal to the tissue of interest. ASL is a technology that is
gaining interest in neuro-oncology in recent years (118,119) since it does not require the
injection of exogenous contrast agent and it has no radiation dose. The ASL method
makes serial perfusion scans even more feasible for monitoring treatment response.
Tumour perfusion can also be investigated using nuclear medicine techniques.
Positron emission tomography (PET) using
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O-labeled water has been used in previous
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reports (120,121), and is considered to be the “gold standard” in quantitative perfusion
imaging. However, the need for an onsite cyclotron and the short half-life of
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O (2

minutes) limits its feasibility in the clinic. Limited spatial resolution is also a
disadvantage of PET when compared to CT and MR.

1.9 Literature Review of Perfusion Imaging
Here, we provide a review of the literature in perfusion imaging of malignant
gliomas. To comprehensively survey the literature, a PubMed search was performed from
January 2002 to May 2012 using the terms (‘glioma’ OR ‘glioblastoma’) AND
(‘perfusion imaging’, ‘dynamic contrast-enhanced’, ‘DCE’, ‘computed tomography’,
‘CT’, ‘dynamic susceptibility’, ‘DSC’, ‘magnetic resonance’, OR ‘MR’) to identify
relevant clinical studies. The search was limited to include studies that involved human
subjects and published in the English language. Preclinical studies, studies that evaluated
only low-grade gliomas, and studies with a sample size ≤ 5 patients were excluded.
We categorized each article according to the investigated application. Five key
areas were identified; they are 1) correlations with molecular and histopathologic
markers, 2) diagnostic efficacy of differentiating high grade from low grade gliomas, 3)
differentiation of malignant gliomas from other malignant lesions, 4) differentiation of
true progression from post-treatment effects, and 5) prediction of survival. Literature
search for applications 4 and 5 were extended to include studies published before January
2014. When considering articles that evaluated tumour grade, only articles that reported
the sensitivity and specificity to differentiate high and low grade gliomas were included.
The article selection process is summarized in Figure 1-4.
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Figure 1-4: Article selection flowchart according to the Preferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA) guidelines.

1.9.1

Correlation with Molecular and Histopathologic Markers
An understanding of the relationships between histopathologic markers and

perfusion imaging could justify the use of perfusion imaging as non-invasive surrogates
for these tissue assays (Table 1-4).

Table 1-4: Correlation of perfusion imaging parameters with histopathologic
markers.
Histopathologic
Markers

Tumour cellularity or
cell density

Techniques

Parameters

Correlation
coefficients (range)

References

DSC-MR

nBV

0.57

(122)

BF

0.498

DCE-CT

(123)
BV

0.482
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PS

0.409

DSC-MR

nBV

0.32 – 0.46

(122,124)

DCE-MR

nBV

0.821 – 0.896

(125,126)

BF

0.527

Microvessel density
(MVD)
DCE-CT

Microvessel area
(MVA)
Microvascular
cellular proliferation
(MVCP)

BV

0.649

DSC-MR

nBV

0.83

(124)

DSC-MR

nBV

nBV were higher in
the presence of
MVCP

(127)

DCE-CT

PS

0.647

(123)

nBV

nBV values
correlated with
VEGF expression

(128)

nBV

0.765 – 0.884

(125,126,129)

nBF

0.849

(129)

Ktrans

0.585

(130)

kep

0.765 – 0.871

(129,130)

ve

0.509

(130)

nBV

0.557

(129)

nBV

0.628 (marginal
significance)

nMTT

0.644 (marginal
significance)

nBV

0.66

DSC-MR
Vascular endothelial
growth factor (VEGF)
DCE-MR

Matrix
metalloproteinase-9
(MMP-9)

DCE-MR

Hypoxia inducible
factor 1-alpha (HIF1α)

DCE-MR

Ki-67

MIB-1

(123)

DSC-MR

DSC-MR

(131)

(132)

Abbreviations: DSC-MR, dynamic susceptibility-contrast magnetic resonance; DCE-MR,
dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced
computed tomography; nBV, normalized blood volume; BF, blood flow; PS,
permeability-surface area product; nBF, normalized blood flow; Ktrans, transfer constant;
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kep, efflux rate constant; ve, volume of extravascular extracellular space per unit volume
of tissue; nMTT, normalized mean transit time.

Microvessel density (MVD) is a histopathologic measure of angiogenesis and a
prognosticator of survival (133). Correlations between MVD and BV were weak for
DSC-MR (< 0.4), moderate for DCE-CT (< 0.7), and strong for DCE-MR (> 0.8).
Microvessel area (MVA) is a more useful predictor of survival than MVD because MVD
cannot characterize the morphological complexity of tumour blood vessels, which are
often tortuous and different in sizes (134). Tumour normalized BV (nBV) showed a
stronger correlation with MVA than MVD (r = 0.83 and 0.32, respectively; p ≤ 0.05)
(124). Moreover, nBV and MVA correlated with overall survival (OS) while MVD did
not. Microvascular cellular proliferation and VEGF expression also showed correlations
with perfusion imaging parameters (Table 1-4). Together, these studies suggest that
perfusion imaging-based measure of BV may be a surrogate marker of the degree of
angiogenesis, which in turn is a predictor of patient survival.
One DCE-CT study explored the associations between the expression of genes
that regulate angiogenesis in GBM and different DCE-CT parameters (135). Nineteen
and nine genes showed significant associations with PS and BV, respectively. BV and/or
PS correlated positively with some pro-angiogenic genes (e.g. KDR (VEGFR-2) and
HIF1A) and negatively with some anti-angiogenic genes (e.g. VASH2 and C3). This
study suggests a molecular genetic basis for PS and BV as candidate imaging biomarkers.
Angiogenesis is crucial for the proliferation and invasion of malignant gliomas,
and it was demonstrated that MVD correlated with tumour proliferation (136). For this
reason, studies have investigated the associations between perfusion imaging parameters
and proliferative potential of malignant gliomas. Tumour cellularity or cell density is a
histologic method to quantify the number of tumour cells. Moderate correlations between
DSC-MR or DCE-CT parameters and tumour cellularity (0.4 < r < 0.6) were reported
(122,123) (Table 1-4). However, cell density cannot distinguish between proliferative,
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apoptotic, and senescence cells. Ki-67 or MIB-1 are cellular markers of proliferation, and
moderate correlations with DSC-MR parameters have been reported (r > 0.6) (131,132).

1.9.2

Differentiation of Tumour Grade
Stereotactic biopsy of tumour specimens for grading can be prone to sampling

error. In a study that compared biopsied specimens with surgically resected specimens, as
much as 60% of anaplastic astrocytoma (WHO grade III) were upgraded to GBM (137).
Imaging

techniques

that

can

determine

tumour

aggressiveness

can

provide

complementary information to establish grade and guide biopsy to sample the most
anaplastic part of the tumour. Functional image-guidance can potentially improve the
accuracy of diagnosis.
We found 20 studies that reported the sensitivities and specificities of using
perfusion imaging to differentiate high versus low grade gliomas (Table 1-5). The
sensitivities ranged from 68 to 100% and specificities ranged from 40 to 100% (138–
157). Different thresholds were used for differentiating high from low grade gliomas.
Thus, while perfusion imaging showed promise for grading, standardization of imaging
protocols and consensus thresholds for differentiating tumour grade need to be
established.
Not all malignant gliomas are enhancing on post-gadolinium T1-weighted MR
images. About 9% of malignant gliomas lack contrast-enhancement and can be mistaken
as low-grade gliomas that do not enhance (158). Perfusion imaging can be an important
tool in this regard. Using DSC-MR, patients with non-enhancing anaplastic gliomas
(WHO grade III) had significantly higher nBV than those with low-grade astrocytomas
(WHO grade II) (159). In a study using DCE-CT, nBV demonstrated a sensitivity and
specificity of 90.9% and 83.3% for differentiating non-enhancing grade III vs. II gliomas
(157).

26

Table 1-5: Summary of sensitivities and specificities of perfusion imaging in differentiating high grade versus low grade
gliomas.
Modality Parameter

Median sensitivity and
specificity (ranges) (%)

References‡

nBV

Sensitivity: 94 (67 – 100)
Specificity: 86 (50 – 100)

(138–151)

nBF

Sensitivity: 86 (73 – 100)
Specificity: 95 (91 – 100)

(138,142)

Ktrans

Sensitivity: 89 (89 – 89)
Specificity: 79 (75 – 82)

(152,153)

*

DSC-MR

DCE-MR

Vp

Sensitivity: 68 (N/A)
Specificity: 89 (N/A)

ve

Sensitivity: 82 (N/A)
Specificity: 94 (N/A)

BV

Sensitivity: 89 (83 – 100)
Specificity: 92 (75 – 100)

(154–157)

Sensitivity: 83 (71 – 90)
Specificity: 94 (82 – 100)

(155–157)

†

DCE-CT

†

BF

Ktrans

Sensitivity: 97 (N/A)
Specificity: 100 (N/A)

Key points from the literature



Regions-of-interest are usually placed in visually contrastenhancing regions only



BV and BF values are generally higher in high-grade
gliomas than low-grade gliomas.



Permeability values (i.e. PS and Ktrans) are higher in highgrade gliomas than low grade gliomas.



Oligodendrogliomas may demonstrate foci with high blood
volume regardless of tumour grade.



Optimal thresholds for differentiating high grade versus
low grade gliomas have not been tested in a prospective
study



Standardization of imaging protocol is need to reduce the
variability in sensitivity and specificity observed in studies

(153)

(152)

(156)
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Modality Parameter

Median sensitivity and
specificity (ranges) (%)

References‡

PS

Sensitivity: 100 (N/A)
Specificity: 83 (N/A)

(154)

MTT

Sensitivity: 93 (N/A)
Specificity: 40 (N/A)

(155)

Key points from the literature

Abbreviations: nBV, normalized blood volume; nBF, normalized blood flow; Ktrans, transfer constant between blood plasma and
extravascular extracellular space; Vp, volume of ‘flowing’ blood within the vasculature per unit mass; ve, volume of extravascular
extracellular space per unit volume of tissue; PS, permeability-surface area product; MTT, mean transit time; DSC-MR, dynamicsusceptibility contrast magnetic resonance; DCE-MR, dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrastenhanced computed tomography; N/A, not applicable.

*

nBV refers to mean or maximum nBV

†

BV and BF refers to absolute or normalized BV and BF, respectively
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Almost all low-grade gliomas eventually progress to high-grade gliomas at an
unpredictable time. In a cohort of low-grade glioma patients that received repeated DSCMR, a continuous increase in nBV was found in those with malignant transformation up
to the point when contrast-enhancement became apparent on post-gadolinium T1weighted images. The nBV for transformers significantly increased to 5.36 at the time of
transformation (p < 0.05), while nBV remained stable and increased to only 1.52 in nontransformers (p > 0.05) (160). Together, these studies suggest perfusion imaging is a
useful method for grading gliomas even in cases where the tumours lack contrastenhancement, and can be an important tool for active surveillance of low grade gliomas.
Perfusion imaging differentiation of tumour grade in oligodendroglial tumours
should be interpreted with caution. Oligodendroglial tumours can have higher BV than
astrocytic tumours irrespective of tumour grade (161) while high grade oligodendroglial
tumours may or may not have higher BV than low grade oligodendroglial tumours
(161,162). Thus, perfusion imaging of oligodendroglial tumours should be considered
separately from astrocytic tumours, and perfusion imaging alone is not reliable for
differentiating oligodendroglial tumour grade.

1.9.3

Differentiation of Malignant Brain Lesions
Solitary brain metastases with no history of primary cancer are found in

approximately 15% of patients and may appear similar to primary malignant gliomas on
MR images (163). We found 18 studies that used perfusion imaging to differentiate brain
metastases from malignant gliomas. Two factors should be considered when using
perfusion imaging to differentiate these two entities. Firstly, current evidence suggests
that BV in the contrast-enhancing lesion of metastasis depends on the site of origin.
Metastases from melanoma and renal carcinoma are reported to have higher BV than
malignant gliomas (164). Studies that considered different sites of origin as one entity (or
those that did not mention the sites of origin) showed that BV of the enhancing metastatic
lesions were either similar (165–168) or lower (141,169,170) than malignant gliomas. For
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example, nBV in studies with mostly lung and breast cancer metastases may be similar to
(164,171) or lower than malignant gliomas (141,169). Together, these studies suggest
that the differentiation of brain metastasis from malignant glioma based on BV of the
contrast-enhancing lesion alone is challenging.
Secondly, BV in the non-enhancing lesion shows more promise for distinguishing
metastases from primary malignant gliomas. The non-enhancing lesion is the
hyperintense region on T2 or FLAIR images outside the contrast-enhancing lesion. BV in
the non-enhancing lesion of brain metastases were lower than that of malignant gliomas
(141,166,170–177). T2/FLAIR changes primarily represent edema without tumour
infiltration in brain metastases (178). In contrast, the high BV in the non-enhancing
lesion of malignant gliomas can be attributed to their aggressive and infiltrative growth,
which often extends into the T2-hyperintense region. The median sensitivity and
specificity for distinguishing the two entities using non-enhancing lesion nBV were 90%
(range, 77 – 100%) and 95% (64 – 100%), respectively (141,169,170). In contrast, the
median sensitivity and specificity for contrast-enhancing lesion nBV were 87% (80 –
91%) and 72% (64 – 88%), respectively (141,171,174–176) .
Perfusion imaging has also been used to differentiate malignant gliomas from
other primary brain tumours. These included differentiating primary lymphomas from
malignant gliomas (165,168,176,177,179–183), meningiomas from malignant gliomas
(165,167,184), hemangioblastomas from malignant gliomas (165), and schwannomas
from malignant gliomas (165). A few studies have used perfusion imaging to differentiate
subtypes of primary brain tumours (161,185–189). Grade II and III oligodendroglial
tumours showed higher nBV than both grade II and III oligoastrocytic and astrocytic
tumours, and oligoastrocytic tumours showed higher maximum nBV than astrocytic
tumours (161). A sensitivity and specificity of 100 and 88% were found when nBV was
used to differentiate grade II and III oligodendroglial tumours from astrocytic tumours.
Although there were differences in BV between different types of primary brain tumours,
the number of brain tumour types make this method of differentiation impractical.
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1.9.4

Differentiation of Progression from Post-treatment Effects
A change in the size of the contrast-enhancing tumour is used as a radiologic

measure of progression, but it can be confounded by other causes of contrast
enhancement. Pseudoprogression and treatment-induced necrosis (TIN) are posttreatment scenarios with a better prognosis than true progression, but their changes in
contrast enhancement can be indistinguishable from progression. Erroneous diagnosis of
pseudoprogression or TIN as tumour progression can lead to unnecessary treatment or
premature abandonment of treatment while the opposite scenario will delay treatment.
Pseudoprogression occurs in 20 – 30% of malignant glioma patients treated with
chemoirradiation and manifests as a transient increase in tumour contrast-enhancement at
one to three months post-treatment that eventually subsides (92,190,191). Although its
pathophysiology remains unclear, chemoirradiation is believed to induce a transient local
inflammatory reaction, edema and increased vessel permeability, which manifests as
increased contrast-enhancement (192). Using DSC-MR, true progression showed a higher
maximum nBV than pseudoprogression when confirmed by radiologic and clinical
follow-ups (sensitivity and specificity of 81.5% and 77.8%, respectively) (191,193).
Another study showed that both nBV and normalized peak height (definition in Table
1-2) could distinguish pseudoprogression from progression with sensitivities and
specificities ≥ 75% (194). Histogram analysis of nBV to characterize percent changes in
nBV skewness and kurtosis is also a potential biomarker to differentiate
pseudoprogression from true progression (195).
In a prospective study, a decrease in nBV at week three of chemoirradiation was
associated with a higher risk of early progression (190). It is unclear why a decrease in
nBV during chemoirradiation is associated with progression (190) while a higher nBV is
found at the time of progression in other studies (191,193). These results suggest that the
vascular response to chemoirradiation is complex, and the time of imaging must be
considered when using perfusion imaging to distinguish between tumour progression and
pseudoprogression.
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TIN occurs three to 12 months after radiotherapy in 3 – 24% of patients (192).
Histopathologic confirmation of necrosis and recurrence were available in some or all of
the patients in each study. Table 1-6 summarizes the performance of 12 perfusion
imaging studies for differentiating TIN from progression (118,196–206). Radiationinduced necrosis and pseudoprogression were collectively defined as radiation-induced
injury in eight DSC-MR studies (196,207–213). Mean and maximum nBV were reported
to differentiate radiation-induced injury from true progression with sensitivities and
specificities ranging from 86 – 100% and 80 – 100%, respectively (207–213). Radiationinduced injury and true progression often co-exist in patients. Hu et al. showed that DSCMR was able to estimate the fractional tumour burden (i.e. progression) and posttreatment effect (i.e. radiation-induced injury) within the same MR contrast-enhancing
lesion (213). This fractional tumour burden strongly correlated with the histologic tumour
fraction obtained from stereotactic biopsy (r = 0.82, P < 0.0001) and correlated with the
OS (P < 0.02). These results demonstrate that DSC-MR may be a useful clinical tool to
differentiate progression from post-treatment effects.

Table 1-6: Differentiation between treatment-induced necrosis and true progression.
Modality

Parameter
*

DSC-MR

nBV

Sensitivity and specificity ranges
(%)
Sensitivity: 67 – 100%
Specificity: 70 – 100%

References†

(118,196–200)

% Recovery

Sensitivity: 78%
Specificity: 76%

(198)

Peak Height

Sensitivity: 89%
Specificity: 81%

(198)

Ktrans

Sensitivity: 100%
Specificity: 83%

(202)

iAUC

Sensitivity: 71 – 85%
Specificity: 71 – 78%

DCE-MR
(201,202)
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mAUCRH

Sensitivity: 94%
Specificity: 88%

(203)

Normalized
maximum slope

Sensitivity: 95%
Specificity: 78%

(201)

BV

Sensitivity: 100%
Specificity: 100%

(204)

BF

Sensitivity: 94%
Specificity: 88%

(206)

BV

Sensitivity: 82 – 83%
Specificity: 90 – 100%

PS

Sensitivity: 82%
Specificity: 82%

(205)

MTT

Sensitivity: 94%
Specificity: 75%

(206)

(205,206)

DCE-CT

Abbreviations: DSC-MR, dynamic susceptibility-contrast magnetic resonance; DCE-MR,
dynamic contrast-enhanced magnetic resonance; DCE-CT, dynamic contrast-enhanced
computed tomography; nBV, normalized blood volume; Ktrans, transfer constant between
blood plasma and extravascular extracellular space; iAUC, initial area under curve;
mAUCRH, see Table 1-2 for definition; BF, blood flow; PS, permeability-surface area
product; MTT, mean transit time.
*

nBV refers to mean or maximum nBV

1.9.5

Survival after Radiotherapy and Chemotherapy
The value of perfusion imaging in predicting progression-free survival (PFS) and

OS has been investigated in numerous studies (124,130,140,148,214–237). The
interpretation of perfusion imaging data for predictive survival depends on treatment
regimen and imaging schedule. Three perfusion imaging schedules for predicting
outcomes have been reported; they are 1) pre-treatment, 2) pre-treatment + midtreatment, and 3) pre-treatment + post-treatment.
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When pre-chemoirradiation DSC-MR images were considered, a higher mean and
maximum nBV were associated with poor PFS and OS for gliomas of all grades
(140,148,216,221–224,228,235,236). This is also true for gliomas of the same grade. The
2-year OS rate for grade III astrocytomas was significantly lower for patients with
maximum nBV > 2.3 (33% vs. 100%, P < 0.01), and it was also lower for GBM (5% vs.
25%, P = 0.013) (221). Using DCE-CT, a combination of high BV and PS was associated
with poor OS for grade III and IV gliomas and grade IV gliomas alone (232,233). In
patients with GBM, kep values ≤ 1.2, between 1.21 – 2.0, and > 2.0 min-1 had 1-year OS
rate of 59%, 33%, and 15%, respectively (P value was not reported) (130). These studies
suggest that pre-treatment BV, PS, and kep were associated with more aggressive
phenotypes that conferred poor survival.
The prognostic value of comparing pre- and mid-radiotherapy perfusion imaging
parameters have been investigated (215,219,220). Based on parametric response map
analysis, a decrease in tumour BV and blood flow (BF) at one and three weeks into
chemoirradiation were predictive of poor OS (219,220). Specifically, patients with >
6.8% of tumour volume showing a decrease in nBV had shorter OS than those with ≤
6.8% of tumour volume showing a decrease in nBV (median OS = 7.1 and 20.4 months,
respectively; P = 0.001) (219). A drop in BV during treatment suggest increased tumour
hypoxia leading to resistance to chemoirradiation. These studies suggest DSC-MR can
potentially identify patients with poor survival even before the completion of
chemoirradiation.
Tumour perfusion after the completion of chemoirradiation and its association
with survival have also been investigated (225–227,231,237). An increase in maximum
nBF between baseline and follow-up (Hazard ratio [HR] = 2.67, P = 0.010) was a better
prognosticator of shorter PFS than an increase in tumour diameter (HR = 1.14, p = 0.049)
(231). At one month post-radiotherapy, Mangla et al. showed that an increase in nBV was
predictive of poor 1-year OS (sensitivity = 90% and specificity = 69%) while tumour size
was not (227). One study showed that perfusion imaging was not predictive of survival
while T1 and T2-weighted tumour diameters were (225). Using Ferumoxytol as the
contrast agent, post-radiotherapy tumour nBV predicted patients with longer OS (P <
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0.001) (237). In the non-enhancing lesion, Li et al. showed that a higher median nBV
immediately after radiation was associated with shorter PFS (p = 0.026) (226).
In summary, a high BV before and after chemoirradiation and a decrease in BV
during chemoirradiation were associated with poor survival. A high BV before and after
treatment is characteristic of tumour growth and progression, while a decrease in BV
during treatment could be indicative of tumour hypoxia.

1.9.6

Survival After Anti-angiogenic Therapies
Radiologic assessment of response to anti-angiogenic agents, especially those that

target VEGF, should be interpreted with caution because a drop in contrast-enhancement
is not necessarily indicative of true response (i.e. pseudoresponse) (92). Batchelor et al.
showed that patients treated with Cediranib demonstrated decreased gadolinium
enhancement as early as one day after the initiation of treatment despite considerable
variability in tumour response (238). Given the vascular effects of anti-angiogenic agents,
perfusion imaging could play an important role in assessing response to these agents.
For recurrent GBM, high nBV and Ktrans prior to anti-VEGF monotherapy or in
combination with Temozolomide were associated with poor survival (239,240). Tumour
BF (238), nBV (238,241), Ktrans (238,240,242–246), and ve (238,242,243,247) decreased
shortly after the initiation of Bevacizumab or Cediranib. In the non-enhancing lesion,
nBV could also decrease after Bevacizumab treatment suggesting an anti-edema effect
(statistical significance was not reported) (248).
There is no consensus on whether a decrease in these parameters is a positive
prognosticator. A decrease in Ktrans and nBV after Bevacizumab treatment did not show a
significant association with PFS or OS in some studies (239,240,246). In another study, a
decrease in tumour subvolume with nBV > 1.00 after Bevacizumab treatment was
associated with longer time-to-progression (229). A reduction in Ktrans after Cediranib
treatment was associated with improved PFS and OS (244). A moderate correlation
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(Spearman’s ρ = 0.58, P = 0.036) between OS and Ktrans at 1 week after stereotactic
radiosurgery and Bevacizumab was reported in patients with recurrent malignant gliomas
(234).
The inconsistent relationships between perfusion imaging parameters and survival
suggest that not all patients responded equally to anti-angiogenic agents. Sorensen et al.
showed that 25% of patients with recurrent GBM treated with Cediranib exhibited
elevated perfusion, and these patients had higher PFS and OS than those with stable or
decreased perfusion (230,238,244). This was demonstrated again in patients with newly
diagnosed GBM that were treated with radiotherapy, Temozolomide, and Cediranib.
Patients with increased perfusion had a significantly longer median OS than patients with
decreased perfusion (OS = 504 vs. 321 days; log-rank P < 0.05) (249). Increased
perfusion was also associated with improved tumour oxygenation, which could
potentially improve the sensitization of tumour cells to chemoirradiation and enhance the
delivery of Temozolomide to the tumour. In a study involving patients with recurrent
malignant gliomas, independent component analysis of DSC-MR images was used to
characterize the extent of abnormal vasculature before and after Bevacizumab treatment.
A decrease in the arterio-venous overlap (i.e. a decrease of abnormal vasculature) was
associated with longer OS in these patients (P < 0.04), whereas a change in the tumour
volume and nBV was not predictive of OS (250). These results suggest that perfusion
imaging may be a tool for selecting the appropriate patients for anti-angiogenic therapies.

1.9.7

Future of Perfusion Imaging
Our review reflected the results from more than 6500 brain tumour patients

scanned using CT or MR perfusion. These studies were primarily conducted in small
cohorts of patients (median N = 31 patients) in a research setting. Different perfusion
imaging protocols were used, and these variations could have led to uncertainties in the
measurements of different perfusion imaging parameters (117,251). Standardization of
imaging protocol is very important for incorporating perfusion imaging into prospective
multi-institutional trials (252). In addition, different perfusion imaging software packages
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were used in these studies. It has been shown that BF and BV values calculated from
different commercial software packages can deviate from the true values (253). The
uncertainties in the acquisition and analysis of these perfusion imaging studies make
optimization and standardization difficult.
In a clinical trial, the imaging protocol should be consistent across the study
population. The software and version used to calculate tumour perfusion parameters
should also be consistent and reported. Quality control should be performed to ensure
consistency in image quality. For example, the Radiation Therapy Oncology Group
(RTOG) 0825 trial comparing “radiation + Temozolomide” versus “radiation +
Temozolomide + Bevacizumab” is incorporating DSC-MRI and DCE-MRI to study these
patients. Participating sites must be qualified through the American College of Radiology
Imaging Network (ACRIN). The participating site must perform all advanced MR (e.g.
perfusion MR) scans following the protocol-specific parameters, and one set of test MR
images acquired from the designated MR scanner must be approved by ACRIN. This
study will yield valuable information on the value of serial perfusion imaging.
Our literature review on perfusion imaging showed that perfusion changes in
response to chemoirradiation and in combination with anti-angiogenic therapies are
complex. Optimization and standardization of image acquisition and analysis can help
facilitate the implementation of perfusion imaging in clinical settings. Serial imaging of
perfusion changes in response to treatment will improve the understanding of the effect
of treatment on tumour hemodynamics, and determine the optimal time for evaluating
response and prognosis in patients.

1.10 Animal Models of Malignant Glioma
Animal models of brain tumours play very important roles in understanding the
pathophysiology cancer, and in evaluating the safety and efficacy of treatments. There are
three general categories of brain tumour models: 1) xenograft models, 2) chemically
induced syngeneic models, and 3) genetically engineered mouse models (254). Rat
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models have several advantages over mouse models. The rat brain is about three times
larger than the mouse brain (1200 vs. 400 mg, respectively) (255). This allows more
precise implantation of tumour cells in rat brains and stereotactic radiosurgery of
tumours. A larger brain also permits a longer time period for tumour growth before death,
and better visualization and localization of the tumour using a variety of imaging
modalities. In addition, there are more in vitro and in vivo studies of rat brain tumours
than mouse brain tumours (255).
Xenograft tumour models refer to the growth of human brain tumours within the
brains of immunodeficient rats. For example, the U87MG cell line is a commonly used
xenograft GBM model. These models exhibit some features of human GBMs, including
the expression of mutated genes and display some levels of angiogenesis. However, they
do not display many characteristics that are typical in human GBM. For instance, growth
patterns are often circumscribed with limited single cell infiltration that are not as
extensive as spontaneous human GBM (256,257). Necrosis and microvascular
abnormalities, which are typical in human GBM, are also limited or absent in many
human cell-derived xenografts (254,256,257).
Chemically induced syngeneic rat models have been used extensively since the
1970s (255). Popular examples include C6, 9L, BT4C, F98, RT-2, and CNS-1 gliomas
(255). The C6 glioma model was created by administering methylnitrosourea to rats
(258,259). It was morphologically similar to GBM, and showed overexpression of many
genes that are also overexpressed in human gliomas. This model has been widely used to
evaluate the safety and efficacy of a variety of treatments including radiotherapy (260–
262), chemotherapy (263,264), and anti-angiogenic therapy (265,266). Chemically
induced syngeneic models can grow in immunocompetent rats; thus, spontaneous tumour
rejection is a drawback. A previous report showed that 11% of rats survived after
implantation of C6 glioma cells (267). Another drawback of chemically induced
syngeneic models is their growth patterns. For example, both C6 and 9L tumour models
demonstrate circumscribed masses as opposed to the highly infiltrative growth of human
gliomas (255). Despite these drawbacks, the C6 model remains attractive because it is
useful for the study of glioblastoma growth, angiogenesis, and development of new
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therapies (266). The C6 glioma model is used in the preclinical work presented in this
thesis.

1.11 Research Goals and Objectives
The work presented in this thesis is focused on two major goals: 1) improving
measurements of DCE-CT parameters, and 2) using DCE-CT to assess treatment
response in malignant gliomas. This was accomplished by achieving the following
objectives which span the spectrum from technical optimization to preclinical imaging to
pilot clinical studies:
1. To improve the measurements of BF, BV, and PS by evaluating the effect of
DCE-CT scan duration on these measurements.
2. To reduce measurement errors of BF, BV, and PS by filtering DCE-CT images
using principal component analysis.
3. To show that DCE-CT can be used as a potential early imaging biomarker of
response to stereotactic radiosurgery in the C6 malignant rat glioma model.
4. To assess the relationship between DCE-CT imaging measurements and eventual
sites of tumour progression in patients with malignant gliomas.
5. To correlate patient survival with DCE-CT and MR volumetric imaging
measurements.
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1.12 Thesis Outline
1.12.1

The Effect of Scan Duration on the Measurement of DCE-CT
Parameters (Chapter 2)

Scan duration is a key factor that influences the measurement of different
perfusion parameters. We investigated the effect of scan duration on BF, BV, and PS
measurements in human gliomas and evaluated the systematic and random errors
associated with reduced scan durations. This chapter is adapted from the published paper
entitled “The effect of scan duration on the measurement of perfusion parameters in CT
perfusion studies of brain tumours”, published in Academic Radiology 20(1): 69-65
(2013) by Yeung TPC, Yartsev S, Bauman G, He W, Fainardi E, and Lee TY.

1.12.2

Improving

Quantitative

DCE-CT

Measurements

Using

Principal Component Analysis (Chapter 3)
The measurements BF, BV, and PS are affected by DCE-CT image contrast-tonoise ratio (CNR). We validated whether principal component analysis (PCA) filtering
can improve the accuracy and precision of these measurements by using a digitally
designed CT phantom. We then evaluated the improvement in image CNR and changes
in tumour BF, BV, and PS after filtering DCE-CT images of tumour bearing rats. This
chapter is adapted from the published paper entitled “Improving quantitative CT
perfusion parameter measurements using principal component analysis”, published in
Academic Radiology 21(5): 624-632 (2014) by Yeung TPC, Dekaban M, De Haan N,
Morrison L, Hoffman L, Bureau Y, Chen X, Yartsev S, Bauman G, and Lee TY.
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1.12.3

DCE-CT Imaging as an Early Biomarker of Differential
Response to Stereotactic Radiosurgery (Chapter 4)

Stereotactic radiosurgery delivers radiation in one or few large dose fractions of 8
to 30 Gy that can result in vascular damage. Timely and accurate assessment of tumour
response is crucial for treatment modification if no response to radiation is detected. This
chapter evaluated serial vascular changes following stereotactic radiosurgery using DCECT, and determined whether DCE-CT can be an early predictor of survival. This chapter
is based on the paper entitled “CT perfusion imaging as an early biomarker of differential
response to stereotactic radiosurgery”, which will be submitted to the journal PLOS ONE
in July 2014 by Yeung TPC, Kurdi M, Wang Y, Al-Khazraji B, Morrison L, Hoffman L,
Jackson D, Crukley C, Lee TY, Bauman G, and Yartsev S.

1.12.4

Relationship of DCE-CT and PET to Tumour Progression in
Malignant Glioma (Chapter 5)

Over 80% of malignant gliomas progress within 2 cm of the irradiated volume
after chemoirradiation. Although an increase in the size of the contrast-enhancing lesion
is one of the criteria for diagnosing progression, early changes in contrast-enhancement
during and after radiotherapy lack utility in identifying active tumour sites that are likely
to persist and progress. This chapter investigates whether multiparametric imaging with
DCE-CT and 18F-Flurodeoxyglucose PET can identify tumour sites that are likely to
correlate to the eventual sites of tumour progression. The chapter is based on the
published paper entitled “Relationship of computed tomography perfusion and positron
emission tomography to tumour progression in malignant glioma”, published in the
Journal of Medical Radiation Sciences 61(1): 4-13 (2014) by Yeung TPC, Yartsev S, Lee
TY, Wong E, He W, Fisher B, VanderSpek L, Macdonald D, and Bauman G.
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1.12.5

Treatment Monitoring of Malignant gliomas in using DCE-CT
and MR (Chapter 6)

Using DCE-CT, this is the first study to evaluate serial changes in tumour BF,
BV, and PS in the contrast-enhancing lesion and the non-enhancing lesion of patients
with malignant gliomas for up to a year after radiotherapy. This study also tested the
predictive values of these data in relation to OS. The chapter is based on the paper
entitled “Treatment monitoring in high-grade gliomas: A serial CT perfusion and MR
study”, which will be submitted to the Journal of Neuro-Oncology in July 2014 by Yeung
TPC, Wang Y, Urbini B, Yartsev S, Bauman G, Lee TY, Fainardi E, and The Project of
Emilia-Romagna region on Neuro-Oncology (PERNO) study group.

1.12.6

Conclusion and Future Work (Chapter 7)

In the final chapter, major findings of this thesis are summarized, and their
clinical and experimental relevance are discussed. Future investigations pertaining to
perfusion imaging of brain tumours are proposed.
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Chapter 2

2

The Effect of Scan Duration on the Measurement of
Perfusion Parameters in CT Perfusion Studies of Brain
Tumours
This chapter is adapted from the research article, “The effect of scan duration on

the measurement of perfusion parameters in CT perfusion studies of brain tumours”
published in Academic Radiology, 2013;20(1):59-65 by Yeung TPC, Yartsev S, Bauman
G, He W, Fainardi E, Lee TY.

2.1 Introduction
Malignant gliomas are highly aggressive brain tumours that are characterized by
increased vascularity with immature and highly permeable blood vessels (1). Given that
blood-brain barrier disruption and neovascularity play an essential role in the progression
of malignant gliomas, recent studies have investigated the use of perfusion imaging for
evaluating brain tumours. Blood flow (BF), blood volume (BV), and permeability–
surface area product (PS) obtained from computed tomography (CT) perfusion studies
have been demonstrated to be useful in differentiating glioma grade (2–4) and
distinguishing treatment-induced necrosis from recurrent or progressive tumours (5). CT
perfusion parameters have also demonstrated correlations with microvascular cellular
proliferation (6) and proangiogenic gene expressions (7).
Although CT perfusion may be helpful in providing important physiologic
information for evaluating brain tumours, there is no consensus regarding the optimal
scan protocol. A scan duration of ≥2 minutes has been suggested for accurate calculation
of tumour permeability (8,9), but scan durations in the range of 45 to 199 seconds have
been used to evaluate tumour perfusion parameters for brain and other tumour sites
(7,10). For example, a 65-second scan was recommended when the Johnson-Wilson
model was used for the calculation of permeability (ie, PS) in colorectal cancer (11),
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while a scan duration of ≥40 seconds was recommended when the Patlak method was
used to calculate permeability (ie, Ktrans, transfer constant) in lung cancer (12).
Given that scan duration is a key factor influencing perfusion measurements, it
would be beneficial to investigate the effect of scan duration on CT perfusion studies of
brain tumours. Standardizing a CT perfusion protocol for diagnostic and research settings
could facilitate comparison among different studies. We evaluated the effect of scan
duration (≤150 seconds) on perfusion parameter measurements in human gliomas and
evaluated the systematic and random errors associated with different reduced scan
durations (<150 seconds) relative to the values obtained from the 150-second scans.

2.2 Materials and Methods

2.2.1

CT Perfusion Imaging
The local research ethics boards approved this study, and all patients provided

written informed consent prior to imaging. Patients (n = 14) with histopathologically
confirmed malignant glioma (World Health Organization grade III and IV) underwent CT
perfusion imaging. Eight patients were scanned on a hybrid positron emission
tomography/CT scanner (Discovery VCT; GE Healthcare, Waukesha, WI) with a
nonionic contrast bolus (Omnipaque, 300 mg iodine/mL, 60–70 mL; GE Healthcare,
Princeton, NJ), and six patients were scanned on a CT scanner (GE LightSpeed VCT; GE
Healthcare, Waukesha, WI) with a nonionic contrast bolus (Iomeron, 350 mg iodine/mL,
40 mL; Bracco Imaging Scandinavia, Göteborg, Sweden). A two-phase CT perfusion
scan, guided by a prior noncontrast CT scan that identified eight 5-mm sections to
maximally cover the tumour, was performed for each patient. The bolus of contrast was
injected into the antecubital vein at a rate of 2 to 4 mL/s at 3 to 5 seconds after the first
phase started. The preselected brain sections were scanned for 45 seconds at 1-second
intervals during the first phase and for a period of 105 seconds at 15-second interval
during the second phase. A tube current of 190 mA was used for the hybrid positron
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emission tomography/CT scanner, and 100 mA was used for the CT scanner. All patients
were scanned at 80 kVp with a 25-cm field of view.

2.2.2

Image Analysis
The 150-second human CT perfusion studies were truncated to scan times of 120,

90, and 60 seconds to simulate the effect of shorter scans. Fifty-six CT perfusion studies
were analyzed using the prototype version of CT Perfusion 4D (GE Healthcare,
Waukesha, WI), which is based on the Johnson-Wilson model and is insensitive to the
delay between arterial and tissue time-attenuation curve (TAC) to generate maps of BF,
BV, and PS.
For each patient, the arterial and venous regions of interest (ROIs) were
automatically chosen by the software from the 150-second study, and the same ROIs
were used for the truncated studies to minimize estimated parameter variability due to
differences in arterial and venous TACs. The arterial and venous ROIs were usually
found in one of the anterior cerebral arteries and the posterior superior sagittal sinus,
respectively. Partial volume averaging of the arterial TAC was corrected using the
venous TAC as a reference (8). Tissue TACs were measured from 2 × 2 pixel blocks of
CT images. Parametric maps of BF, BV, and PS were calculated by deconvolving the
arterial TAC with each tissue TAC using the Johnson-Wilson model (8). The generation
of parametric maps was repeated for different scan durations by using the same arterial
and venous ROIs for each patient. ROIs of 15 mm2 were randomly placed in the normal
white and gray matter and contrast-enhanced tumour rim and nonenhancing tumour core
to measure BF, BV, and PS (20 ROIs per tissue).

2.2.3

Measurement Errors of Perfusion Parameters Due to
Truncation
We used the systematic and random errors to evaluate the mean and standard

deviation of measurement errors associated with a reduced scan time relative to the 150-
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second scan time, respectively. The differences between parameter values obtained from
the original study and the truncated study in the same ROI of the same tissue type were
accepted as the measurement error. The mean and standard deviation of measurement
errors were, respectively, the systematic and random errors for each tissue type for each
patient.
We also used the percentage error to examine whether the differences in
parameter values associated with a reduced scan time were clinically meaningful. The
percentage error for each parameter in each ROI was calculated using the equation
Percent Error % 

value from a shorter scan - value from the original scan

value from a shorter scan  value from the original scan 2

 100

(2.1)

2.2.4

Statistical Analysis
Values of BF, BV, and PS were first transformed using the Box-Cox

transformation to obtain a normal distribution (13). The normality of the Box-Cox–
transformed data for each parameter and each tissue type was checked using the ShapiroWilk test (P > .05). Student's t test confirmed that there was no difference between the
hybrid positron emission tomography/CT and CT scanners when measuring BF, BV, and
PS in the different tissue types at 150 seconds (P > .05). Differences in each parameter
obtained from different scan durations were tested using repeated-measures analysis of
variance with post hoc paired t test and Bonferroni correction applied. Systematic and
random errors were correlated with scan durations using Spearman's rank correlation. All
statistical tests were done using SPSS version 19.0 (SPSS, Inc, Chicago, IL), and P
values < .05 were considered significant.

2.3 Results
Box plots of BF, BV, and PS values of different tissue types measured from
different scan durations are shown in Figure 2-1. BF and BV values were not affected by

72

shorter scan durations (P > .05). PS values in the tumour rim at 60 seconds were
significantly higher than in the 150-second scans (P < .01). Median percentage errors and
interquartile ranges associated with different scan durations are presented in Table 2-1.
Median percentage error was highest at 60 seconds for tumour core PS (median, 32.1%;
interquartile range, 16.5%–43.0%). Systematic and random errors associated with
different scan durations are displayed in Figure 2-2 and Figure 2-3, respectively. Tumour
rim BV and PS and tumour core BF systematic errors were correlated with scan durations
(r = 0.42, −0.50, and −0.50, respectively; P < .01). Random errors were negatively
correlated with scan durations for all tissue types (P ≤ .01) except for white matter BV
(Table 2-2). Figure 2-4 demonstrates the visual differences in the maps of BF, BV, and
PS due to scan-time truncation in a sample patient.

Figure 2-1: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c)
permeability–surface area product (PS) values measured from different scan
durations. Outliers (circles) are defined as data that are 1.5 box lengths away
from the 25th or 75th quartile. ∗Significantly different from the 150-second scan
(P < .01).

73

Table 2-1: Median (interquartile range) percentage errors associated with scan
durations of < 150 seconds.

Figure 2-2: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c)
permeability–surface area product (PS) systematic errors associated with different
scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away
from the 25th or 75th quartile. Extreme outliers that are three box lengths away
from the quartiles are not displayed.

Figure 2-3: Box plots of (a) blood flow (BF), (b) blood volume (BV), and (c)
permeability–surface area product (PS) random errors associated with different
scan durations. Outliers (circles) are defined as data that are 1.5 box lengths away
from the 25th or 75th quartile. Extreme outliers that are three box lengths away
from the quartiles are not displayed.

74

Table 2-2: Spearman's rank correlation of systematic and random errors with scan
duration.
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Figure 2-4: Differences between perfusion maps obtained from a 150-second
scan versus a 60-second scan. The 15-mm2 regions of interest in the contrastenhancing rim (1) and nonenhancing core (2) are displayed. Maps of blood
flow (BF), blood volume (BV), and permeability–surface area (PS) are
enlarged and centered at the tumour. White arrows point to regions with PS
values that appeared to be higher at 60 seconds relative to 150 seconds. The
window and level used for computed tomography, BF, BV, and PS were 20 to
100 Hounsfield units, 0 to 180 mL/min/100 g, 0 to 12 mL/100 g, and 0 to 25
mL/min/100 g, respectively.

2.4 Discussion
There is no consensus regarding the optimal CT perfusion scan duration, and
durations of 45 to 199 seconds have been reported in the literature for calculating tumour
perfusion parameters (7,10). This study sought to investigate the effect of scan duration
on the measurements of BF, BV, and PS.
Perfusion parameters were calculated using the Johnson-Wilson model (8,14). It
models the diffusion of a bolus of contrast across the capillary endothelium into the
interstitial space as it traverses from the arterial to the venous end of a tissue region. A
theoretical function, called the impulse residue function, represents the fraction of
contrast that remains in the tissue as a function of time after a bolus injection of a unit
amount of contrast into the arterial inlet. The impulse residue function has two distinct
phases. The first phase is a rectangular function at a height of unity that represents the
retention of the contrast in the tissue region, regardless of its distribution either in the
vascular or extravascular space, before any venous outflow occurs. The duration (or
width) of the first phase is the minimum transit time of this bolus. The second phase
starts at a height of the extraction fraction at the minimum transit time and decays
exponentially toward baseline with time. This describes the clearance of the extravasated
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contrast from the interstitial space via back flux into the bloodstream. The BF-scaled
impulse residue function is derived by deconvolving the arterial TAC with the tissue
TAC (8). The peak value and area under the first phase of the BF-scaled impulse residue
function are the BF and BV, respectively. PS is obtained using the equation PS = −BF ×
ln(1 − extraction fraction).
We did not find a statistical difference in BF and BV when comparing the 150second to the 120-second, 90-second, and 60-second studies. Hirata et al (15) found that
the first circulation time is approximately 40 seconds in brain tissue, and scanning up to
the first circulation time is sufficient for measurements of BF and BV. Our results are
consistent with their results and are expected given that a scan time of 60 seconds is well
beyond the first circulation time of contrast through the brain and would permit an
accurate determination of the first phase of the impulse residue function.
A scan time of 60 seconds is not adequate for the estimation of PS in brain tumour
rim. The significantly higher permeability that we observed with a shorter scan is
consistent with other studies (11,12). Goh et al (11) found that 45 seconds was too short
for PS measurements in colorectal cancer. The longer scan time required could be
explained by the fact that the accumulation of contrast in a brain tumour is much slower
than that of colorectal cancer because PS is lower in a brain tumour. A longer scan
duration is required to have sufficient signal-to-noise ratio to estimate PS values
accurately and reproducibly. PS values in the normal brain, which should be close to
zero, were unaffected by scan duration because the estimation algorithm was constrained
only to give nonzero PS values.
The effect of scan duration on the systematic and random errors of CT perfusion
parameters was also investigated. With the exception of white matter BV, the random
error of perfusion parameter measurements increased with shorter scan duration.
Systematic error in tumour rim BV and PS and tumour core BF also increased with
shorter scan durations because fewer data were available for estimating BF, BV, and PS.
The optimization algorithm for estimating these parameters was a constrained
optimization algorithm, in which all parameters were constrained to give only values that
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are zero or higher. The random error increased with a shorter scan time because the
signal-to-noise ratio deteriorated with a shorter scan time. This is analogous to the
decrease in the standard error when more samples are used to estimate the mean. With the
use of a constrained optimization algorithm, the random error would not go up as much
as a nonconstrained optimization process, because all parameter values had to be zero or
higher. This constraint led to the increase in systematic bias that we observed when the
signal-to-noise ratio deteriorated with reduced scan time.
Other technical settings of a CT perfusion protocol can also affect perfusion
parameter values. For instance, the frequency of image acquisition, particularly in the
first circulation phase, could result in significantly different values of BF and BV (1618). The molecular weight of contrast agent can influence the estimation of tissue
permeability as well. Most iodinated CT contrast agents are low–molecular weight agents
(about 0.75 kDa) and leak more easily from the blood into the interstitial space compared
to higher molecular weight contrast agents (19,20). Because endothelial permeability is
dependent on the molecular weight of a contrast agent, PS values measured with a lower
molecular weight agent will be higher than the values measured with a higher molecular
weight agent. As such, perfusion protocols to measure PS need standardization with
respect to contrast agent used as well as scan time.
Radiation dose is of concern when performing a CT perfusion scan. At 80 kVp
and 190 mA, the estimated effective doses for scan durations of 150, 120, 90, and 60
seconds are 5.4, 5.2, 5.0, and 4.8 mSv, respectively. Similarly, the imaging doses at 80
kVp and 100 mA are 2.9, 2.7, 2.6, and 2.5 mSv, respectively. Because the second phase
of a CT perfusion scan involves x-ray exposures that are taken every 15 seconds, the
reduction in radiation dose by truncating the scan time is minimal. Reducing the scan
time is not an effective way to reduce radiation dose. Adaptive statistical iterative
reconstruction and reducing the imaging frequency during the first phase are more
effective at reducing the radiation dose (17,21).
Some limitations of this study must be considered. The number of patients was
relatively small, and there was little variation in terms of brain tumour types, because all
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patients were diagnosed with malignant glioma, which accounts for approximately 70%
of all adult primary brain tumours (22). In addition, patients were not scanned with the
same CT scanner or the same contrast agent. As the molecular weights for the two
contrast agents used in this study were both approximately 0.8 kDa, the small difference
in molecular weights should have minimal effect on the measurement of CT perfusion
parameters. Although there was no statistical difference in terms of perfusion parameter
values measured from the two scanners using two different tube currents, a simulation
study showed that x-ray tube current could potentially affect the accuracy of perfusion
parameters in the brain (23). A subgroup analysis using the patients acquired with 100mA tube current showed that BF and BV at 60 seconds were significantly different from
the values obtained at 150 seconds (data not shown). A lower signal-to-noise ratio due to
a lower tube current could have affected the measurement of BF and BV when the scan
time was reduced. Our recommendation of 90 seconds is a conservative estimate of the
shortest scan time required to be consistent with the above results. In both cases (100 and
190 mA), the 120-second and 90-second data were not significantly different from the
150-second data. Additional study scanning patients with various types of brain tumours
using the same scanner and contrast agent is needed to confirm the current results.

2.5 Conclusions
Relative to a 150-second scan duration, BF and BV values in the normal brain and
brain tumours were not affected by reducing scan duration to 60 seconds, whereas PS
values in the tumour rim were significantly higher at 60 seconds. The random errors
associated with BF, BV, and PS could suffer with shorter scan durations. A scan duration
of ≥90 seconds is recommended, and investigation of the effects of other scanning
parameters on the measurement of perfusion parameters is warranted.
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Chapter 3

3

Improving Quantitative CT Perfusion Parameter
Measurements Using Principal Component Analysis
This chapter is adapted from the research article, “Improving quantitative CT

perfusion parameter measurements using principal component analysis” published in
Academic Radiology, 2014;21(5):624-632 by Yeung TPC, Dekaban M, De Haan N,
Morrison L, Hoffman L, Bureau Y, Chen X, Yartsev S, Bauman G, Lee TY.

3.1 Introduction
Computed tomography (CT) perfusion is a diagnostic tool for the evaluation of
acute ischemic stroke, and it is becoming increasingly used for measuring blood flow
(BF), blood volume (BV), and permeability–surface area product (PS) in malignant brain
tumours (1). The measurements of BF, BV, and PS in tumours are affected by CT
perfusion image contrast-to-noise ratio (CNR). Recently, Balvay et al. (2) showed that
filtering CT perfusion images with principal component analysis (PCA) improved CNR
in CT perfusion images of patients with ovarian and metastatic renal tumours. It is not
known whether PCA can improve CNR of CT perfusion images of patients with
malignant brain tumours, which have a lower CNR because of lower tumour blood flow
in the brain compared to other malignancies such as metastatic renal tumours (3-6). In
preclinical imaging of cancer models with a clinical CT scanner, a high spatial resolution
is desirable to detect small tumours. However, CNR from scanning small animals is low
because: (1) image noise increases with higher spatial resolution (ie, smaller pixel size);
and (2) the effect of partial volume averaging is more prominent in small animals than in
humans. Therefore, we hypothesized that CT perfusion images of a preclinical model of
malignant glioma are useful to evaluate the ability of PCA in improving image quality
under low-CNR condition. It has not been demonstrated that an increase in CNR after
PCA filtering improves the measurements of BF, BV, and PS. Accurate and precise
measurements of these parameters are important because they have been shown to be
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valuable for grading gliomas (1,6) and for distinguishing recurrent tumour from
treatment-induced necrosis (7).
In this study, we first designed a digital phantom to validate PCA image filtering
by comparing the accuracies and precisions of BF, BV, and PS without and with PCA
filtering of simulated CT perfusion images. We then evaluated the improvement in CNR
and changes in BF, BV, and PS measurements after PCA filtering CT perfusion images
of a malignant rat glioma model.

3.2 Materials and Methods
3.2.1

Validation of PCA by Simulation
A digital phantom of CT perfusion images with time-attenuation curves (TAC)

reflecting known values of BF, BV, and PS was developed. The phantom consisted of 16
CT slices and 44 sequential images for each slice simulating a two-phase CT perfusion
protocol. Images were simulated at 1.4-second intervals during the first phase of 30seconds and then at 15-second intervals during the second phase of 300-seconds. Each
image contained 3 × 4 tiles of 10 × 10 pixels, which resembled the number of pixels in an
axial rat brain CT image. Pixels in each tile had the same TAC simulating known values
of BF, BV, and PS. Each tile was assigned with increasing mean transit times (MTTs; 4,
4.5, 5.0, …, 9.5 s) and extraction fraction (E; 0.05, 0.06, …, 0.14, 0.3, 0.4). Each slice
was assigned to two different BV values, the range of values were 0.5, 1.0, 1.5, …, 8
mL/100 g. BF values (3.2–120 mL/min/100 g) were calculated as BV/MTT, and PS
values (0.4–25.8 mL/min/100 g) were obtained using −BF × ln(1−E) (8). Based on the
Johnson–Wilson model, these values were used to simulate different impulse residue
functions for each tile (9). A population-averaged arterial TAC was generated by
averaging TACs from carotid arteries of nine Wistar rats.
Each impulse residue function was convolved with the population-averaged
arterial TAC to generate a tissue TAC. A time-attenuation curve (TAC), Q(t), can be
described by the following equation:
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𝑄(𝑡) = 𝐵𝐹 ⋅ 𝐶𝑎 (𝑡)⨂𝐻(𝑡) = 𝐶𝑎 (𝑡)⨂[𝐵𝐹 ⋅ 𝐻(𝑡)]

Equation 3-1

where BF is blood flow, Ca(t) is the arterial TAC (also known as the arterial input
function), ⊗ is the convolution operator, H(t) is the impulse residue function. This
mathematical operation is graphically illustrated in Figure 3-1.

Figure 3-1: Graphical illustration showing how a tissue time-attenuation curve
(TAC), Q(t), is simulated from a population-averaged arterial TAC, Ca(t), and a
blood flow–scaled impulse residue function, H(t), with known values of blood flow
(BF), blood volume (BV), permeability–surface area product (PS), extraction
fraction (E), and mean transit time (MTT).
The arterial TAC used in this simulation was a population-averaged arterial TAC.
The impulse residue function describes the fraction of contrast that remains in the tissue
as a function of time after a bolus injection into the arterial inlet. The blood flow–scaled
impulse residue function, BF⋅H(t), has two phases. The first phase is a rectangular
function with a height of BF that is maintained for the duration of the mean transit time
and has an area equal to blood volume (BV). It represents the retention of contrast in the
tissue region before venous outflow. The second phase starts at a height of the extraction
fraction and decays exponentially; it describes the back flux of extravasated contrast from
the interstitial space into the intravascular space. The values of the TACs at different time
points were embedded into the corresponding pixels to generate CT perfusion images of
the digital phantom. In total, the set of noise-free CT perfusion images in the digital
phantom gave rise to 192 different TACs with different combinations of BF, BV, and PS
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values. This phantom reflected values of BF, BV, and PS in the physiological range of a
rat. The design of this phantom is illustrated in Figure 3-2.

Figure 3-2: An example of one slice (out of 16 slices) of the digital computed
tomography (CT) perfusion phantom with image noise. Each tile contains tissueenhancement curves reflecting a combination of extraction fraction (E), mean
transit time (MTT), blood volume (BV), blood flow (BF), and permeability–surface
area product (PS).

To add image noise to the set of noise-free CT perfusion images, a rat was
scanned without contrast injection in high-resolution mode with a clinical CT scanner
(Discovery 750 HD; GE Healthcare, Waukesha, WI) using the same two-phase CT
perfusion protocol as the simulation. The scanning parameters were 80 kVp, 120 mAs,
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0.4 s/rotation, 10 cm field of view, 16 slices, and 1.25 mm slice thickness (voxel size is
0.2 × 0.2 × 1.25 mm). A high-definition bone filter with a limiting in-plane resolution of
0.33 mm was used to reconstruct the images. Adaptive statistical iterative reconstruction
(ASIR) was used to reconstruct the images. The skull was used to rigidly register the
images using the prototype version of CT Perfusion 4D (GE Healthcare) to minimize
misregistration due to motion in the axial plane. A “noiseless” CT image for each slice
was generated by averaging the series of noncontrast CT images of the same slice. The
set of noise only images of each slice was obtained by subtracting the average CT image
from each CT image of the same slice. This set of noise images was added one by one to
the set of noise-free CT perfusion images. The final set of noisy images was designated
as the unfiltered CT perfusion images of the digital phantom, and they were then filtered
using PCA.

3.2.2

Principal Component Analysis
Principal component analysis (PCA) is a statistical technique that linearly

transforms a set of multidimensional observations into different principal components
that describe the variance of the original set of observations (2). In the context of a series
of m dynamic images from a computed tomographic perfusion study, attenuation in each
pixel p as a function of time was measured as a time-attenuation curve (TAC). If one
interprets a TAC as a set of observations of x-ray attenuation changes (due to contrast)
versus time, then each TAC consists of m number of variables and can be written as an m
× 1 vector Qp with p as the index for the image pixel. PCA linearly transforms the
possibly correlated m variables into a set of transformed variables called principal
components, which are linear combinations of the original variables and are uncorrelated
with each other. These linear transformations are defined so that the first principal
component has the largest variance. Each subsequent principal component would
describe the next largest variance with the condition that it is uncorrelated to all the
previous principal components.
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It can be shown that the coefficients defining these linear transformations are the
eigenvectors of the covariance matrix of the TACs whereas the corresponding
eigenvalues are the variances of the principal components. In addition, each TAC can be
noise filtered by expressing it as the weighted sum of the eigenvectors with the weights
given by the scores of the TAC on the principal components (or loadings of the
eigenvector in the TAC):
N
~
Qp   wip  ai

Equation 3-2

i 1

where N is the number of principal components with the largest variances used to noise
filter Qp, ai is the ith eigenvector and wip is the corresponding weight which can be
calculated as:

wip  ai  Qp  Q 
T

where

is the mean of all TACs and

Equation 3-3

is the transpose of ai.

CT perfusion images can be noise filtered using the first few principal
components. In general, more temporal TAC smoothing is achieved with lesser number
of principal components used. CT perfusion images of each slice of the phantom were
analyzed with an in-house PCA program developed using the C++ programming
language. Two, four, six, eight, and ten principal components were used to reconstruct
five different sets of noise-filtered CT perfusion images.

3.2.3

In Vivo Experiments
All experiments were approved by the Animal Use Subcommittee of the Canadian

Council on Animal Care at our institution. C6 glioma cells (106 cells in 10 μL) were
stereotactically implanted into the right caudate putamen of eight Wistar rats (10). At an
average of 13 days (range, 11–17 days) after tumour implantation, the brain of each
animal was scanned in high-resolution mode with a clinical CT scanner using the same
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two-phase protocol as the simulation. A bolus of contrast (Isovue; Bracco Diagnostics
Inc, Vaughan, Canada; 300 mg iodine/mL, 2.5 mL/kg body weight) was injected into the
lateral tail vein at a rate of 8 mL/min, at 3–4 seconds after the start of the first phase.
Two, four, and six principal components were used to reconstruct three different sets of
noise-filtered CT perfusion images for each animal.

3.2.4

Assessment of Image Quality and Information Loss after
PCA Filtering
For both simulation and in vivo experiments, pixel noise and CNR were used to

evaluate the image quality of CT perfusion images after PCA noise filtering (2). To
evaluate the enhancement of contrast, the mean baseline attenuation is subtracted from
the TAC to give the corresponding time-enhancement curve. The standard deviations
(SD) of the baseline (first four to five time points) and the late steady state phase (last 10
time points) were calculated and averaged for each of the original and filtered image sets
̅̅̅̅̅𝑜 and ̅̅̅̅̅
to give ̅̅̅̅̅
𝑆𝐷𝑜 and ̅̅̅̅̅
𝑆𝐷𝑓 , respectively. These values (𝑆𝐷
𝑆𝐷𝑓 ) were used as
measurements of pixel noise.
For each CT perfusion image set, the average norm of the time-enhancement
‖𝑄‖ is composed of the average norm of signal ̅̅̅̅̅
‖𝑆‖ and average norm of noise
curves ̅̅̅̅̅̅
√𝑚 ∙ ̅̅̅̅̅
‖𝑆‖ was
𝑆𝐷2 , where m is the number of time points. The average norm of signal ̅̅̅̅̅
‖𝑄‖ − 𝑚 ∙ ̅̅̅̅̅
estimated using √̅̅̅̅̅̅
𝑆𝐷2 . The CNR of the original and filtered image sets were
defined as

̅̅̅̅̅𝑜
‖𝑆‖
2
̅̅̅̅̅̅
𝑚∙𝑆𝐷
𝑜

and

̅̅̅̅̅𝑓
‖𝑆‖
2
̅̅̅̅̅̅
𝑚∙𝑆𝐷
𝑓

, respectively.

The fractional residual information (FRI) was described by Balvay et al (2) and
was used to evaluate the amount of information loss due to filtering. The residual signal
of pixel p, Rp, was the difference between the original TAC, Qp, and the filtered TAC
~
( Q p ). The residual signal (Rp) of pixel p has two components: informative signal (Sp) and
noise (Np). The FRI for a pixel (FRIp) after filtering with PCA was defined as:
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FRI p 

Sp
Rp

2



2

Sp

2

Sp  Np

Equation 3-4

2

FRIp ranges from 0 to 1, and the optimal number of principal components that
should be used for filtering TACs minimizes the FRI in order to keep as much valuable
information as possible in the filtered data in both the tumour and normal brain tissue. To
2

estimate S p we used the autocorrelation function of the residual, Rp, between the
original and filtered TAC of pixel p, which is defined as:

C p k  

1
m k

mk

 R i  R i  k 
i 1

p

Equation 3-5

p

where m is the number of time points, k is the time lag and Rp(i) is the ith element of the m
× 1 residual vector Rp. Cp(k) can identify signal (Sp) hidden in the noise (Np) of Rp in the
following way. In general, the autocorrelations of Np and Sp are approximately zero for
time lag k > kn and ks, respectively. If ks > kn, then the autocorrelation of the residual
Cp(k) can be used to approximate Sp for time lag kn < k < ks. In particular, extrapolation of
Cp(k) in the range kn < k < ks to k = 0 will give the autocorrelation of Sp at k = 0, which by
2

analogy to Equation 3-5 gives S p when multiplied by (m-|k|). We used a second order
polynomial to extrapolate Cp(k) in the range kn < k < ks to k = 0. The kn and ks used were
fixed to 1 and 30 time lags, respectively.

3.2.5

Calculation of BF, BV, and PS
For both simulation and in vivo experiments, maps of BF, BV, and PS of the

unfiltered and filtered image sets were generated using CT Perfusion 4D. Tissue TACs
were measured from 2 × 2 pixel blocks of CT images. Parametric maps of BF, BV, and
PS were calculated by deconvolving the arterial TAC with each tissue TAC using the
Johnson–Wilson model (8,9). The population-averaged TAC was used for the simulation
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while a region of interest (ROI) was placed in the carotid artery to measure the arterial
TAC for each animal.

3.2.6

Statistical Analysis
For digital phantom maps, a square-shaped ROI of 8 × 8 pixels was placed at the

center of each tile to measure the mean BF, BV, and PS. Intraclass correlation coefficient
was used to assess the reliability of measurements between the simulated true values and
the values obtained without or with PCA filtering (11). Measurement error was the
difference between the mean with the simulated true value of each tile. Map noise was
the SD of each tile. The agreement in measurement errors and map noises in BF, BV, and
PS without and with PCA filtering was assessed using Bland–Altman analysis (12).
Repeated measures analysis of variance (ANOVA) followed by Bonferroni multiple
comparisons was used to compare the differences in absolute measurement errors and
map noise before and after PCA filtering (SPSS, version 20.0; SPSS, Chicago, IL) (13).
For animal experiments, the tumour and contralateral normal brain were
delineated. Noise level, CNR, BF, BV, and PS in each ROI were expressed as mean ±
SD. These metrics before and after filtering were compared using repeated measures
ANOVA followed by Bonferroni multiple comparisons to evaluate the differences
between the normal brain and tumour without or with PCA filtering. The mean
percentages of pixels that had an FRI ≥ 5% in the normal brain and tumour were
calculated. All statistical tests were done using SPSS (SPSS, version 20.0; SPSS,
Chicago, IL), and a P ≤ .05 was considered significant.

3.3 Results
For simulation, filtering with four or lesser principal components resulted in intraclass
correlation coefficients that were significantly greater than the intraclass correlation
coefficients without PCA filtering for BF, BV, and PS (Table 3-1). Figure 3-3 illustrates
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visual improvements in maps of BF, BV, and PS after PCA filtering. The mean error and
the 95% limits of agreement (mean ± 2 SD) decreased after PCA filtering and with lesser
number of principal components (Figure 3-4). Similarly, the mean map noise and 95%
limits of agreement decreased after PCA filtering (Figure 3-5). Reductions in absolute
measurement errors and map noises for BF, BV, and PS were significant (P < .05). The
mean FRI ± SD was ≤0.5% ± 0.7% after filtering with any number of principal
components. The maximum mean FRI for ten, eight, six, four, and two principal
components were 3.0%, 2.9%, 3.7%, 4.9%, and 6.5%, respectively.

Table 3-1: Intraclass correlation coefficient of different CT perfusion parameters
with the true values.
Number
of PCs

No PCA
10 PCs
8 PCs
6 PCs
4 PCs
2 PCs

BF
Intraclass
correlation
coefficient (95%
CI)
0.73
(0.34 – 0.86)
0.79
(0.64 – 0.87)
0.79
(0.68 – 0.86)
0.79
(0.66 – 0.86)
0.82
(0.75 – 0.87)
0.82
(0.77 – 0.86)

P
value*
0.57
0.19
0.12
0.15
0.01#
0.00#

BV
Intraclass
correlation
coefficient (95%
CI)
0.96
(0.95 – 0.97)
0.98
(0.96 – 0.98)
0.98
(0.97 – 0.99)
0.98
(0.97 – 0.99)
0.98
(0.97 – 0.98)
0.98
(0.97 – 0.98)

P
value†
0.42
0.05
0.00#
0.00#
0.00#
0.00#

PS
Intraclass
correlation
coefficient (95%
CI)
0.77
(0.16 – 0.91)
0.87
(0.73 – 0.93)
0.91
(0.83 – 0.95)
0.91
(0.84 – 0.94)
0.90
(0.87 – 0.93)
0.92
(0.89 – 0.94)

P
value‡
0.59
0.06
0.00#
0.00#
0.00#
0.00#

*

Statistical comparison with intraclass correlation coefficient = 0.73

†

Statistical comparison with intraclass correlation coefficient = 0.96

‡

Statistical comparison with intraclass correlation coefficient = 0.77

#

Statistically significant at a P < 0.01

Abbreviations: PCs = principal components; BF = blood flow; BV = blood volume; PS =
permeability-surface area product; PCA = principal component analysis; CI = confidence
interval
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Figure 3-3: Maps of blood
flow (BF), blood volume (BV),
and

permeability–surface

area product (PS) of the
digital phantom without noise
(ie, truth), with noise, and
after

principal

component

analysis (PCA) filtering with
four principal components.
Some values of BF, BV, and
PS are labeled.

Figure 3-4: Mean error and 95% limits of agreement (ie, mean ± 2 standard
deviation from Bland–Altman analysis) without and with principal component
analysis (PCA) filtering for (a) blood flow (BF), (b) blood volume (BV), and (c)
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permeability–surface area product (PS). Solid line is the mean and dashed lines are
the upper and lower limits of agreement.

Figure 3-5: Mean map noise and 95% limits of agreement (ie, mean ± 2 standard
deviation from a Bland–Altman analysis) without and with principal component
analysis (PCA) filtering for (a) blood flow (BF), (b) blood volume (BV), and (c)
permeability–surface area product (PS). Solid line is the mean and dashed lines are
the upper and lower limits of agreement.

For experiments, Figure 3-6 shows the removal of noise from a sample timeenhancement curve in the tumour. Figure 3-7 shows examples of source CT perfusion
images and maps of BF, BV, and PS without and with PCA filtering; the first four
principal components used for filtering are also shown. Table 3-2 reports the significant
improvements in noise reduction and CNR in animal CT perfusion images. The loss of
signal was minimal after filtering the images with four or more principal components, in
which no >1% of pixels had an FRI of ≤5% in both the normal brain and the tumour. An
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average of 26% (range, 11%–49%) of pixels in the tumour had an FRI of ≥5% when
filtering with only two principal components (Table 3-2). PCA showed significant effect
on BV and PS irrespective of ROI (ie, normal brain vs. tumour), and ROI had a
significant effect on BF, BV, and PS irrespective of PCA (Table 3-3). Although PCA had
no overall effect on BF, the interaction between PCA and ROI had a significant effect,
suggesting that ROI had an effect on PCA filtering. Figure 3-8 shows that there was no
regional difference in BF without PCA (P = .72), but tumour BF was significantly
different than brain BF after filtering with four or lesser principal components (P < .03).
This supports the effect of region on the PCA as indicated in Table 3-3, which led to a
higher contrast between tumour and normal brain tissue in BF maps. Figure 3-8 also
illustrates measurements of BV and PS in the normal brain and tumour before and after
PCA filtering.

Figure 3-6: Examples of tumour time-enhancement curves obtained without and
with principal component analysis (PCA) filtering. Filtering with two principal
components can lead to loss of information as represented by the reduced height in
the time-enhancement curve.
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Figure 3-7: (A) Examples of source computed tomography (CT) images and maps of
blood flow (BF), blood volume (BV), and permeability–surface area product (PS)
without and with filtering using four principal components (PCs) . (B) The first four
PCs as a function of time.
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Table 3-2: Evaluation of quality of computed tomography perfusion image filtering.
Noise level ± SD (HU)
Number of
PCs
No PCA
6 PCs
4 PCs
2 PCs

CNR ± SD

% of voxels with FRI ≥ 5%

Brain

Tumour

Brain

Tumour

Brain

Tumour

16.9 ± 0.5

16.6 ± 0.6

0.6 ± 0.1

1.4 ± 0.4

N/A

N/A

5.2 ± 0.6*

5.6 ± 0.6*

1.9 ± 0.3*

3.8 ± 1.2*

0.2 ± 0.2

0.3 ± 0.5

3.3 ± 0.4*

3.9 ± 0.7*

2.9 ± 0.4*

5.5 ± 2.4*

0.5 ± 0.3

1.1 ± 1.0

1.6 ± 0.3*

2.2 ± 0.6*

6.2 ± 1.3*

6.5 ± 1.8*

4.2 ± 2.2

26.4 ± 14.2

*

Significantly different than No PCA of the same region (P < 0.05)

Abbreviations: PCA = principal component analysis; PCs = principal components; SD =
standard deviation; HU = Hounsfield unit; CNR = contrast-to-noise ratio; FRI =
fractional residual information; N/A = not applicable

Table 3-3: P values of repeated-measures ANOVA for measurements of BF, BV, and
PS.
Factor
PCA
Region
Interaction between PCA and region

BF

BV

PS

0.21

<0.02

<0.01

<0.05

<0.03

<0.01

<0.01

<0.01

<0.01

Abbreviations: BF, blood flow; BV, blood volume; PCA, principal component analysis;
PS, permeability–surface area product.
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Figure 3-8: Brain and tumour blood flow (BF), blood volume (BV), and
permeability–surface area product (PS) before and after filtering with different
number of principal components. Asterisk (*) indicates a marginal significance of P
= .06. Dagger (†) indicates 0.01 ≤ P < .03. Double dagger (‡) indicates P < .01.

3.4 Discussion
CT perfusion provides crucial information regarding brain tumour hemodynamics
for the evaluation of tumour angiogenesis (1). The visualization of small objects of
interest, such as tumours and ischemia, and accurate and precise measurements of BF,
BV, and PS require good CNR. Balvay et al. (2) demonstrated an automated method to
perform PCA. Our simulation provides the first evidence that PCA is effective in
improving the reliability, accuracy, and precision of BF, BV, and PS measurements.
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We applied PCA in this study to improve CNR of CT perfusion images of
malignant rat gliomas that have an even lower CNR than previously reported (2). PCA is
a statistical technique that separates image noise from signal by determining principal
components with successively decreasing variance. Filtering with too many principal
components results in ineffective denoising of the data whereas filtering with too few
principal components runs the risk of removing genuine signal from the original data. We
used the noise level, CNR, and FRI as metrics to evaluate the tradeoff between the
improvement in image contrast and the loss of information. In this study, both image
noise and CNR of CT perfusion images were improved after PCA. Filtering with only
two principal components resulted in substantial information loss in the tumour that was
not observed with greater than four principal components. Rat brain CT perfusion images
required few principal components for filtering because there are few tissue types with
different patterns of contrast enhancement in rat brain tissues. Unlike human brain, which
has substantial amount of white matter, the rat brain consists mostly of gray matter (14).
Furthermore, the rat brain, like human brain, is not permeable to most exogenous
molecules including iodinated contrast. The shape of the time-enhancement curve in the
normal rat brain is mainly governed by that of the arterial input and venous output.
However, in the implanted glioma, contrast agent is able to extravasate into the brain
parenchyma. The extravasation of contrast agent contributes to the higher contrast
enhancement during the latter phase of the time-enhancement curves. Because there are
only two major tissue types (normal and tumour) with two different patterns of contrast
uptake (minimal vs. high extravasation) in the rat gliomas of this study, four principal
components were able to filter the CT perfusion images without substantial loss of
information. After filtering the CT perfusion images, differences in BF, BV, and PS
measured in the tumour and contralateral normal brain were consistent with reported data
measured using synchrotron radiation CT perfusion of the same tumour model (15).
There have been advances in the development of new CT reconstruction methods
that can improve CT image quality. ASIR is one example of these advances and has been
shown to provide equal image quality in brain imaging with ≥30% reduction in radiation
dose when compared to filtered back projection (16). Images from this study were
reconstructed with 80% ASIR. Thus, the improvement in image quality from PCA was
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additional gain in CNR of the time-enhancement curves after ASIR was applied,
suggesting that PCA further contributes to the improvement in CT perfusion image
quality.
PCA has important potential application for lowering radiation dose when
performing repeated CT perfusion studies to evaluate treatment response. A typical
human brain CT perfusion protocol produces an effective dose of 2.9–5.4 mSv (17).
Radiation dose is inversely proportional to the square of image noise. For instance, a
nine-fold reduction in radiation dose can be achieved by filtering CT perfusion images
with six principal components to achieve a three-fold improvement in image noise (Table
3-2). PCA filtering of CT perfusion images can improve the accuracy and precision of
BF, BV, and PS measurements obtained with low CNR CT perfusion images; thus,
making repeated low dose CT perfusion studies feasible. Lowering radiation exposure for
better radiation safety or increasing spatial resolution of CT images will increase image
noise, which in turn lowers CNR. Effective filtering of CT perfusion source images
without the loss of information to obtain more accurate and precise measurements of BF,
BV, and PS is imperative for both improving visibility of small objects of interest and for
lowering radiation dose.
There are several limitations in this study. A simulation was performed to
evaluate the improvement in accuracy and precision of BF, BV, and PS measurements.
Although we did not perform an in vivo validation, CT perfusion imaging of brain
tumour tissue has been validated in vivo (18). PCA analysis of the experimental data was
applied to each slice of the brain separately (ie, two-dimensional analysis). A threedimensional PCA of the entire brain could improve the quality of filtering by increasing
the number of pixel TACs used to determine the principal components. It is important to
note that the simulation results obtained in this study may not be applicable to other
pharmacokinetic models (ie, the analysis software). Using a similar digital phantom,
Kudo et al. (19) showed that different commercial software packages showed
discrepancies in BF and BV measurements from simulated values. This is because
available commercial software may or may not correct the arrival delays of the TACs,
and the impulse residue functions are constrained differently in these software packages
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because of the different assumptions used in their tracer kinetic models. A separate
simulation using our digital phantom is needed to validate the measurement of different
tracer kinetic parameters after PCA filtering of CT perfusion images for each commercial
software.

3.5 Conclusions
PCA filtering of CT perfusion images improved CNR in vivo and reduced
measurement errors of BF, BV, and PS by simulation. PCA is an effective tool for
filtering CT perfusion images of malignant rat gliomas with low CNR. Filtering with four
principal components could achieve the gain in CNR without substantial loss of
information.
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Chapter 4

4

CT Perfusion Imaging as an Early Biomarker of
Differential Response to Stereotactic Radiosurgery
This chapter is adapted from the manuscript entitled “CT perfusion imaging as an

early biomarker of differential response to stereotactic radiosurgery”. This manuscript
will be submitted to the journal PLOS ONE in July 2014 to be considered for publication.
The authors of this manuscript are Yeung TPC, Kurdi M, Wang Y, Al-Khazraji B,
Morrison L, Hoffman L, Jackson D, Crukley C, Lee TY, Bauman G, Yartsev S.

4.1 Introduction
Patients with glioblastoma multiforme, the most common form of adult brain
tumours, have a median survival of approximately 12 – 15 months (1). Radiotherapy has
played an important role in prolonging the survival of these patients since the 1970s (2).
Magnetic resonance (MR) and computed tomography (CT) are currently the standard
imaging modalities for assessing treatment response. Tumour progression is usually
detected by increased contrast-enhancement on gadolinium-enhanced T1-weighted MR
images, and T2-weighted or fluid-attenuated inversion recovery MR images (3).
However, early changes in contrast enhancement after radiotherapy is not a specific tool
to predict treatment failure as changes in contrast enhancement can occur in
pathophysiological processes that disrupt the blood brain barrier. For instance, radiationinduced injury (e.g. radiation-induced necrosis and pseudoprogression) can mimic the
appearance of tumour progression on T1-weighted MR (3).
Due to the poor survival rates, timely and accurate assessment of response to
radiation is important as treatment can be altered if a non-responder to radiation can be
identified early enough. In preclinical studies, radiotherapy is usually delivered using a
technique called stereotactic radiosurgery (SRS). It is delivered in one or few large dose
fractions of 8 – 30 Gy and would result in tumour growth delay and survival benefit (47). Radiotherapy, particularly SRS, can result in vascular damage in the irradiated area

104

(4, 8-10), and radiosensitivity of tumour vasculature can augment response to SRS (11).
Hypofractionation schemes that also use a large dose per fraction to treat patients with
malignant gliomas is also an attractive treatment strategy. Recently, clinical studies have
investigated the use of hypofractionated intensity modulated radiotherapy to treat these
patients (12-14). Hypofractionation have some advantages over conventional
fractionation. Hypofractionation is expected to increase the biological effect of radiation
due to increased cell damage resulting from a higher dose per fraction (15). It also
reduces the effect of tumour repopulation by reducing treatment time (16). Thus, imaging
of tumour perfusion is a promising biomarker of response to high dose per fraction
radiotherapy (e.g. SRS and hypofractionation) that warrants investigation.
The C6 rat glioma is a widely used experimental model for the study of malignant
glioma (17), including the effects of SRS (6,7,9,10). Tumour microcirculation can be
noninvasively measured by CT or MR perfusion imaging techniques. In particular, CT
perfusion imaging is a validated method that allows simultaneous mapping of blood flow
(BF), blood volume (BV), and permeability-surface area product (PS) (18,19). CT
scanners and iodinated contrast agents are also widely available, and they are ubiquitous
in radiation oncology departments. The purpose of this study was to evaluate vascular
changes following SRS using CT perfusion, and determine whether acute vascular
changes within one week of SRS is predictive of survival. In addition, early (four days
post-SRS) and late (eight weeks post-SRS) histopathologic findings were examined.

4.2 Materials and Methods
4.2.1

C6 Glioma Model
All experiments were compliant with our institutional Animal Use Subcommittee

guidelines. Wistar rats weighing 300 – 400 g (N = 33) were used in this study. The
animals were anaesthetized with 2% isoflurane during all procedures. C6 glioma cells
(American Type Culture Collection, Manassas, VA) were cultured in F12k 15% horse
serum, 2.5% bovine serum, and 1% penicillin-streptomycin. For the implantation of C6
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glioma cells, each animal was secured into a stereotactic surgical frame. After scalp
incision at midline and exposing the bregma, a 1 mm diameter burr hole was drilled at 1
mm anterior and 3 mm right of the bregma. A total of 106 C6 glioma cells were slowly
injected for 5 minutes at 3 – 4 mm below the burr hole, which corresponded to the
location of the caudate putamen (20). The burr hole was sealed with bone wax, and the
scalp was closed with sutures.

4.2.2

Baseline CT Perfusion Imaging
All rats underwent the first CT perfusion scan on an average of 11 days (range, 7

– 16 days) after implantation of C6 glioma cells to monitor tumour growth and prepare
for SRS. The rats were scanned using a clinical CT scanner (Discovery 750 HD, GE
Healthcare, Waukesha, WI). A two-phase CT perfusion scan, guided by a prior noncontrast CT scan that identified 16 × 1.25 mm thick sections to cover the entire brain, was
performed for each animal. The brain was scanned with high resolution mode for 32 s at
1.4 s intervals during the first phase and for a period of 165 s at 15 s intervals during the
second phase. A bolus of contrast (Isovue, Bracco Diagnostics Inc, Vaughan, Canada,
300 mg iodine/ml, 2.5 mL/kg body weight) was injected into the lateral tail vein at a rate
of 8 mL/min at 3 – 4 s after the start of the first phase. The scanning parameters were 80
kVp, 120 mAs, 10 cm field of view, and high-definition bone filter. The visibly
distinguishable spatial resolution was 1 line pair per 500 μm measured on a rat-size
phantom (21).
CT perfusion images of the same slice were averaged over the whole scan
duration using the prototype version of CT perfusion 4D (GE Healthcare) to produce a set
of contrast-enhanced images called averaged CT images. The tumour diameter on the
averaged CT images was measured immediately after the scan. The rats were assigned
randomly to either the control group (N = 8) or the SRS group (N = 25) once a tumour
diameter of 4 mm was reached.
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4.2.3

Stereotactic Radiosurgery
A custom-made plastic stereotactic frame was used to secure the animals for

treatment planning. A non-contrast helical CT scan was performed (25 cm field-of-view,
80 kV, 110 mAs, 1.25 mm slice thickness) for treatment planning. CT images were
transferred to the Helical Tomotherapy Treatment Planning System (Accuray Inc,
Madison, WI, USA). Using the averaged CT images for anatomical guidance, a dose of
12 Gy was prescribed to at least 80% of the contrast-enhanced tumour volume with the
brainstem receiving no more than 4 Gy and less than 10% of the normal brain receiving
more than 8 Gy.
For SRS, the rats were fixed in the same plastic stereotactic frame. A 3.5 MV CT
study was acquired prior to treatment. This MV CT study was co-registered with the
planning kV CT study and couch position was shifted in the lateral, anterior-posterior,
and superior-inferior directions. The rats were repositioned in the stereotactic frame if
there were rotational positioning errors. The average SRS delivery time was 6 minutes.
Rats in the control group were put under anesthesia and secured in the stereotactic frame
for 6 minutes to mimic the procedure without radiation.

4.2.4

Follow-up CT Perfusion Imaging
Rats in the SRS group were further assigned to either 1) acute imaging group (N =

12) or 2) the longitudinal imaging group (N = 13). Rats in the acute imaging group were
imaged with CT perfusion at 4 days post-SRS, and were euthanized on the same day.
Rats in the longitudinal group and control group were imaged for a maximum of 8 weeks
post-SRS to monitor tumour changes and survival. Rats were euthanized if they showed
any of the following signs and symptoms: weight loss of ≥ 15% from the heaviest
recorded weight, lethargy, refusal to eat, neurologic signs such as one-sided limb
weakness.
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4.2.5

Image Analysis
Maps of BF, BV, and PS were generated using the prototype version of CT

perfusion 4D (GE Healthcare). The time-attenuation curve (TAC) from the carotid artery
was selected as the arterial input. The arterial TAC was deconvolved with tissue TACs
measured from 2 × 2 pixel blocks of CT images using the Johnson-Wilson model to
produce maps of BF, BV, and PS (18,22). Using the averaged CT images for anatomical
guidance, tumour volume, BF, BV, and PS in the tumour, peritumoural region, and
contralateral normal brain were measured. Peritumoural region was defined as normal
brain that is 2 – 3 mm adjacent to the tumour. Mean BF and BV values were normalized
to the contralateral normal brain to obtain the relative BF (rBF) and relative BV (rBV)
values.

4.2.6

Histopathologic Examination
On the same day as the last CT perfusion scan, the animals were euthanized with

an overdose of potassium chloride. The animals were perfusion-fixed with phosphate
buffered saline followed by 4% paraformaldehyde. The brains were removed and fixed in
4% paraformaldehyde for 24 hours. The brain specimens were sectioned into 3 mm thick
blocks, paraffin-embedded, then sectioned at 5 μm. Hematoxylin and eosin stain (H&E)
was applied on each section.
A blinded neuropathology resident (M.K.) examined all H&E slides at different
magnifications (20x and 40x) to evaluate histologic signs of radiation damage. The
presence of tumour was evaluated as “no”, “yes”, or “diminished due to radiation effect”.
“Diminished due to radiation effect” means the presence of a circumscribed hypocellular
lesion showing features of irradiation. The diameter of each lesion (control and SRStreated animals) was measured. Tumour cellularity was defined as 1) hypercellular when
less than 30% of the tumour area appeared pale or major tumour was found, and 2)
hypocellular when more than 50% of the tumour area appeared pale excluding necrosis.
Tumour was graded based on the World Health Organization criteria (23). Tumour
edema was defined as the presence of extensive intracellular cytoplasmic swelling or
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intercellular spaces between tumour cells. Peritumoural edema was defined as
intracellular cytoplasmic swelling or presence of intercellular spaces and reactive gliosis
in the peritumoural region. Necrosis was described as 1) pseudopalisading necrosis that
indicates high-grade glioma, 2) fibrinoid necrosis, or 3) background necrosis (neither
pseudopalisading nor fibrinoid necrosis) that indicate post-radiation effect. 8) Presence of
endothelial hyperplasia was recorded as a feature of angiogenesis in high-grade glioma.
Increased vascularity and hyalinzed blood vessels were recorded as features of postradiation effect. Percentage of animals exhibiting these signs was calculated. Mean
percent necrosis by area was also calculated.
The brain sections were also stained with monoclonal anti-actin, α-smooth muscle
antibody (α-SMA) (1:500, clone 1A4, Sigma-Aldrich) to identify mature vessels (24-26).
The α-SMA positive vessels were qualitatively classified as intact or fragmented vessels.
α-SMA positive vessel density was defined as the number of vessels that stained positive
for α-SMA in 6 separate fields (20×) in the most vascular region of the tumour and
peritumoural region. Intact and fragmented α-SMA positive vessel densities were
measured separately. The percentage of fragmented α-SMA positive vessels was also
recorded.

4.2.7

Statistical Analysis
The Shapiro-Wilk test was used to test the normality of the data. Temporal

changes in the acute imaging group were tested by the Wilcoxon signed-rank test. The
end point of the longitudinal imaging group was survival at 8 weeks post-SRS. The
longitudinal group was also subdivided into those that survived more than 2 weeks
(responder group), and those that survived less than 2 weeks post-SRS (nonresponder
group). The omnibus Kruskal-Wallis test was used for comparisons between groups
followed by the Mann-Whitney U test. The omnibus Friedman test was used for
longitudinal comparisons within-group followed by the Wilcoxon signed-rank test. All
data were reported as mean ± standard error of the mean (SE). Survival of the groups was
compared using the log-rank test. Spearman’s rank correlation was used to assess the
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associations between different imaging parameters (tumour volume, rBF, rBV, PS) and
the percentage of fragmented α-SMA positive vessels. PS is the product between
microvessel surface area and permeability, and BV has been shown to correlate with
microvessel area (27). We used the PS:BV ratio as a surrogate of permeability and
correlated this parameter with the percentage of fragmented α-SMA positive vessels as
well.
We investigated whether the imaging parameters correlated with overall survival,
and whether these parameters on day 7 post-SRS could predict survival. Each imaging
parameter was assessed by applying a threshold that is below the lower 50% confidence
interval (CI) boundary of the variations across all treated animals derived from the
between-subject variation on day 7 post-SRS. This threshold was used to categorize each
animal into two groups (i.e. higher or lower than the threshold). Survivals of the different
groups were compared. The sensitivity, specificity, and accuracy of each parameter in
predicting survival were assessed. A P ≤ 0.05 was considered statistically significant.

4.3 Results
4.3.1

Acute Vascular Changes and Histopathologic Features
Irradiated rats received 12 Gy in the tumour and peritumoural region, and

different CT perfusion changes were observed in these two regions. Tumour volume,
rBF, and rBV decreased significantly while peritumoural rBF, rBV, and PS increased
significantly in the SRS group (Table 4-1). These opposite CT perfusion changes in the
tumour and peritumoural regions are illustrated in Figure 4-1.

110

Table 4-1: Acute changes (± standard error) in CT perfusion parameters.
Percent Change (%)
Regions-of-interest Treatment Tumour volume
rBF
rBV
PS
SRS
-37.3 ± 13.2*
-18.2 ± 7.9* -23.1 ± 7.6*
-9.2 ± 9.7
Tumour
Control
95.1 ± 34.7*
-13.1 ± 9.3
-6.4 ± 9.4
7.4 ± 15.1
SRS
N/A
20.9 ± 7.9* 28.7 ± 7.7** 54.3 ± 11.6**
Peritumoural
Control
N/A
-5.0 ± 5.3
2.0 ± 5.0
13.9 ± 20.2

Abbreviations: SRS, stereotactic radiosurgery; rBF, relative blood flow; rBV, relative
blood volume; PS, permeability-surface area product.
* Significantly different compared to baseline at P ≤ 0.05 level
** Significantly different compared to baseline at P ≤ 0.01 level

Figure 4-1: Acute CT perfusion changes on the fourth day after stereotactic
radiosurgery (SRS). Tumour relative blood flow (rBF) decreased from 1.48 to 0.68,
relative blood volume (rBV) decreased from 1.70 to 0.78, while permeability
surface-area (PS) decreased from 4.67 to 3.87 ml/min/100g. On the contrary,
peritumoural rBF increased from 0.96 to 1.49, rBV increased from 1.06 to 1.52, and
PS increased from 2.13 to 3.81 ml/min/100g.
H&E histological examination revealed that all tumours were grade IV gliomas.
Hypercellularity, mitosis, pseudopalisading necrosis, and endothelial hyperplasia were
observed as signs of grade IV glioma in the control animals. For the acute imaging group
that received SRS, fibrinoid or background necrosis, increased vascularity, and
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hyalinized blood vessels were identified. Atypical nuclei, calcification, and gliosis were
also observed in some lesions. Examples of H&E images of unirradiated tumour, acute
effects of SRS, and late effects of SRS are demonstrated in Figure 4-2, and a summary of
histological findings is provided in Table 4-2.

Figure 4-2: Histological examples of stereotactic radiosurgery (SRS) effects.
Representative Hematoxylin & Eosin images of an untreated control, acute
histological change at 4 days post-SRS, and late histological change at 59 days postSRS. Hypercellularity (four point star) and pseudopalisading necrosis (five point
star) are classic signs of grade IV glioma, and these were observed in the control
animals. Hyalinized blood vessels (arrow) and hypocellularity can be observed
shortly after SRS. Regression of tumour and hyalinization of tissue were observed at
a later stage after SRS.
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Table 4-2: Summary of histological finding on Hematoxylin and Eosin (H&E) specimens.
Presence of
Tumour

Tumour
Diameter
(mm)
7.3 ± 4.0

Hypocellularity

Types of
Necrosis

% Area
Necrosis

Vascularity

Tumour
Edema

Peritumoural
Edema

0%

88% PPN
13% FN

46 ± 27

0%

0%

50% PPN
25% FN
33% BN
None

37 ± 19

25%

42%

0%

0%

67% PPN
0% FN
17% BN

55 ± 13

75% EH
25% Increased
25% HBV
58% EH
58% Increased
100% HBV
0% EH
43% Increased
14 % HBV
67% EH
50% Increased
67% HBV

17%

33%

Controls

88% Yes
0% Diminished

Acute
Histology

75% Yes
25% Diminished

5.8 ± 3.0

25%

Responder

0% Yes
0% Diminished

N/A

N/A

4.6 ± 1.5

33%

Non-responder 50% Yes
33% Diminished

N/A

Abbreviations: PPN, pseudopalisading necrosis; FN, fibrinoid necrosis; BN, background necrosis; EH, endothelial hyperplasia; HBV,
hyalinized blood vessels
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Immunohistochemical staining revealed fragmented α-SMA positive vessels were
identified mostly in the SRS-treated tumours (Figure 4-3). Fragmented α-SMA positive
vessel densities in the tumour (P = 0.006) and peritumoural regions (P < 0.001) were
significantly higher in the irradiated animals than the control animals (Figure 4-4). In the
tumour, a positive borderline significant correlation between the percentage of
fragmented α-SMA positive vessels and PS:BV ratio was identified for the treated
animals (ρ = 0.58, P = 0.06) while a significant negative correlation was found for the
control animals (ρ = -0.84, P = 0.02). However, the amount of fragmented α-SMA
positive vessels in the controls was very small (Figure 4-4). In the peritumoural region of
the treated animals, negative correlations were found between the percentage of
fragmented α-SMA positive vessels with rBF (ρ = -0.62, P = 0.03) and rBV (ρ = -0.58, P
= 0.05).

Figure 4-3: α-smooth muscle actin (α-SMA) positive vessels in the normal brain,
peritumoural region, and tumour of a control and a treated animal after stereotactic
radiosurgery (SRS). Intact α-SMA positive vessels were observed in control animals,
but fragmented coverage of vessels by α-SMA is mostly seen in treated animals (red
arrow).
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Figure 4-4: Boxplots of intact and fragmented α-smooth muscle actin (α-SMA)
positive vessels in the control and SRS groups. Pairs with P < 0.01 are connected by
black lines.

4.3.2

Treatment Response, Longitudinal Changes, and Late
Histopathologic Features

Median survival of the control group was 10 days post-baseline scan (95% CI = 6 –
14 days), and median survival of the SRS group was not reached (log-rank P < 0.04).
However, survival in the SRS group was heterogeneous with 46% of the animals not
surviving for more than 15 days. We designated these relative low survival animals as
non-responders and animals with survival > 15 days as responders. Statistical
comparisons were performed for the first 4 time points because all controls died before
the 5th time point. Changes in tumour volume, rBF, rBV, and PS of these three groups are
shown in Figure 4-5. Significant tumour growth was observed in the controls (Friedman
P = 0.001, Wilcoxon signed-rank P < 0.03). Significant tumour shrinkage was observed
in the responders (Friedman P = 0.04, Wilcoxon signed-rank P < 0.05). There was no
significant tumour volume change in the non-responders. Tumour rBF in the responders
was significantly lower than the non-responders and controls on day 14 post-SRS

115

(Kruskal Wallis P = 0.01, Mann-Whitney U P < 0.04). Tumour rBV in responders were
significantly lower than the non-responders and controls on day 4 (Kruskal Wallis P =
0.04, Mann-Whitney U P < 0.04) and day 7 post-SRS (Kruskal Wallis P = 0.01, MannWhitney U P = 0.01). Responders’ tumour PS was significantly lower than the other
groups on day 7 post-SRS (Kruskal Wallis P = 0.007, Mann Whitney U P ≤ 0.008).
Between-group differences and longitudinal changes in PS:BV ratio in the tumour were
not significant.

Figure 4-5: Changes in (i) tumour volume, (ii) relative blood flow (rBF), (iii) relative
blood volume (rBV), and (iv) permeability-surface area (PS) in the tumour for
controls, responders, and non-responders. *Significantly different from baseline
(Friedman test and Wilcoxon-signed rank test). †Significantly different from
controls and #significantly different from non-responders (Kruskal-Wallis followed
by Mann-Whitney U test).

Figure 4-6 shows an elevation in peritumoural rBF in both responders and nonresponders on days 4 and 7 post-SRS compared to the controls (Kruskal Wallis P ≤
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0.006, Mann-Whitney U P ≤ 0.008). Significant elevation was observed in peritumoural
rBV of responders when compared to controls (Kruskal Wallis P < 0.01, Mann-Whitney
U P = 0.001), and a similar trend was observed for peritumoural PS albeit not significant.
This elevation in CT perfusion parameters eventually dissipated with time. Betweengroup differences and longitudinal changes in PS:BV ratio in the peritumoural region
were not significant.

Figure 4-6: Changes in (i) rBF, (ii) rBV, and (iii) PS in the peritumoural region for
controls, responders, and non-responders. *Significantly different from baseline
(Friedman test and Wilcoxon-signed rank test). †Significantly different from
controls (Kruskal-Wallis followed by Mann-Whitney U test).

Histological examination revealed no presence of tumour in any of the responders.
Increased vascularity was the major sign of late radiation-induced histologic change
(Table 4-2). Figure 4-2 shows an example of late radiation-induced damage after the
regression of tumour. For the non-responders, tumours were detected on H&E histology;
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pseudopalisading necrosis was the major type of necrosis observed. Increased vascularity,
endothelial hyperplasia, and hyalinized blood vessels were also observed.

4.3.3

Early Prediction of Survival after Stereotactic Radiosurgery
Tumour volume, rBF, rBV, PS, and PS:BV ratio at baseline and on day 4 post-

SRS did not correlate with overall survival. However, tumour rBV (ρ = -0.61, P < 0.05)
and PS (ρ = -0.85, P = 0.001) on day 7 post-SRS correlated with overall survival. We
evaluated whether each of the imaging parameter was predictive of overall survival by
grouping the treated animals based on the measurement on day 7 post-SRS. KaplanMeier survival plots are shown on Figure 4-7. SRS-treated animals with lower tumour
rBF, rBV, and PS had significantly longer survival than SRS-treated animals with higher
rBF, rBV, and PS (log-rank P ≤ 0.02). Treated animals with lower tumour volumes were
associated with longer survival than those with higher tumour volumes, but this was not
significant. Similarly, animals with a low PS:BV ratio did not have significantly different
survival than those with high PS:BV ratio. In terms of predictive performance, both rBV
and PS had the highest sensitivity (86%), specificity (100%), and accuracy (92%). rBF
had a sensitivity, specificity, and accuracy of 71%, 100%, and 83%, respectively. Tumour
volume had a sensitivity, specificity, and accuracy of 57%, 80%, and 67%, respectively.
The PS:BV ratio had sensitivity, specificity, and accuracy of 67%, 60%, and 64%,
respectively.
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Figure 4-7: Kaplan-Meier plots of response to treatment categorized by (A) tumour
volume, (B) relative blood flow (rBF), (C) relative blood volume (rBV), and (D)
permeability-surface area product (PS). For each imaging parameter, two response
groups were identified based on whether the measured value was less than the lower
50% confidence interval of variations across all treated animals derived from the
between-subject variation on day 7 post-SRS. Those that met this criteria were
ranked as “low” by applying this threshold, and the others were ranked as “high”.
Animals with low rBF, rBV, and PS on day 7 post-SRS showed significantly longer
survival than the rest of the treated animals (i.e. high rBF, rBV, and PS) and control
animals. *Significantly different from control group. †Significantly different from
the other treated animals with a “high” value. Significant at P ≤ 0.02 level (log-rank
test).
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4.4 Discussion
Although radiotherapy offers an overall survival benefit at the population level,
accurate assessment of tumour response for each patient is crucial for treatment
modification if no response to radiation is detected. Therefore, we need to develop noninvasive imaging biomarkers as early indicators of response to radiation. Such
biomarkers may help design combination therapies (drugs + radiation) in future clinical
trials. Combining SRS with an anti-angiogenic agent is an attractive treatment option (28)
because Bevacizumab appeared to ameliorate radiation-induced necrosis (29). Preclinical
studies also suggested that anti-angiogenic agent like DC101 is a radiosensitizer to SRS
(30).
From preclinical studies, overall survival benefits post-SRS are commonly
reported, with some treated animals surviving substantially longer than others (4-6). In
our study, SRS demonstrated an overall survival benefit and histological confirmation of
radiation-induced damage. Similar to previous studies, we observed substantial
heterogeneity in treatment response. We found that CT perfusion can be a potential
noninvasive imaging method to predict response to SRS, and that rBF, rBV, and PS
showed better predictive performance of survival than tumour volume.
In clinical studies, the survival benefit of SRS in combination with fractionated
radiotherapy is unclear with some studies suggesting a 2-year overall survival benefit
(31,32), while randomized trials showed that SRS did not confer a survival benefit over
fractionated radiotherapy alone (33,34). Current clinical evidence from fractionated
radiotherapy support our preclinical results in that a higher rBV after the completion of
radiotherapy is associated with poor survival (35,36). However, the correlation between
survival post-SRS and perfusion imaging parameters is lacking in the clinical literature,
and there is no imaging biomarker to assess patients who might respond to SRS. Our
results provide corroborating evidence to support the hypothesis that CT perfusion is an
early biomarker of response to SRS. Use of CT perfusion parameters to characterize
tumour vascular profiles and correlate with treatment response might identify patients
who would benefit from SRS or hypofractionation treatment schemes. The use of an early
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imaging biomarker to assess response to SRS or hypofractionated treatment schemes in
randomized clinical trials might better define the role of altered fractionation schemes in
this group of patients.
From the acute imaging study, PS did not correlate with the percentage of
fragmented α-SMA positive vessels, this could because PS is the product between
permeability and surface area of the endothelium (18). Since BV has been shown to
correlate with microvessel area (27), we investigated the PS:BV ratio as a surrogate
marker of permeability. After SRS, a positive correlation between PS:BV and the
percentage of fragmented α-SMA positive vessels points to the effect of radiation on the
permeability of the blood-tumour barrier. From our survival study, it is PS that correlated
with survival and not the PS:BV ratio. This suggests a low permeability (i.e. poor
delivery) but a high surface area of SMA coverage after SRS is associated with poor
survival. Vessels that are covered by SMA are mature vessels (24-26), and tumour vessel
maturity is associated radiation resistance (8,37-38). Together, this points to a possible
link between the vessel SMA coverage and survival. We were unable to show a
correlation between survival and SMA coverage of mature vessels directly since any
assessment of tumour vessels would require the sacrifice of animals. Further investigation
into the direct associations between tumour PS and SMA coverage of mature vessels with
tumour response is warranted.
It is important to study the effect of radiation on the adjacent normal brain tissue
(i.e. peritumoural region) because it is usually included in the irradiated volume that
receives a significant dose of radiation in clinical practice, particularly for linear
accelerator-based SRS. Complications and radiation-induced changes of brain tissue,
such as edema and blood-brain barrier breakage, after SRS of arteriovenous
malformations correlated with the volume of irradiated tissue that received 12 Gy (3940). The effect of SRS on peritumoural normal brain region in malignant glioma is not
well understood and seldom reported (10). Zawaski et al. showed that radiation caused
significant changes in permeability and leukocyte-endothelial interactions in the
peritumoural normal brain that were indicative of acute inflammatory reaction and
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radiation-induced astrogliosis. Our study provides supporting evidence by showing an
increase in blood-brain barrier PS.
A few limitations of this study must be considered. First, a relationship exists
between radiation effect and dose (2,4). We chose 12 Gy because this dose can be
delivered safely using Helical Tomotherapy, and it is used in the SRS boost of newly
diagnosed glioblastoma (31-32) and salvage therapy of recurrent glioblastoma for linear
accelerator-based SRS (41). Second, different tumour cell lines display different
radiosensitivities (42). Therefore, dose-response of vascular changes measured by CT
perfusion in other glioma models could be different. Thirdly, the sample size was
relatively small and all untreated rats and most of the non-responders have died after the
fourth CT perfusion scan. Thus, we could not compare the imaging data between these
groups at later time points. Finally, while we used stereotactic techniques for radiation of
the tumours, treatment volumes were still large relative to the size of the rat brain with
the irradiated volume encompassing the ipsilateral cerebral hemisphere. Thus, the volume
of normal brain irradiated was larger than would be the case in clinical radiosurgery
treatments. It is possible that these volume differences have contributed to the perfusion
changes seen in the peritumoural region.

4.5 Conclusions
This study showed that CT perfusion is a candidate to be an early biomarker of response
to SRS. A CT perfusion imaging study in the clinical setting would potentially allow for
timely and accurate assessment of early response to radiosurgery. It could help
understand the role of SRS in these patients and also in combination with anti-angiogenic
therapies. Evaluation of CT perfusion in prospective clinical studies are necessary to
validate this technique as a predictive assay. Validation of the relevant CT perfusion
indices used in this study for response assessment is warranted.
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Chapter 5

5

Relationship of Computed Tomography Perfusion and
Positron Emission Tomography to Tumour Progression
in Malignant Glioma
This chapter is adapted from the research article, “Relationship of computed

tomography perfusion and positron emission tomography to tumour progression in
malignant glioma” published in Journal of Medical Radiation Sciences, 2014;61(1):4-13
by Yeung TPC, Yartsev S, Lee T-Y, Wong E, He W, Fisher B, VanderSpek LL,
Macdonald D, Bauman G.

5.1 Introduction
In malignant glioma, over 80% of tumour progression occurs within 2 cm of the
original tumour site after radiotherapy and concurrent and adjuvant temozolomide
chemotherapy (1). Radiological assessment of tumour progression is primarily based on
gadolinium-enhanced magnetic resonance (MR) or iodinated contrast-enhanced
computed tomography (CT) (2). An increase in the size of the contrast-enhancing lesion
is one of the criteria for diagnosing progression (2). However, early changes in contrast
enhancement after treatment lack utility in identifying active tumour sites that are likely
to persist after treatment.
Functional imaging is gaining popularity as it has demonstrated utility in
differentiating tumour grade, predicting treatment response and survival and in
identifying active tumour after treatment prior to progression (3). Pre-treatment
functional imaging measurements of tumour perfusion and metabolism have been shown
to predict survival in newly diagnosed and recurrent malignant glioma (4-7). Similarly,
changes in blood flow (BF) and blood volume (BV) during radiotherapy have been
shown to be predictive of survival (8,9). The use of multiparametric imaging data may
have an added value for predicting survival. For example, tumour metabolism and BF
were combined into a metric called the metabolism-flow ratio, and this was found to be
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predictive of poor survival in pancreatic cancer (10). Metabolism and BF are usually
tightly coupled in normal tissue; however, an increase in metabolism in the presence of
low BF may be indicative of a tumour's adaptation to hypoxia (11). This suggests that the
metabolism-flow ratio may be a valuable biomarker of hypoxia, which is associated with
treatment resistance.
CT perfusion can simultaneously measure BF, BV and permeability-surface area
product (PS) in brain tumours (12), and 18-Fluorodeoxyglucose positron emission
tomography (FDG-PET) is in routine clinical use for measuring tumour metabolism. The
combination of FDG-PET and CT perfusion using a hybrid PET/CT scanner is a practical
technique for assessing metabolism and perfusion in quick succession. This can also be
used to calculate the metabolism-flow ratio, which circumvents the need for specialized
synthesis capabilities to produce hypoxia tracers such as 18-Fluoro-azomycin
arabinoside.
No functional imaging studies have been reported near the completion of
radiotherapy as an attempt to detect residual malignant gliomas. This study investigated
the associations between the pre-radiotherapy gross tumour as defined on contrastenhanced MR, near-end-of-radiotherapy enhancing lesion as defined on contrastenhanced CT, near-end-of-radiotherapy CT perfusion and FDG-PET parameters with
post-treatment MR-defined tumour progression. We then assessed the value of using
these imaging parameters for predicting post-treatment MR-defined tumour progression.
Therefore, the goal of this study was to assess whether functional imaging has the
potential in predicting sites of future progressive tumour on a voxel-by-voxel basis after
radiotherapy and chemotherapy. This can help identify biologically significant volumes
of disease present at the end of conventional radiotherapy that could serve as a target for
treatment intensification.
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5.2 Methods
5.2.1

Patients
All study procedures were approved by Institutional Research Ethics Board.

Patients with newly diagnosed malignant glioma were prospectively recruited to the
study with informed consent prior to the last week of radiotherapy. The inclusion criteria
were: (1) at least 18 years of age, (2) histologically confirmed malignant glioma, (3)
Karnofsky Performance Status ≥60, (4) no previous cranial radiotherapy and (5) preradiotherapy MR were performed within 12 weeks of radiotherapy treatment planning.
Recurrent gliomas, multiple intracranial lesions, or patients that were not suitable for
radical radiotherapy (40–60 Gy in 15–30 fractions) were excluded.

5.2.2

Multi-modality Imaging Schedule
After surgery but before radiotherapy, each patient underwent a standard MR

imaging comprised of at least one series of T1- and T2-weighted images using a 1.5 T
MR scanner (Signa Excite, General Electric Medical Systems, Milwaukee, WI). This MR
scan was performed within 12 weeks of the treatment planning CT. Contrast-enhanced
T1-weighted images were acquired using a fast spoiled gradient echo sequence
(repetition time = 10 msec, echo time = 4 msec and flip angle = 15°) after an intravenous
injection of gadopentetate dimeglumine (0.2 mL/kg; Magnevist; Berlex Laboratories,
Wayne, NJ).
A FDG-PET and CT perfusion scan was performed during the final week of
radiotherapy using a hybrid PET/CT scanner (Discovery VCT, General Electric
Healthcare, Waukesha, WI). After an intravenous injection of FDG (385 MBq), positron
emission data were collected in list mode for 60 min and binned into 5 min frames in the
last 40 min. Each PET data set consisted of 47 axial PET images with a 3.26 mm slice
thickness and a 26 cm axial field of view (FOV).
The FDG-PET CT attenuation correction maps in the FDG-PET study were used
to select eight 5 mm sections to maximally cover the tumour for a 150 sec two-phase CT
perfusion scan. A non-ionic contrast bolus (Omnipaque, General Electric Healthcare,
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Princeton, NJ, 300 mg iodine per mL, 0.8 mL/kg of body weight) was injected at a rate of
2–4 mL/sec at 3–5 sec before the start of the scan. While the selected brain sections were
scanned continuously for 45 sec and the images reconstructed at 1-sec intervals during
the first phase, the same sections were scanned once every 15 sec for seven times during
the second phase. The scanning parameters for both phases were 80 kVp, 190 mA, 1 sec
per rotation and a 25-cm FOV.
Post-radiotherapy follow-ups were both clinical and radiological. Routine MR
images were obtained at 4–6 weeks post-radiotherapy and every 3 months thereafter, and
were reviewed by a neuro-oncologist or radiation oncologist. Tumour progression was
defined as a continual enlargement of new enhancing lesion (without subsequent
resolution) on serial MR imaging along with deterioration of clinical signs and symptoms
(2).

5.2.3

Image Processing
CT perfusion images were analyzed using the prototype version of CT Perfusion

4D (Advantage Windows, GE Healthcare, Waukesha, WI). Arterial and venous timeattenuation curves were measured from an anterior cerebral artery and the posterior
superior sagittal sinus respectively. BF, BV and PS maps were calculated by
deconvolving the arterial time-attenuation curve with the tissue time-attenuation curve
from 2 × 2 voxel blocks of CT images (12). The CT images were averaged together to
produce average CT images, which have better grey and white matter contrast than
conventional contrast-enhanced CT images.
Software provided with the PET/CT scanner was used to correct the PET
emission data for random and scatter coincidences, dead time and attenuation. PET
images from the last 5 min bin were rigidly co-registered with the average CT using the
3D Slicer software (13). The registered PET voxel values were converted to standard
uptake values (SUV) corrected for body surface area (14). SUV maps were divided by
the BF maps to generate SUV:BF ratio maps.
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Gadolinium-enhanced T1-weighted MR images from pre-radiotherapy and at
progression were rigidly co-registered with the near-end-of-radiotherapy average CT. All
images (MR and average CT) and functional maps (CT perfusion and PET SUV) were
then resampled to 170 × 170 voxels to minimize registration error. From here on, the
contrast-enhancing lesion in the pre-radiotherapy T1-weighted MR lesion is the gross
tumour, the contrast-enhancing lesion on the average CT acquired at the last week of
radiotherapy is the near-end-of-radiotherapy enhancing lesion, and the contrastenhancing lesion on follow-up T1-weighted MR at the time of progression is the
progressive tumour. Contours around the pre-radiotherapy gross tumour, near-end-ofradiotherapy enhancing lesion and progressive tumour were delineated by a radiation
oncologist (G.B.). Table 5-1 summarizes the labelling and time of acquisition of the
images.

Table 5-1: Summary of images acquired in this study.
Name
Gross tumour
volume
Near-end-ofradiotherapy
enhancing lesion
BF
BV
PS
PET
Progressive
tumour

Type of
Image(s)
T1weighted
MR
Averaged
CT
BF map
BV map
PS map
SUV map
T1weighted
MR

Image signal

Time of acquisition

Gadolinium
enhancement

Post-surgery/biopsy and preradiotherapy (must be within 12
weeks of treatment planning CT)

Iodine
enhancement
(HU)
mL/min/100g
mL/100g
mL/min/100g
FDG uptake
Gadolinium
enhancement

Last week of radiotherapy
Last week of radiotherapy
Last week of radiotherapy
Last week of radiotherapy
Last week of radiotherapy
Time of progression based on routine
clinical and radiological follow-up
assessments (4 – 6 weeks postradiotherapy and every 3 months
after)

Abbreviations: MR, magnetic resonance; CT, computed tomography; BF, blood flow;
BV, blood volume; PS, permeability-surface area product; PET, positron emission
tomography; SUV, standard uptake value; FDG, 18-Fluorodeoxyglucose.
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5.2.4

Logistic Regression
A custom MATLAB (MathWorks Incorporated, Natick, MA) program was

developed for this analysis. A 2-cm bounding box around the union of the preradiotherapy gross tumour and the progressive tumour was created to reduce the amount
of information for analysis for each patient. Major blood vessels, surgical cavities,
ventricles and voxels outside the bounding box were excluded. Each voxel inside the
bounding box was assigned three binary statuses: pre-radiotherapy gross tumour (yes/no),
near-end-of-radiotherapy enhancing lesion (yes/no) and progressive tumour (yes/no).
Logistic regression was used to assess the association between tumour progression and
the following sets of independent imaging variables: (1) pre-radiotherapy gross tumour,
(2) near-end-of-radiotherapy enhancing lesion, (3) BF, BV, PS and SUV and (4) BV, PS,
SUV:BF (15). The last regression was used to investigate the association between tumour
progression and SUV:BF as a marker of hypoxia. The strength of association between
each parameter and progressive tumour status was evaluated by the odds ratio. Odds
ratios were converted to probabilities of recurrence for easier interpretations.

5.2.5

Cross-validation
Leave-one-out cross-validation was used to assess the value of using different

imaging parameters to predict tumour progression (16). Each round of cross-validation
used one patient data set as the validation set and the data sets from the other patients as
the training set. Probability maps of progression for an individual patient (i.e. the
validation set) were calculated using the logistic regression equation from the training set.
We first considered seven single variable models: (1) Pre-radiotherapy gross tumour, (2)
Near-end-of-radiotherapy enhancing lesion, (3) BF, (4) BV, (5) PS, (6) SUV and (7)
SUV:BF. We then considered two multivariate models: (1) BV, PS, SUV:BF and (2) BF,
BV, PS and SUV. Using receiver operating characteristic (ROC) analysis, the area under
the ROC (AUC) curve was calculated. The optimal sensitivity and specificity was
calculated using the Youden Index, which is the probability threshold that maximizes the
sum of sensitivity and specificity for all possible probabilities from 0% to 100% (16).
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5.2.6

Statistical Analysis

Pre-radiotherapy gross

tumour,

near-end-of-radiotherapy enhancing

lesion

and

progressive tumour volumes within the 4 cm CT perfusion scan length were compared
using the Wilcoxon signed-rank test. AUCs of the different logistic models were
compared using the Friedman test followed by the Wilcoxon signed-rank test. Models
with AUCs that are significantly higher than the AUCs of the pre-radiotherapy gross
tumour and end-of radiotherapy enhancing lesion were reported. All statistical tests were
done using SPSS version 19.0 (SPSS Incorporated, Chicago, IL), and P-values <0.05
were considered significant.

5.3 Results
Ten patients with newly diagnosed malignant glioma were prospectively recruited to the
study between the years 2008 and 2011. After surgery, all patients underwent
radiotherapy (60 Gy in 30 fractions) with concurrent and adjuvant temozolomide
chemotherapy. Patient characteristics are listed in Table 5-2. Tumour progression with no
evidence of necrosis was histopathologically confirmed in two patients (Patient 9 and 10
in Table 5-2); the remaining patients had tumour progression defined on clinical and
imaging grounds only.
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Table 5-2: Patient Characteristics.
Patient
No.

Age WHO
Grade

Tumour Location

Type of
Resection

Site of
Tumour
Progression

Treatment Steroid
Use

Survival
Status

Partial

Months Between
RT and Appearance
of Progressive
Tumours
8.6

1

36

3

Left Frontal
Temporal

a

RT, TMZ

Yes

Deceased

2

47

4

Left Parietal

Partial

12.0

In-field

RT, TMZ

Yes

Deceased

3

55

4

Left temporal

Partial

2.3

In-field

RT, TMZ

Yes

Deceased

4

37

3

Left frontal temporal

Partial

8.4

RT, TMZ

No

Deceased

5

50

4

Left Frontal lobe

Partial

5.0

In-field and
b
out-of-field
In-field

RT, TMZ

Yes

Deceased

6

71

4

Right temporal
parietal

Biopsy

2.1

In-field

RT, TMZ

Yes

Deceased

7

71

4

Left frontal

Biopsy

4.3

In-field

RT, TMZ

Yes

Deceased

8

61

4

Left posterior frontal
parietal inter-axial
tumour

Partial

14.8

In-field

RT, TMZ

Yes

Deceased

9

60

4

Left Frontal Parietal

Partial

11.0

In-field

RT, TMZ

Yes

Alive

10

54

4

Left Temporal

Partial

15.6

In-field

RT, TMZ

Yes

Alive

In-field

Abbreviations: WHO, World Health organization; RT, radiation therapy; TMZ, concurrent + adjuvant temozolomide
a
In-field = within 2 cm of the primary contrast-enhancing tumour; bOut-of-field = beyond 2 cm of the primary contrast-enhancing
tumour

135

The mean volumes ± standard deviation (SD) of pre-radiotherapy gross tumour,
near-end-of-radiotherapy enhancing lesion and the progressive tumour within the CT
perfusion scan volume were 10.8 ± 11.1, 14.1 ± 20.8 and 16.1 ± 18.0 cm3 respectively.
The differences in volumes were not significant (P > 0.05). Figure 5-1 displays the
images of patient 3.

Figure 5-1: Pre-radiotherapy gross tumour (T1-weighted MR), near-end-ofradiotherapy enhancing lesion (averaged CT) and progressive tumour (T1-weighted
MR); and the corresponding parametric maps of blood flow (BF), blood volume
(BV), permeability-surface area (PS) product, standard uptake value (SUV) and
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SUV:BF acquired using CT perfusion and FDG-PET. Blue outlines show the
contrast-enhancing lesions delineated by a radiation oncologist. Yellow outline is the
2-cm bounding box that was set for performing logistic regression. MR, magnetic
resonance; CT, computed tomography; FDG-PET, 18-Fluorodeoxyglucose positron
emission tomography.

5.3.1

Multivariate Logistic Regression

When compared with normal brain tissue, the pre-radiotherapy gross tumour and the
near-end-of-radiotherapy enhancing lesion had odds ratios of 12.7 (95% confidence
interval [CI], 12.1–13.4) and 43.3 (95% CI, 41.4–45.3), respectively, for tumour
recurrence. These odds can be expressed as recurrence probabilities of 54.4% and 69.8%
respectively. Multivariate logistic regression showed that the odds of tumour progression
increased with lower BF, BV and SUV; and with higher PS and SUV:BF (P < 0.0001)
(Table 5-3).

Table 5-3: Multivariate logistic regression.
95%
Confidence
Regression
Probability
Model Parameter
P
Interval
Coefficients (β)
(%)
+95% -95%
BV
<0.0001
-0.15
0.86
0.84
0.87
7.1
PS
<0.0001
0.41
1.51
1.49
1.52
11.9
1
SUV:BF <0.0001
2.63b
13.88
11.38 16.94
55.4
Constant <0.0001
-2.41
0.09
0.09
0.09
8.2
BF
<0.0001
-0.01
0.99
0.99
0.99
23.1
BV
<0.0001
-0.07
0.93
0.91
0.95
22.1
2
PS
<0.0001
0.39
1.48
1.47
1.50
31.0
SUV
<0.0001
-0.93
0.39
0.37
0.41
10.7
Constant <0.0001
-1.19
0.30
0.29
0.32
23.3
Abbreviations: BV, blood volume; PS, permeability-surface area product; SUV, standard
uptake value; BF, blood flow.
a

a

Odds
Ratio
(eβ)

Degrees of freedom = 128,330
An increase in SUV:BF value by 0.01 was associated with an odds ratio = 1.03; this
corresponded to a probability of 8.4%.
b
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5.3.2

Cross-validation
The AUCs for the three models (1) PS alone, (2) BV, PS, SUV:BF and (3) BF,

BV, PS and SUV were 0.72 ± 0.12, 0.74 ± 0.13 and 0.77 ± 0.11 respectively. These
AUCs were significantly higher than the AUCs of the pre-radiotherapy gross tumour and
near-end-of-radiotherapy enhancing lesion (Friedman P < 0.001; Wilcoxon signed-rank P
≤ 0.03), which were 0.64 ± 0.14 and 0.65 ± 0.14 respectively. Although the AUCs of the
two multivariate models were higher than that of PS, the differences were not statistically
significant (P > 0.05). Table 5-4 shows model pairs that are significantly higher than the
pre-radiotherapy gross tumour and the end-of-radiotherapy enhancing lesion. The model
using PS alone had a sensitivity and specificity of 0.6 ± 0.1 and 0.7 ± 0.1, respectively
(Figure 5-2). The model using BF, BV, PS and SUV had the highest combination of
sensitivity and specificity (0.7 ± 0.1 and 0.7 ± 0.1). Probability maps of progression were
generated using these logistic models, examples of probability maps for patient 3 are
shown in Figure 5-3.

Table 5-4: Statistical differences in area under the receiver operating characteristics
curve.
Model 1

Model 2
PS
Pre-radiotherapy gross BV, PS, SUV:BF
tumour
BF, BV, PS, SUV
PS
End-of-radiotherapy
BV, PS, SUV:BF
enhancing lesion
BF, BV, PS, SUV
BV, PS, SUV:BF
PS
BF, BV, PS, SUV

% Difference = (Model 2 –
Model 1)/(Model 1)×100
14.2
16.4
21.4
12.7
15.4
21.1
2.1
7.5

± SD
p
18.1 0.03
18.6 0.03
18.6 < 0.01
10.7 0.02
16.7 0.03
20.4 0.02
7.2
0.29
15.9 0.29
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Figure 5-2: Area under the operating characteristic curve (AUC) (top), sensitivities
(middle) and specificities (bottom) for the selected logistic regression models.
Models with an AUC that is significantly higher than the pre-radiotherapy gross
tumour and the end-of-radiotherapy enhancing lesion are indicated with an asterisk
(*). 1, Pre-radiotherapy gross tumour; 2, End-of-radiotherapy enhancing lesion; 3,
BF; 4, BV; 5, PS; 6, SUV; 7, SUV:BF; 8, BF, PS, SUV:BF; 9, BF, BV, PS, SUV.
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Figure 5-3: Probability of tumour progression (patient 3) within the 2-cm bounding
box generated using the different logistic regression models. Black line outlines the
boundary of the progressive tumour. Based on cross-validation, the magenta line
delineates the region with the probability threshold that maximizes the sum of
sensitivity and specificity in predicting progression.

5.4 Discussion
We investigated whether near-end-of-radiotherapy CT perfusion and FDG-PET
can add value to the assessment of malignant glioma in terms of predicting voxels that
are likely to progress after treatment. PS alone was found to be the best predictor of
tumour progression when compared to other CT perfusion and FDG-PET parameters;
however, voxel-based prediction of progression had only modest sensitivity and
specificity.
PS describes the unidirectional flow of contrast as it leaks from the intravascular
space into the interstitial space (i.e. brain parenchyma) (12). It is not the same as contrast
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enhancement because it quantitatively measures the rate of contrast extravasation. In this
study, not only did PS show a significant association with progressive tumour but it had a
higher AUC than the pre-radiotherapy gross tumour and near-end-of-radiotherapy
enhancing lesion for identifying tumour voxels that are more likely to progress. This
suggests that PS adds value to contrast enhancement in determining active tumour
regions after treatment, and also provides corroborating evidence to support that PS is
associated with tumour aggressiveness. PS can be a potential biomarker of tumour
aggressiveness because of the underlying pathological aspect that it represents. PS has
larger value in high-grade gliomas compared to low-grade gliomas (17), which is
important for prognosis. It also showed correlations with aggressive phenotypes
including microvascular cellular proliferation (18) and the expression of pro-angiogenic
genes (19). Finally, PS has been used to distinguish true tumour progression from
treatment effect like treatment-induced necrosis (20).
The observation that both lower BF and BV showed significant associations with
tumour progression is noteworthy. A lower BF and BV may suggest resistance to therapy
due to the presence of hypoxia. In support of this, dynamic susceptibility contrast MR
studies at pre- and mid-radiotherapy showed that a drop in relative BF and BV were
predictors of poor survival (8,9). However, the associations observed in this study were
obtained from one time point only, and they do not suggest a causal relationship with
progression.
We found that a lower SUV, when considering the entire tumour, is associated
with an increased risk of progression. This is contrary to studies that showed an increased
FDG uptake is associated with poor survival in patients at various stages of treatment
(21) or in patients with recurrent tumours (7,22). In these prior studies, FDG uptake in the
hypermetabolic region was used to assess correlation with survival. This usually
coincides with the contrast-enhancing region of the tumour where the perfusion is high;
hence, an FDG delivery was unimpeded. Our results suggest that when considering the
tumour as a whole, a lower FDG uptake is associated with higher odds of progression. A
low FDG uptake does not necessarily infer a lack of metabolic demand. We instead
showed a higher SUV:BF ratio was associated with an increased risk of recurrence,
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which suggests that a low SUV was due to poor delivery resulting in uncoupling between
metabolism and perfusion. This is consistent with PET-based measure of SUV:BF in
pancreatic cancer in which a higher SUV:BF was associated with poor survival (10).
These observations provide evidence to support the Warburg Effect hypothesis (10,11).
Cancer cells can maintain anaerobic respiration to keep up with its metabolic demand
under hypoxic stress and can be therapeutically resistant. This could lead to tumour
regions that remain active despite treatment.
Some limitations of this study must be considered. Although the AUCs of the
multivariate models were higher than those of the univariate PS model, we were unable
to demonstrate the statistical significance of multivariate models superiority. A larger
sample size is required to determine whether (1) BF, BV, PS and SUV and (2) BV, PS
and SUV:BF can provide more information than PS alone for identifying tumour regions
that are likely to progress. Other radiotracers with a higher tumour-to-background ratio in
the brain can improve the detection of residual tumour at the end of radiotherapy. For
example, both 3′-Deoxy-3′-18F-fluorothymidine (FLT) (23) and 11C-methionine PET
(24) were reported to be more sensitive than FDG in evaluating progressive tumours.
Deformable registration could potentially improve the quality of registration. Most
deformation of the tumour would occur from before and after surgery. This study used
only post-surgery images; thus, physical deformation of the tumour is minimal. In
addition, the majority of patients received dexamethasone during radiotherapy, which
could decrease tumour permeability resulting in less edema and hence less deformation
(25). The use of dexamethasone can also decrease cerebral glucose metabolism (26,27).
The effect of dexamethasone on glucose metabolism is global rather than localized; it is
unlikely to affect the current results because the logistic regression is based on imaging
data obtained from both the normal brain and tumour tissues. Finally, we focused our
investigation on the tumour site and its immediate surroundings, the potential effects of
radiation on normal brain tissue perfusion and metabolism were not investigated in detail.
A small radiation dose-dependent relationship (<10%) was observed for both brain tissue
metabolism and perfusion (28). We evaluated the relationship between normal brain
tissue BF, BV and PS with radiation dose in seven patients and did not find a significant
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relationship (data not shown). Thus, the effect of radiation on normal tissue BF, BV and
PS is unlikely to affect the current results.

5.5 Conclusions
We developed a technique for voxel-wise analysis of CT perfusion and FDG-PET images
acquired at the end of radiotherapy for patients treated for malignant glioma. On the basis
of our analysis, near-end-of-radiotherapy PS was the best predictor of tumour progression
on a voxel-by-voxel basis when compared to other CT perfusion and FDG-PET
parameters. However, voxel-based analysis had only modest sensitivity and specificity.
Exploration of these findings among a larger patient cohort would help confirm the value
of PS imaging in predicting recurrence and in confirming the trend towards improved
prediction with multivariate imaging data.
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Chapter 6

6

Treatment monitoring in high-grade gliomas: A serial CT
perfusion and MR study
This chapter is adapted from the manuscript entitled “Treatment monitoring in

high-grade gliomas: A serial CT perfusion and MR study”. This manuscript will be
submitted to the Journal of Neuro-Oncology in July 2014 to be considered for
publication. The authors of this manuscript are Yeung TPC, Wang Y, Urbini B, Yartsev
S, Bauman G, Lee TY, Fainardi E, and the Project of Emilia-Romagna region on NeuroOncology (PERNO) Study Group. Member of the PERNO Study Group is provided in
Appendix E.

6.1 Introduction
High-grade gliomas account for over 70% of all malignant brain tumours, and
survival rates remain dismal even after maximal safe resection, radiotherapy, and
temozolomide chemotherapy. The typical median survival for patients with World Health
Organization (WHO) grade IV gliomas is typically 12 – 15 months, and it is 2 – 5 years
for those with WHO grade III gliomas (1). However, there is considerable heterogeneity
in patients’ treatment response. At present, widely accepted prognostic factors of survival
in high-grade gliomas are WHO grade, extent of surgical resection, age, and performance
status (2). Molecular biomarkers, such as isocitrate dehydrogenase 1 (IDH1) methylation
status, O6-methylguanine-DNA-methyltransferase (MGMT) methylation status and
1p19q loss of heterozygosity, are also recognized as predictive and prognostic biomarkers
in these patients (3).
High-grade gliomas, particularly WHO grade IV gliomas, are highly infiltrative
tumours with recurrence typically arising within 2 cm of the irradiated volume (4,5).
Magnetic resonance (MR) imaging is the standard imaging method for brain tumour
diagnosis, treatment planning, and response assessment. The typical MR protocol
involves a T2-weighted or fluid-attenuated inversion recovery (FLAIR) MR and a
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gadolinium-enhanced T1-weighted MR (6). Following this protocol is preferable because
it detects two types of anatomical abnormalities. The gadolinium-enhanced T1-weighted
MR images depict the contrast-enhancing lesion (CEL) with disrupted blood-brain
barrier. The T2-weighted or FLAIR MR images detect regions of T2 hyperintensity that
are suspicious of tumour infiltration and vasogenic edema. Such T2 hyperintense region
is the non-enhancing lesion (NEL) that cannot be seen on T1-weighted MR.
Functional imaging techniques are non-invasive methods to provide quantifiable
information regarding tumour biology that may be related to tumour aggressiveness and
patient prognosis (7). One important functional imaging technique is perfusion imaging.
Measurements of perfusion imaging parameters such as tumour blood flow (BF), blood
volume (BV), and permeability have been shown to correlate with WHO grade (8,9),
histopathologic marker of tumour angiogenesis (e.g. microvessel density) (10,11), and
survival (12,13,14). Most perfusion imaging studies that evaluated the relationships
between tumour perfusion parameters and overall survival (OS) have focused on MR
perfusion at a single time point (15) or two time points (16). CT perfusion has not been
studied extensively (17) despite the ubiquity of CT scanners in radiation oncology
departments. However, CT perfusion can help distinguish between high and low grade
gliomas (8,18-20) and between tumour recurrence and radiation necrosis (21,22). In
addition, CT perfusion can simultaneously measure absolute BF, BV, and permeabilitysurface area (PS) in a single scan. Therefore, CT perfusion should be considered as a
valuable perfusion imaging modality in oncology.
This study is the first study to evaluate serial changes in tumour BF, BV, and PS
in the CEL and NEL of patients with high-grade gliomas for up to a year after
radiotherapy. The objective of this study was to evaluate the prognostic value of CT
perfusion for predicting overall survival (OS) of patients with high-grade gliomas.
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6.2 Materials and Methods
6.2.1

Patient Population
This study was conducted in compliance with the local research ethics committee,

and informed consent was obtained from patients. Patients with suspected WHO grade III
and IV gliomas were prospectively recruited prior to surgery. Exclusion criteria were 1) a
brain lesion that is not WHO grade III and IV gliomas after histopathologic confirmation,
2) prior diagnosis or therapy of brain lesion, 3) unwillingness to participate during
follow-up examinations, 4) clinically unstable, 5) contraindications to intravenous
administration of iodinated or gadolinium contrast materials, 6) poor quality images due
to motion artifacts, and 7) inability to undergo MR due to contraindications such as
metallic implants, claustrophobia, and obesity. Our study included 29 patients with highgrade gliomas. Patients with WHO grade III gliomas (N = 5) had anaplastic
oligodendrogliomas and the rest had WHO grade IV glioblastoma multiforme. The
median age of diagnosis was 61 years (range, 31 – 81 years). Patients underwent serial
MR and CT perfusion examinations prior to surgery and one, three, six, nine, and 12
months after radiotherapy. The median follow-up was 18.2 months (range, 4.7 – 60.4
months).
After the pre-surgery MR and CT perfusion examinations, all patients underwent
surgery followed by external beam radiotherapy (60 Gy in 30 fractions, N = 28; 45 Gy in
15 fractions with stereotactic boost of 24 Gy in 3 fractions, N = 1). Twenty-six patients
received concurrent and adjuvant temozolomide chemotherapy. Six patients underwent
additional surgery after radiotherapy, and corticosteroids were administered to patients
before the second surgery. At the time of progression, glioblastoma patients were given
Fotemustine while anaplastic oligodendroglioma patients were given Procarbazine +
CCNU (Lomustine).
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6.2.2

Conventional MR and CT Perfusion Examinations
MR images were acquired with either a 1.5T Signa HDXT (GE Healthcare,

Milwaukee, WI) or a 1.5 T Achieva scanner (Philips Medical Systems, Best, The
Netherlands). The MR protocol consisted of the following sequences: axial T1-weighted
spin-echo, axial T2-weighted spin-echo or axial FLAIR, coronal FLAIR, and postgadolinium axial T1-weighted spin echo.
All CT perfusion studies were performed using a multidetector-row CT scanner
(Lightspeed VCT, GE). A noncontrast CT scan (350 mA, 120 kV, 5 mm slice thickness)
of the head was acquired to locate the brain volume for the CT perfusion scan that would
cover eight 5-mm sections of tissue. Ten patients were imaged with a one-phase CT
perfusion protocol while 19 patients were imaged with a two phase CT perfusion
protocol. A bolus of non-ionic contrast (Iomeron, Bracco Imaging, Konstanz, Germany;
350 mg I/ml, 40 ml) was injected at a rate of 4 mL/s. For the one-phase CT perfusion
protocol, a cine scan was initiated at 5 s after the injection. The imaging parameters were
100 mA, 80kV, 1 rotation/s for a duration of 50 s, and images were reconstructed at 0.5 s
intervals. For the two-phase protocol, the initial 50 s cine scan was acquired with images
reconstructed at 0.5 s intervals, then 8 additional axial images were acquired for each
section at 15 s intervals for another 105 s. The total scan duration was 150 s. The CT
gantry was tilted to avoid radiation dose to the lens, signs of radiation toxicities from CT
perfusion scans were documented. Skin erythema, dizziness, loss of equilibrium,
modified gait, stupor of thought, loss of memory, air loss, cataract formation during the
CT and MR follow-ups were some of the radiation-induced side effects assessed by the
attending radiologist.

6.2.3

Image Analysis
Maps of BF, BV, and PS were computed using the prototype version of CT

Perfusion 4D (GE Healthcare) (23,24). Averaged CT images were produced by averaging
the cine CT images of the same sections. Axial gadolinium-enhanced T1-weighted MR
and axial T2-weighted or FLAIR MR images were rigidly registered to the averaged CT
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images using 3D Slicer (25). A radiologist with 8 years of experience manually
delineated the contrast-enhancing lesion (CEL) on gadolinium-enhanced T1-weighted
images and the non-enhancing lesion (NEL). The NEL was the entire T2 hyperintense
lesion outside the CEL, necrosis, and surgical cavity. Mean volume, BF, BV, and PS in
both CEL and NEL at each time point were used for statistical analysis.

6.2.4

Statistical Analysis
Statistical analysis was performed using SPSS software package (IBM ® SPSS®,

version 21.0, Chicago, IL). OS was the time between the first surgery and death. OS was
censored for patients that were alive at their last follow-up. Patients were stratified by
their OS using 12, 18, and 24 months OS as cut points. Longitudinal analyses examined
the imaging parameter differences in patients with short versus long OS. The omnibus
Friedman test followed by the Wilcoxon signed-rank test were used for longitudinal
comparisons within-group, and the Mann-Whitney U test examined the differences
between groups. The imaging time points that were analyzed were pre-surgery, one,
three, and six months post-radiotherapy. Nine and 12 months post-radiotherapy data were
not analyzed due to patient dropouts resulting from deaths or complete regression of
tumours.
A series of statistical analyses were carried out to evaluate whether the imaging
parameters were prognostic of OS. Receiver operating characteristic analyses were
performed to consider all possible cut points to differentiate patients with long and short
OS. The imaging parameter cut points with the highest combination of sensitivity and
specificity were selected for use in Cox proportional hazards regression and KaplanMeier survival analyses.
Cox proportional hazards regression analyses were performed to determine the
relationships between OS and each of the imaging parameters. Separate Cox proportional
hazards regression models were computed for each of the imaging parameters (volume,
BF, BV, and PS) at each time point while adjusting for age, performance status
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(Karnofsky Performance Status), extent of surgical resection, and WHO grade. The
hazard ratios (HR) and their 95% confidence intervals (CI) were computed. We did not
consider the impact of change in imaging parameters over time on OS by treating the
serial imaging measurements as time-dependent covariates. This is because this study
sought to evaluate whether one of these imaging time points can be used as an early
biomarker of OS in a prospective setting. We then used Kaplan-Meier survival analysis
and log-rank test to compare the OS of patients with high versus low values of imaging
parameters. A P value ≤ 0.05 was considered statistically significant.

6.3 Results
6.3.1

Patient Characteristics and Outcomes
A total of 150 CT perfusion and 150 MR examinations were obtained from 29

patients. No radiation toxicity from serial CT perfusion scans was noted. The median OS
was 18 months (range, 5 – 60 months) with three patients censored. Table 6-1
summarizes the characteristics of this patient cohort and OS estimates based on patient
characteristics. In univariate analyses, differences in gender, extent of surgical resection,
Karnofsky Performance Status, and re-operation were not significant predictors of OS.
Older patients (≥ 50 years) had worse OS than younger patients, but this was marginally
significant (P = 0.06). Patients with WHO grade IV tumours were associated with
significantly shorter OS compared to those with WHO grade III tumours (P = 0.04). The
six patients who received reoperation did not show significantly different OS than the
rest.

Table 6-1: Patient characteristics, percentages of patients alive 12, 18, and 24
months, and median OS estimates.
Demographics
Age
< 50

n

12 Months
OS

18 Months
OS

24 Months
OS

Median OS in
months (95% CI)

P
Value*

5

100%

80%

75%

32.7 (20.7 - 44.7)

0.06
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≥ 50 24
Gender
Female 11
Male 18
WHO Grade
III 5
IV 24
Extent of resection
Total 18
Subtotal 11

63%

38%

23%

16.6 ( 10.1 - 23.1)

55%
78%

45%
44%

27%
33%

16.7 (9.4 - 24.0)
18.2 (9.8 - 26.6)

0.58

100%
63%

80%
38%

67%
26%

29.7 (13.0 - 46.4)
16.6 (10.1 - 23.1)

0.04

89%
36%

56%
27%

38%
20%

22.3 (12.5 - 32.1)
11.4 (10.0 - 12.8)

0.37

61%
82%

39%
55%

28%
38%

16.4 (7.9 - 24.9)
24.4 (16.9 - 31.9)

0.70

83%
65%

50%
52%

0%
38%

16.7 (12.2 - 21.2)
22.3 (12.3 - 32.3)

0.40

Karnofsky Performance Status
≤ 80 18
> 80 11
Re-operation
Yes 6
No 23

Abbreviations: OS, Overall survival; CI, Confidence interval; WHO, World Health
Organization
*Log-rank P value comparing OS for the demographic factor

6.3.2

Longitudinal Analysis
Figure 6-1 shows the serial changes of each imaging parameter in the CEL in

terms of 12, 18, and 24 months OS. Patients appeared to show a reduction in CEL
volumes after surgery and radiotherapy compared to baseline, and this was significant for
patients with OS over 18 months (P < 0.04). There were also decreasing trends in BF,
BV, and PS in the CEL after surgery. These trends were significant for BF and BV in
patients who lived over 12 (P < 0.02) and 18 months (P < 0.05 and P < 0.03,
respectively), and for BV in patients who lived less 24 months (P < 0.04). With the
exception of BV in the CEL of patients who survived beyond 18 months, CEL volumes,
BF, BV, and PS were stable between one to six months post-radiotherapy. In general,
CEL volumes, BF, BV, and PS appeared to be higher in patients that survived below 18
and 24 months compared to other patients. BV at three months (P = 0.03) and PS at one
month (P = 0.04) post-radiotherapy were significantly higher in patients with OS < 24
months compared to other patients.

152

Figure 6-1: Serial changes in mean volumes (top row), blood flow (BF, second row),
blood volume (BV, third row), and permeability-surface area product (PS, bottom
row) in the contrast-enhancing lesions (CEL) of patients stratified by 12 (left
column), 18 (middle column), and 24 months (mo) overall survival (OS, right
column). Horizontal line represents significant changes between two highlighted
time points of the same group. Dotted box represents a significant difference
between the groups. Error bar represents one standard deviation.
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Figure 6-2 illustrates the serial changes in the NEL by different OS. NEL volumes
decreased after surgery and radiotherapy. This change (compared to baseline) was
significant for patients who lived more than 12 months (P < 0.05), more than 18 months
(P < 0.03), more than 24 months (P < 0.05), and also for patients who lived less than 24
months (P < 0.03). However, there was no between-group difference in NEL volumes in
patients with long (≥ 12, 18, and 24 months) versus short OS (< 12, 18, and 24 months).
BF values in the NEL were stable over time with the exception of a significant decrease
between pre-surgery and 6 months post-radiotherapy in patients that lived less than 24
months (P < 0.005). BF values in the NEL before surgery were significantly higher in
patients that deceased before 18 (P = 0.003) and 24 months (P = 0.004); and they were
also significantly higher at three months post-radiotherapy (P = 0.05) in patients with OS
below 18 months. In comparison with pre-surgery measurements, BV values in the NEL
decreased significantly (P < 0.04) at three and six months post-radiotherapy in patients
with OS below 24 months. However, BV values in the NEL were significantly higher at
one and three months post-radiotherapy in patients with OS below 18 months (P = 0.04
and 0.02, respectively) when compared to those with OS beyond 18 months. BV values
were also significantly higher at pre-surgery and one month post-radiotherapy for those
with OS less than 24 months when compared to those that lived beyond 24 months (P =
0.01 and 0.03, respectively). PS values in the NEL significantly decreased after surgery
and radiotherapy in patients who survived beyond 12 and 18 months (P < 0.01, and ≤
0.03, respectively), and also in patients who survived less than 18 and 24 months (P <
0.04 and < 0.04, respectively). More importantly, PS values in the NEL at one month
post-radiotherapy were significantly higher in patients who deceased before 18 and 24
months (P < 0.01), and these values measured at three months post-radiotherapy were
also significantly higher in patients with OS below 18 months (P = 0.02).
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Figure 6-2: Serial changes in mean volumes (top row), blood flow (BF, second row),
blood volume (BV, third row), and permeability-surface area product (PS, bottom
row) in the non-enhancing lesions (NEL) of patients stratified by 12 (left column), 18
(middle column), and 24 months (mo) overall survival (OS, right column).
Horizontal line represents significant changes between two highlighted time points
of the same group. Dotted box represents a significant difference between the
groups.

Error

bar

represents

one

standard

deviation.
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6.3.3

Survival Analysis
The Cox proportional hazards regression model of the classical prognostic factors

(i.e. age, performance status, extent of resection, and WHO grade) showed that higher
WHO grade (HR = 49.6, 95% CI = 5.1 – 483.2, P < 0.001) and lower extent of resection
(HR = 19.0, 95% CI = 3.6 – 99.5, P < 0.001) were associated with significant hazards of
death. A total of 96 Cox proportional hazards regression models were considered while
adjusting for age, performance status, extent of resection and WHO grade. Table 6-2
reports parameters with cut points that were associated with both significant hazard ratios
and significant differences in OS, and Figure 6-3 illustrates the Kaplan-Meier plots of
these parameters.
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Table 6-2: Cox proportional hazards regression and Kaplan-Meier analysis results.

Imaging Time

Pre-surgery

1 month postradiotherapy

3 months
postradiotherapy
6 months
postradiotherapy

Cut point
selected
based on

Parameter Cut Point

Hazard ratios
(95% CI)

Cox
regression
P Value

12 mo OS

BF ≥ 16.1 ml/min/100g

10.9 (2.9 – 41.5)

< 0.001

18 mo OS

BF ≥ 16.8 ml/min/100g

9.9 (2.3 – 42.5)

0.002

24 mo OS

BF ≥ 16.1 ml/min/100g

10.9 (2.9 – 41.5)

< 0.001

CEL

12 mo OS

Volume ≥ 12.3 cm3

7.4 (1.9 – 28.5)

0.004

NEL

18 mo OS

Volume ≥ 11.6 cm3

4.1 (1.1 – 15.3)

0.04

NEL

24 mo OS

Volume ≥ 11.6 cm3

4.1 (1.1 – 15.3)

0.04

NEL

24 mo OS

PS ≥ 1.4 ml/min/100g

4.9 (1.4 – 17.3)

0.01

BV ≥ 1.7 ml/100g

5.2 (1.2 – 21.7)

0.03

VOL ≥ 13.9 cm3

5.7 (1.1 – 28.7)

0.04

BV ≥ 1.3 ml/100g

12.9 (2.8 – 58.9)

0.001

Region

NEL

CEL
CEL
NEL

12 mo OS
18 mo OS
24 mo OS
18 mo OS
24 mo OS
18 mo OS
24 mo OS

Median OS (95% CI)
High: 16.4 (9.3 – 23.4)
Low: 28.8 (19.3 – 38.3)
High: 16.4 (9.8 – 23.0)
Low: 24.4 (16.5 – 32.3)
High: 16.4 (9.3 – 23.4)
Low: 28.8 (19.3 – 38.3)
High: 9.1 (5.8 – 12.4)
Low: 18.0 (15.0 – 20.9)
High: 16.6 (7.2 – 26.0)
Low: 32.7 (26.5 – 38.9)
High: 16.6 (7.2 – 26.0)
Low: 32.7 (26.5 – 38.9)
High: 12.6 (6.3 – 18.9)
Low: 28.8 (19.7 – 37.9)
High: 11.7 (9.2 – 14.2)
Low: 23.6 (5.6 – 41.7)
High: 12.6 (6.3 – 18.9)
Low: 18.2 (12.2 – 24.1)
High: 12.6 (5.4 – 19.8)
Low: 24.4 (20.7 – 28.1)

Log-rank P
Value
0.001
0.003
0.001
0.007
0.03
0.03
0.002
0.007
0.05
0.004

Abbreviations: NEL, non-enhancing lesion; CEL, contrast-enhancing lesion; mo, month, OS, overall survival; BF, blood flow; PS,
permeability-surface area product; BV, blood volume
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Figure 6-3: Kaplan-Meier survival plots of blood flow in the non-enhancing lesion (BFNEL), volume of the contrast-enhancing
lesion (VOLCEL), volume in the NEL (VOLNEL), permeability-surface area product in the NEL (PSNEL), blood volume in the
CEL (BVCEL), and BV in the NEL (BVNEL) measured at different time points. Higher values in these parameters were
associated with worse overall survival (log-rank P < 0.05 for all comparisons).
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Although some imaging parameters did not show a significant association with OS, they could still be useful in stratifying
patients by OS. Table 6-3 shows the sensitivities and specificities of imaging parameters that are ≥ 70% in stratifying patients based
on OS. While some CT perfusion parameters showed sensitivities and specificities ≥ 70%, volumes of NEL and CEL did not. In
addition, BF in the NEL at pre-surgery and BV in the CEL at three months post-radiotherapy had the highest combination of
sensitivities (83% and 82%, respectively) and specificities (86% and 100%, respectively) in stratifying patients based on 24 months
OS. Figure 6-4 illustrates pre-surgery CT perfusion and MR images of two patients with different survival (16.7 vs. 41.6 months).
Higher BF, BV, and PS in the NEL can be seen in the patient with shorter survival.

Table 6-3: Receiver operating characteristic analysis of imaging parameters with sensitivities and specificities ≥ 70%.
Imaging Time
Pre-surgery

1 Month Post-radiotherapy
3 Months Post-radiotherapy

Region

Cut-point selected based on

Parameter cut point

AUC

Sensitivity

Specificity

NEL

18 mo OS
24 mo OS
24 mo OS
18 mo OS
24 mo OS
24 mo OS

BF ≥ 16.8 ml/min/100g
BF ≥ 16.1 ml/min/100g
BF ≥ 26.0 ml/min/100g
PS ≥ 1.4 ml/min/100g
PS ≥ 3.4 ml/min/100g
BV ≥ 1.7 ml/100g

0.76
0.88
0.73
0.76
0.81
0.85

80%
83%
78%
71%
75%
82%

77%
86%
71%
79%
80%
100%

CEL
NEL
CEL
CEL

Abbreviations: NEL, non-enhancing lesion; CEL, contrast-enhancing lesion; mo, months, OS; overall survival ; BF, blood flow; BV,
blood volume; PS, permeability-surface area product; AUC, area under the receiver operating characteristic curve
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Figure 6-4: Illustrative pre-surgery CT perfusion and MR images of patients with WHO grade IV gliomas. Both patients
presented with a contrast-enhancing lesion on post-gadolinium T1-weighted MR images, which also had elevated blood flow
(BF), blood volume (BV), and permeability-surface area product (PS). Patient A presented with low BF, BV, and PS in the
non-enhancing lesion (NEL, asterisk). However, Patient B presented with regions of elevated BF, BV, and PS in the NEL (red
arrows). The survival for patient A was 41.6 months and Patient B was 16.7 months. Identical window and level were used for
the color maps.
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6.4 Discussion
OS in patients with high-grade gliomas remains poor despite aggressive
treatments. Deployment of advanced functional imaging that can stratify patients by
expected OS can potentially facilitate timely selection of appropriate treatments for these
patients. This study examined the serial changes in CT perfusion parameters in
conjunction with volumetric changes in the CEL and NEL of patients with high-grade
gliomas. We also examined whether these imaging parameters could predict OS.
Perfusion changes after radiotherapy have previously been studied only in a few
reports (26,27). An increase in BV was associated with progression (26) and poor
survival (27). This is the first study to investigate serial changes in BF, BV, and PS in
both the CEL and NEL for up to one year post-radiotherapy. The initial decline of all
imaging parameters in the CEL after surgery and radiotherapy could be attributed to
surgical debulking of the tumour and therapeutic effect of radiotherapy and
chemotherapy. After stratifying patients based on 18 and 24 months OS, all three
perfusion parameters in the CEL started to diverge three months after radiotherapy with
elevated BF and BV seen in patients with shorter OS. On the other hand, BF, BV, and PS
in the NEL were consistently higher in two groups of patients with shorter OS (< 18 and
24 months). Although statistical differences were identified only at some of the time
points, in general our data provided corroborating evidence that part of the heterogeneity
in OS is related to variation in tumour perfusion characteristics both in the CEL and NEL
regions. This variation in perfusion characteristics presumably reflected the differences in
angiogenesis and vascularity between patients. Angiogenesis as a mechanism for
promoting tumour growth is now an active target in cancer therapies (28). Angiogenesis
leads to an increase in tumour microvessel area, which has been shown to correlate with
tumour BV and patient survival (11). More recently, vasculogenesis, a process by which
bone marrow-derived cells are recruited to form new tumour blood vessels, has been
shown to govern tumour recurrence after radiotherapy (29). It is not known what
percentage of tumour vessels are derived from vasculogenesis, but given that recurrence
occurs within 2 cm of the irradiated volume (4,5) it is critical to assess perfusion
parameters in both the CEL and NEL after radiotherapy.
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None of the imaging measurements made in the CEL before surgery showed a
significant correlation with OS. This could be because total resection of the tumour
(mostly CEL) is a stronger predictor of OS. Over 60% of patients in this study underwent
total resection and the extent of resection showed a significant association with OS.
Prediction of survival using pre-surgery CT perfusion parameters in the CEL may be
more appropriate for patients who are not candidates for total resection. For example,
pre-surgery tumour BV is a predictor of survival in a study with a mixture of patients that
received biopsy, subtotal resection, and total resection (12). However, pre-surgery
measurement of BF in the NEL proved to be useful in predicting OS in this study. This
result points to the role of tumour burden in the T2 hyperintense lesion that is not
typically removed by surgery.
Although a larger sample size is required to show consistent associations between
OS and CT perfusion parameters across all time points, our results are consistent with
previous reports that higher BV and PS are associated with poor outcomes (12,13,26,27).
It is also noteworthy that while we showed significant hazards of death associated with
both volumetric and CT perfusion parameters, only CT perfusion parameters resulted in
sensitivities and specificities ≥ 70% in predicting OS. CT perfusion parameters can
provide complementary information to volumetric MR measurements in predicting
survival in high-grade glioma patients. Volume of the CEL may not be a reliable
predictor of outcome because the volume of contrast-enhancement may be affected by
many

nontumoural

processes

including

inflammation,

postsurgical

changes,

pseudoprogression, and treatment-induced necrosis (30-33). Similarly, the volume of the
NEL encompasses many causes of T2 hyperintensity such as vasogenic edema, gliosis,
cystic changes, inflammation, and tumour infiltration (34-36). It is evident from Figure
6-4 that tumours can have regions of high BF, BV, and PS that are bigger than the CEL.
These regions can potentially lead to future sites of recurrence. Although this is
hypothesis-generating, there is preliminary evidence to suggest that there could be better
spatial concordance between CT perfusion parameters with the site of future recurrence
than the CEL with the site of future recurrence (23).
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Some limitations must be considered. Our sample size was relatively small and
five patients had anaplastic oligodendrogliomas, which are known to have a higher BV
than astrocytic gliomas despite better survival (37,38). This can hamper the ability to
stratify OS based on BV. In addition, we did not have information regarding other known
biologic biomarkers like MGMT methylation status that are associated with OS and thus
we could not correct for those effects in our regression models. Likewise, the variable use
of salvage therapies like second surgery and chemotherapy may have influenced OS
although in glioblastoma patients these effects could be expected to be modest (39).
Another limitation was the use of a one-phase CT perfusion protocol in one third of the
patients. The duration of the CT perfusion protocol can affect the measurements of CT
perfusion parameters, in particularly PS (24). Although we did not find a statistical
difference in these parameters in the CEL and NEL at baseline between the two protocols
(data not shown), it is important to use a two-phase CT perfusion protocol in future
studies. We did not consider the impact of change in each of the imaging parameters over
time on OS by treating the serial measurements as time-dependent covariates in a joint
model of survival and time-dependent covariates. This is because we first want to
evaluate the predictive value of these imaging parameters as independent predictors of
survival in order to limit the number of CT perfusion follow-ups in future studies.
Finally, a perfusion imaging scan at the time point of pre-radiotherapy but post-surgery
could be a better baseline scan than a pre-surgery perfusion imaging scan. This may have
helped extract the relative contribution of perfusion imaging parameters versus the extent
of surgical resection in predicting survival.

6.5 Conclusions
BF, BV, PS are potential biomarkers of OS in patients with high-grade gliomas
treated with multi-modality therapy (surgery, radiation, chemotherapy) even after
adjustments for age, WHO grade, Karnofsky Performance Status, and the extent of
resection. The results of this study, if verified in a larger cohort of patients, could
establish CT perfusion imaging as a reliable predictor of survival.
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Chapter 7

7

Conclusion and Future Work

7.1 Summary of Findings
This thesis demonstrated 1) the importance of mitigating some of the uncertainties
associated with CT perfusion imaging and 2) the possibilities of using CT perfusion
imaging to stratify outcomes in brain tumour patients and in an experimental model of
brain tumour. In this chapter, major findings of the five studies in this thesis are
summarized, and future investigations are discussed.

7.1.1

Mitigating Uncertainties in CT Perfusion
Although much research has been done in the field of CT perfusion imaging,

interpretation of these results can be confounded by variations in image acquisition
protocols affecting the measurements of different CT perfusion parameters (e.g. blood
flow, BF). The absence of a standardized protocol has led to the procedure variability
observed amongst published studies. One imaging acquisition parameter that varied
widely in the literature is the scan duration. Chapter 2 addressed the role of scan duration
in the measurements of BF, blood volume (BV), and permeability-surface area product
(PS). Systematic and random errors in BF, BV, and PS measurements increased with
shorter scan duration. Tumour rim PS values computed from shorter (60 s) scans were
significantly different from the corresponding values computed from the longer (150 s)
scans (P < 0.01). As a result of these analyses, a minimum scan duration of 90 s is
recommended.
CT image noise not only affects the visualization of anatomical structures; it
affects the calculated BF, BV, and PS values. Chapter 3 evaluated the improvements in
the measurements of these parameters after filtering CT perfusion images using principal
component analysis (PCA). From the simulation, PCA filtering reduced the measurement
errors of BF, BV, and PS. Similarly, the noise of BF, BV, and PS measurements also
decreased after PCA filtering. From experiments, we showed that PCA improved the
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contrast-to-noise ratio of CT perfusion images. At a noise level of 17 HU, a minimum of
4 principal components was recommended for filtering CT perfusion images.
While other aspects of CT perfusion imaging remain to be optimized, the
development of recommended minimum scan duration and an optimized image noise
filtering technique are important components of developing standardized approaches to
perfusion imaging.

7.1.2

CT Perfusion as a Biomarker of Treatment Outcomes
Clinical outcomes of patients with malignant gliomas vary widely with some

patients surviving longer than others despite standard treatments. Thus, a biomarker that
can stratify patients by survival can potentially personalize treatments for these patients.
To contribute to this goal, we examined the ability of CT perfusion in identifying “longterm survivors” and “short-term survivors” in both malignant glioma patients and a
preclinical animal model.
Stereotactic radiosurgery (SRS) has garnered clinical interests over the years for
the treatment of malignant gliomas, but clinical trials of SRS have not demonstrated
clinically meaningful improvements in survival over conventional fractionated
radiotherapy. Using the C6 glioma model for rats (Chapter 4), we investigated the
efficacy of CT perfusion as a potential early imaging biomarker of response to SRS. Our
results showed that response to SRS was heterogeneous. Stratification of treated animals
based on 15 day survival showed that responders (surviving > 15 days) had lower relative
BV and PS on day 7 post-SRS when compared to controls and non-responders (P < 0.05).
In addition, relative BV and PS on day 7 post-SRS were predictive of survival with 92%
accuracy while tumour volume was not predictive of survival. These findings point to the
potential role of CT perfusion as an early biomarker of response to SRS.
Identifying active tumour regions that are likely to persist after treatment can help
tailor radiotherapy to target these regions. Chapter 5 investigated whether
multiparametric imaging with CT perfusion and 18F-Fluorodeoxyglucose positron
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emission tomography (FDG-PET) can identify tumour sites that are likely to correlate
with the eventual location of tumour progression. We developed a method to generate
probability maps of tumour progression based on CT perfusion, FDG-PET, and
anatomical MR imaging data. Our results showed that PS had the highest area under the
receiver operating characteristic curve for identifying tumour regions that are likely to
coincide with future sites of progression (AUC = 0.72 ± 0.12). Although the sensitivity
and specificity were modest for identifying tumour regions that were likely to progress,
this study demonstrated the use of voxel-based analysis of multi-parametric imaging data
in relations to future sites of progression.
The final study of this thesis (Chapter 6) examined the serial changes in tumour
volumetric and CT perfusion parameters and evaluated the predictive values of these data
in stratifying malignant glioma patients by overall survival. Patients were imaged with
conventional MR and CT perfusion before surgery and regularly after radiotherapy for up
to a year. A trend towards higher BF, BV, and PS in the contrast-enhancing lesion (CEL)
and the non-enhancing lesion (NEL) were found in patients with overall survival less
than 18 and 24 months, and these values were significant at some time points (P < 0.05).
Pre-surgery BF in the NEL and BV in the CEL three months after radiotherapy had the
highest combination of sensitivities and specificities of ≥ 80% in predicting 24 months
overall survival. These results suggest using BF, BV, and PS as early predictors of
survival.

7.2 Clinical Translational Potential
The findings of this thesis contributed important information for the clinical
translation of CT perfusion in brain tumour imaging. Here, we describe how this research
is clinically relevant.
Decision making based CT perfusion information relies on accurate and precise
measurements of BF, BV, and PS. This thesis proposed two ways to improve the
accuracy and precision of CT perfusion parameter measurements. Our investigation of
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the effect of scan duration demonstrated that protocol standardization is a simple first
step in reducing the uncertainties associated with CT perfusion parameters. This work is
important and two more studies investigating the effect of CT perfusion scan duration
have cited our work since our study was published in January, 2013 (1,2). Image filtering
using PCA is another way to mitigate some of the uncertainties in the measurements of
BF, BV, and PS. PCA filtering of CT perfusion images has important clinical relevance
in terms of improving image quality and reducing radiation dose. Radiation dose is of
concern when performing serial CT perfusion studies. Thus, dose reduction will facilitate
the use of serial CT perfusion follow-ups in the clinic. Reducing the image acquisition
frequency has been proposed as a method to reduce radiation dose (3-5). This method is
simple to implement and reduces radiation dose effectively. However, the lesser number
of acquired images translates into a reduction in the amount of data available for
estimating BF, BV, and PS. As a result, it is recommended that the frequency of image
acquisition be less than 4 s per image. Our method can be more effective in reducing
image noise because PCA filtering is a post-image acquisition technique. Future
investigation should examine the ability of PCA in maintaining image quality while
reducing radiation dose.
One of the challenges in the treatment of malignant gliomas is the heterogeneity
in clinical outcomes. Here we propose several roles that CT perfusion imaging can play
to improve the care of these patients in terms of spatial targeting and temporal monitoring
of these tumours.
Image-guidance has improved the precision of surgical resection of brain tumours
and spatial targeting in radiotherapy. Image-guidance has largely been limited to postgadolinium T1-weighted and T2-weighted or fluid attenuated inversion recovery
(FLAIR) MR. These techniques predominately assess the structural abnormalities of
tumours. The results described in chapters 5 and 6 point to a possible spatial mismatch
between the CEL on MR and tumour regions with high CT perfusion parameter values.
In radiotherapy, the CEL is called the gross tumour volume. Biologic imaging modalities,
such as CT perfusion, have been proposed to help delineate a “biologic target volume” in
radiotherapy (6). The spatial mismatch between the gross tumour volume (i.e. CEL) and
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the biologically active tumour volume has been studied in a few PET imaging studies (710). The spatial mismatch suggested in this thesis could serve for improving the
delineation of targets for radiotherapy dose escalation. CT perfusion is of particular
importance in this respect because CT scanners/simulators are readily available in
radiotherapy centers and an integral part of the radiation treatment planning workflow.
The use of CT perfusion imaging facilitates the registration of treatment planning CT
images with CT perfusion parameter maps. It is also inexpensive compared with other
imaging techniques such as MR perfusion, and can acquire data for generating maps of
BF, BV, and PS within a few minutes. Therefore, CT perfusion is currently the easiest
modality to implement as a biologic imaging modality in radiation therapy.
Chapters 4 and 6 point to the potential role of CT perfusion in the follow-up of
patients post-treatment. Results from the pre-clinical study (Chapter 4) are consistent
with the results of the clinical study (Chapter 6). Both studies showed that higher BF,
BV, and PS after radiation treatments are associated with worse survival. These findings
are clinically important because they indicate that tumours with higher BF, BV, and PS
are more aggressive and less likely to respond to radiotherapy. These patients might
benefit from additional treatments. Currently, salvage treatments for recurrent
glioblastomas are not standardized. Treatments options include second surgery, repeat
irradiation, chemotherapy, and anti-angiogenic therapies (11). Therefore, early selection
of patients with aggressive tumours based on CT perfusion parameters may facilitate
earlier administration of salvage therapies.

7.3 Future Work
This thesis addressed many important questions regarding CT perfusion imaging
of malignant gliomas. As with any research, this thesis generated a number of new and
important questions. The following section outlines possible future projects.
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7.3.1

A Framework for Quality Assurance (QA) in CT Perfusion
Imaging
As alluded to earlier, quality assurance (QA) is important for widespread

implementation of CT perfusion imaging in oncology trials and practice. Consensus
guidelines for the use of CT perfusion were published in 2012 (12). However, a QA
framework is needed to establish tolerance limits and best practices guidelines. Figure
7-1 proposes a QA framework for CT perfusion imaging so that tolerance limits and best
practices guidelines can be established in the future. This framework proposes four areas
of QA: (i) protocol QA, (ii) machine QA, (iii) user QA, and (iv) software QA. Protocol
QA should include a checklist to ensure that a standardized CT perfusion protocol is
followed. Machine QA involves the use of a physical phantom to check image quality
and the variability in time concentration curves obtained from different scanning
conditions (13). At present, flow phantoms are available to check the variability in time
concentration curves (13,14). User education is needed to ensure proper analysis of CT
perfusion datasets and minimize interobserver variability. Digital phantoms like the one
developed in this thesis and other studies (15-17) can be used to assess the variability in
CT perfusion parameter measurements computed from different software. It can also be
used to assess the quality of image filtering. A physiological flow phantom that mimics
tissue hemodynamics (flow, volume, and permeability) can potentially replace the
physical phantom and digital phantom by evaluating measurements of CT perfusion
parameters. However, research is needed to develop a physiological flow phantom that
mimics tissue hemodynamics. Such a phantom can be used for accreditation of CT
perfusion imaging across sites (13). By establishing this QA framework, we hypothesize
that tolerance limits and best practices guidelines can be established.
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Figure 7-1: Quality assurance (QA) framework in CT perfusion imaging.

7.3.2

Delineating a Biologic Target Volume (BTV) in Radiotherapy
Our results point to a mismatch between regions of contrast enhancement and

regions of high BF, BV, and PS in some patients with malignant gliomas. The potential
application of using BF, BV, and PS maps for radiotherapy treatment planning warrants
further investigations. Two important research questions need to be answered:

a. Will maps of BF, BV, and PS affect radiation oncologists’ decision in
defining a target volume for radiotherapy?
b. Will targeting a biological target volume based on these CT perfusion
maps improve treatment outcomes when compared to conventional
targeting of the gross tumour volume?
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The above questions can potentially change clinical practice and the care of patients with
malignant gliomas.

7.3.3

CT Perfusion Imaging to Monitor Response to Combined
Anti-angiogenic Therapy, Radiotherapy, and Chemotherapy
Bevacizumab is an anti-angiogenic agent that is under active investigation for the

treatment of newly diagnosed glioblastomas. Results from a randomized placebocontrolled trial showed that Bevacizumab did not prolong overall survival compared to
conventional treatments (18). Bevacizumab treatments in this trial started during week
four of radiotherapy. However, preclinical evidence showed that judicious timing of antiangiogenic agent before radiotherapy could exert a synergistic effect on tumour control
suggesting further optimization of radiotherapy and bevacizumab combinations may be
possible (19). Further work could examine the combined effects of radiotherapy and
Bevacizumab on tumour perfusion in pre-clinical models of glioma to further optimize
the use of this agent. In doing so, the C6 glioma model may not be the optimal tumour
model for this investigation because the efficacy of binding of Bevacizumab to rodent
vascular endothelial growth factor (VEGF) is controversial (20-22). A xenograft model
such as the human glioblastoma cell line U87MG model is a more appropriate tumour
model to use in this investigation (23).
The ultimate goal remains to use functional imaging to tailor the appropriate
treatments of cancer patients. It is hoped that the publications from this PhD dissertation
will raise community awareness to the potential benefits of CT perfusion imaging –
offering a readily accessible functional imaging modality that might personalize cancer
treatments for patients affected by this disease.
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